Predictive Oncology (POAI) S-1/A26 Nov 14IPO registration (amended)Financial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
Document And Entity Information	Sep. 30, 2014
Document Information [Line Items]	'
Entity Registrant Name	'Skyline Medical Inc.
Entity Central Index Key	'0001446159
Entity Filer Category	'Smaller Reporting Company
Document Type	'S-1
Amendment Flag	'false
Document Period End Date	30-Sep-14

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Current Assets:	'	'	'
Cash	$244,044	$101,953	$13,139
Accounts Receivable	238,604	97,245	39,711
Inventories	315,620	122,175	145,209
Prepaid Expense and other assets	148,950	60,588	27,409
Total Current Assets	947,218	381,961	225,468
Fixed Assets, net	216,946	158,110	3,521
Intangibles, net	72,701	53,355	140,588
Total Assets	1,236,865	593,426	369,577
Current Liabilities:	'	'	'
Current portion of convertible debt, net of discounts of $0 and $21,138 (See Note 6)	'	0	1,081,187
Accounts payable	1,577,818	1,062,108	733,595
Accrued expenses	2,089,885	2,057,957	1,599,519
Short-term note payable net of discounts of $353,583 and $0(See Note 4)	1,169,677	280,000	0
Deferred Revenue	5,000	69,000	0
Total Current Liabilities	4,842,380	3,469,065	3,414,301
Long-term debt and convertible debt, net of discounts of $0 and $0 (See Note 6)	'	0	89,300
Accrued Expenses	229,318	331,216	0
Liability for equity-linked financial instruments (See Note 8)	0	11,599	169,179
Total Liabilities	5,071,698	3,811,880	3,672,780
Commitments and Contingencies	'	'	'
Stockholders' Deficit:	'	'	'
Series A Convertible Preferred Stock, $.01 par value, $100 Stated Value, 40,000 authorized, 20,550 outstanding	206	0	'
Common stock, $.01 par value, 10,666,667 authorized, 2,999,386 and 2,932,501 outstanding	29,993	29,325	13,900
Additional paid-in capital	29,380,273	25,449,636	15,974,008
Deficit accumulated during development stage	-33,245,305	-28,697,415	-19,291,111
Total Stockholders' Deficit	-3,834,833	-3,218,453	-3,303,203
Total Liabilities and Stockholdersâ€™ Deficit	$1,236,865	$593,426	$369,577

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS [Parenthetical] (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Allowance for Doubtful Accounts Receivable (in dollars)	'	$0	$4,073
Accumulated discounts on current portion of convertible debt (in dollars)	'	0	21,138
Accumulated discounts on long-term debt and convertible debt (in dollars)	'	0	0
Discount on short term note payable (in dollars)	$353,583	$0	'
Series A convertible preferred stock, par value (in dollars per share)	0.01	0.01	'
Series A convertible preferred stock, stated value (in dollars per share)	$100	$100	'
Series A convertible preferred stock, shares authorized	40,000	40,000	'
Series A convertible preferred stock, shares outstanding	20,550	20,550	'
Common stock, par value (in dollars per share)	$0.01	$0.01	$0.01
Common stock, shares authorized	10,666,667	10,666,667	10,666,667
Common stock, shares outstanding	2,999,386	2,932,501	1,389,964

CONDENSED_STATEMNETS_OF_OPERAT

CONDENSED STATEMNETS OF OPERATION (USD $)	3 Months Ended		9 Months Ended		12 Months Ended		140 Months Ended
CONDENSED STATEMNETS OF OPERATION (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Revenue	$397,254	$107,835	$785,767	$386,418	$468,125	$188,772	$769,559
Cost of goods sold	134,726	26,181	264,174	135,120	189,707	128,540	381,467
Gross Margin	262,528	81,654	521,593	251,298	278,418	60,232	388,092
General and administrative expense	737,519	3,195,589	3,247,024	5,906,805	7,530,037	6,285,905	23,280,400
Operations expense	183,154	354,027	740,012	763,422	1,096,969	761,047	3,387,550
Sales and marketing expense	325,141	164,712	849,364	357,274	578,793	172,970	1,640,248
Interest expense	131,935	407,516	164,962	629,722	636,503	259,349	1,562,959
Gain on valuation of equity-linked financial instruments	0	-65,287	-11,599	-153,960	-157,580	3,116	-785,650
Total expense	1,377,749	4,056,557	4,989,763	7,503,263	9,684,722	7,482,387	29,085,507
Net income (loss) available to common shareholders	($1,115,221)	($3,974,903)	($4,468,170)	($7,251,965)	($9,406,304)	($7,422,155)	($28,697,415)
Loss per common share - basic and diluted (in dollars per share)	($0.37)	($2.18)	($1.51)	($4.30)	($4.64)	($8)	($28.80)
Weighted average shares used in computation - basic and diluted (in shares)	2,984,335	1,821,006	2,967,483	1,687,625	2,026,115	927,838	996,362

STATEMENTS_OF_STOCKHOLDERS_DEF

STATEMENTS OF STOCKHOLDERS' DEFICIT (USD $)		Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Balance at Apr. 22, 2002		'	'	'	'	'
Issuance of common stock 9/1/02, $1.25	[1]	$10,000	'	$80	$9,920	$0
Issuance of common stock 9/1/02, $1.25 (in shares)	[1]	'	'	7,981	'	'
Issuance of common 10/23/02, $125.25/share		5,000	'	'	5,000	'
Issuance of common 10/23/02, $125.25/share (in shares)		'	'	40	'	'
Net loss		-51,057	'	'	'	-51,057
Balance at Dec. 31, 2002		-36,057	'	80	14,920	-51,057
Balance (in shares) at Dec. 31, 2002		'	'	8,021	'	'
Issuance of common stock	[2]	400	'	3	397	'
Issuance of common stock (in shares)	[2]	'	'	320	'	'
Issuance of common 6/11 & 12, $125.25	[3]	35,000	'	3	34,997	'
Issuance of common 6/11 & 12, $125.25 (in shares)	[3]	'	'	288	'	'
Net loss		-90,461	'	'	'	-90,461
Balance at Dec. 31, 2003		-91,118	'	86	50,314	-141,518
Balance (in shares) at Dec. 31, 2003		'	'	8,629	'	'
Issuance of common 5/25/04, $1.25	[4]	110	'	1	109	'
Issuance of common 5/25/04, $1.25 (in shares)	[4]	'	'	88	'	'
Net loss		-90,353	'	'	'	-90,353
Balance at Dec. 31, 2004		-181,361	'	87	50,423	-231,871
Balance (in shares) at Dec. 31, 2004		'	'	8,717	'	'
Issuance of common stock	[5]	250	'	2	248	'
Issuance of common stock (in shares)	[5]	'	'	200	'	'
Vested stock options and warrants		2,793	'	0	2,793	'
Net loss		-123,852	'	'	'	-123,852
Balance at Dec. 31, 2005		-302,170	'	89	53,464	-355,723
Balance (in shares) at Dec. 31, 2005		'	'	8,917	'	'
Issuance of common 5/16 & 8/8, $1.25	[6]	1,451	'	12	1,439	'
Issuance of common 5/16 & 8/8, $1.25 (in shares)	[6]	'	'	1,159	'	'
Issuance of common 10/19 & 23, $1.25	[7]	650	'	5	645	'
Issuance of common 10/19 & 23, $1.25 (in shares)	[7]	'	'	519	'	'
Issuance of common 12/01, $125.25	[8]	44,810	'	4	44,806	'
Issuance of common 12/01, $125.25 (in shares)	[8]	'	'	384	'	'
Vested stock options and warrants		13,644	'	'	13,644	'
Net loss		-273,026	'	'	'	-273,026
Balance at Dec. 31, 2006		-514,641	'	110	113,998	-628,749
Balance (in shares) at Dec. 31, 2006		'	'	10,979	'	'
Issuance of common stock	[9]	1,000	'	0	1,000	'
Issuance of common stock (in shares)	[9]	'	'	8	'	'
Vested stock options and warrants		73,907	'	0	73,907	'
Capital contributions resulting from waivers of debt		346,714	'	0	346,714	'
Value of equity instruments issued with debt		132,938	'	0	132,938	'
Net loss		-752,415	'	'	'	-752,415
Balance at Dec. 31, 2007		-712,497	'	110	668,557	-1,381,164
Balance (in shares) at Dec. 31, 2007		'	'	10,987	'	'
Issuance of common stock	[10]	1,593,502	'	607	1,592,895	'
Issuance of common stock (in shares)	[10]	'	'	60,705	'	'
Shares issued to finders, agents		0	'	268	-268	'
Shares issued to finders, agents (in shares)		'	'	26,836	'	'
Shares issued to pay direct legal fees		0	'	38	-38	'
Shares issued to pay direct legal fees (in shares)		'	'	3,810	'	'
Issuance of common due to anti-dilution provisions		0	'	27	-27	'
Issuance of common due to anti-dilution provisions (in shares)		'	'	2,746	'	'
Shares issued to pay investor relations services 6/23/08, $26.25		87,500	'	33	87,467	'
Shares issued to pay investor relations services 6/23/08, $26.25 (in shares)		'	'	3,334	'	'
Vested stock options and warrants		354,994	'	0	354,994	'
Capital contributions resulting from waivers of debt		129,684	'	0	129,684	'
Net loss		-1,762,628	'	'	'	-1,762,628
Balance at Dec. 31, 2008		-309,445	'	1,084	2,833,264	-3,143,792
Balance (in shares) at Dec. 31, 2008		'	'	108,418	'	'
Cumulative effect of adoption of EITF 07-5		-479,910	'	0	-486,564	6,654
Vested stock options and warrants		111,835	'	0	111,835	'
Shares issued 3/20/09 to pay for fund raising		0	'	17	-17	'
Shares issued 3/20/09 to pay for fund raising (in shares)		'	'	1,667	'	'
Shares issued under PMM in 2009, $37.50		1,073,905	'	286	1,073,619	'
Shares issued under PMM in 2009, $37.50 (in shares)		'	'	28,638	'	'
Capital contributions resulting from waivers of debt		84,600	'	0	84,600	'
Value of equity-linked financial instruments issued in connection with PPMs		-222,296	'	0	-222,296	'
Shares issued to consultant for fund raising		0	'	4	-4	'
Shares issued to consultant for fund raising (in shares)		'	'	400	'	'
Shares issued upon conversion of debt and interest, $20.25		256,454	'	125	256,329	'
Shares issued upon conversion of debt and interest, $20.25 (in shares)		'	'	12,473	'	'
Value of equity instruments issued with debt		30,150	'	0	30,150	'
Shares issued upon conversion of shareholder note, $26.25		4,906	'	2	4,904	'
Shares issued upon conversion of shareholder note, $26.25 (in shares)		'	'	187	'	'
Net loss		-2,892,230	'	'	'	-2,892,230
Balance at Dec. 31, 2009		-2,342,031	'	1,518	3,685,820	-6,029,368
Balance (in shares) at Dec. 31, 2009		'	'	151,783	'	'
Vested stock options and warrants		11,382	'	0	11,382	'
Shares issued in 2010 under PPM, $37.50		177,275	'	47	177,228	'
Shares issued in 2010 under PPM, $37.50 (in shares)		'	'	4,728	'	'
Shares issued to consultants for IR and consulting, $37.50		187,045	'	50	186,995	'
Shares issued to consultants for IR and consulting, $37.50 (in shares)		'	'	4,988	'	'
Value of equity instruments issued for consulting services		354,602	'	0	354,602	'
Value of equity-linked financial instruments issued in connection with PPM in first quarter		-25,553	'	0	-25,553	'
Shares issued in May 2010 to consultant, $37.50		6,425	'	2	6,423	'
Shares issued in May 2010 to consultant, $37.50 (in shares)		'	'	172	'	'
Shares issued in May 2010 to 2008 investors as a penalty for late registration, $37.50		355,124	'	95	355,029	'
Shares issued in May 2010 to 2008 investors as a penalty for late registration, $37.50 (in shares)		'	'	9,470	'	'
Value of equity instruments issued with debt		119,474	'	0	119,474	'
Value of equity-linked financial instruments issued in connection with PPM in second quarter		-31,332	'	0	-31,332	'
Value of equity-linked financial instruments issued in connection with PPM in third quarter		-31,506	'	0	-31,506	'
Shares issued in September 2010 under PPM, $7.50		25,000	'	33	24,967	'
Shares issued in September 2010 under PPM, $7.50 (in shares)		'	'	3,334	'	'
Shares issued to consultants in third quarter at $16.50 per share		107,549	'	65	107,484	'
Shares issued to consultants in third quarter at $16.50 per share (in shares)		'	'	6,519	'	'
Shares issued in November 2010 upon exercise of warrants at $10.13 per share		17,357	'	17	17,340	'
Shares issued in November 2010 upon exercise of warrants at $10.13 per share (in shares)		'	'	1,715	'	'
Shares issued in November 2010 to directors as compensation at $11.25 per share		45,000	'	40	44,960	'
Shares issued in November 2010 to directors as compensation at $11.25 per share (in shares)		'	'	4,000	'	'
Vested stock options in fourth quarter		161,107	'	0	161,107	'
Equity instruments issued to consultants in fourth quarter		26,234	'	0	26,234	'
Net loss		-1,352,709	'	'	'	-1,352,709
Balance at Dec. 31, 2010		-2,189,557	'	1,867	5,190,654	-7,382,077
Balance (in shares) at Dec. 31, 2010		'	'	186,709	'	'
Value of equity instruments issued with debt		47,908	'	0	47,908	'
Equity instruments issued to consultants in first quarter		91,504	'	0	91,504	'
Shares issued at $5.63 per share under PPM		400,000	'	711	399,289	'
Shares issued at $5.63 per share under PPM (in shares)		'	'	71,112	'	'
Shares issued at $6.38 per share under PPM		160,000	'	251	159,749	'
Shares issued at $6.38 per share under PPM (in shares)		'	'	25,099	'	'
Shares issued at $6.75 per share under PPM		18,000	'	27	17,973	'
Shares issued at $6.75 per share under PPM (in shares)		'	'	2,667	'	'
Shares issued at $7.50 per share under PPM		15,000	'	20	14,980	'
Shares issued at $7.50 per share under PPM (in shares)		'	'	2,000	'	'
Stock issued upon conversion of debt in first quarter		20,000	'	55	19,945	'
Stock issued upon conversion of debt in first quarter (in shares)		'	'	5,547	'	'
Stock issued to pay interest on debt		22,500	'	21	22,479	'
Stock issued to pay interest on debt (in shares)		'	'	2,108	'	'
Shares issued at $5.25 per share under PPM		75,000	'	143	74,857	'
Shares issued at $5.25 per share under PPM (in shares)		'	'	14,286	'	'
Stock issued upon conversion of debt and interest		32,000	'	125	31,875	'
Stock issued upon conversion of debt and interest (in shares)		'	'	12,548	'	'
Equity instruments issued to consultants		12,256	'	0	12,256	'
Equity instruments issued to consultants		147,116	'	0	147,116	'
Shares issued at $4.50 per share under PPM		210,000	'	467	209,533	'
Shares issued at $4.50 per share under PPM (in shares)		'	'	46,667	'	'
Shares issued at $15.00 per share under PPM		275,000	'	183	274,817	'
Shares issued at $15.00 per share under PPM (in shares)		'	'	18,334	'	'
Restricted stock issued to consultants		55,000	'	110	54,890	'
Restricted stock issued to consultants (in shares)		'	'	10,972	'	'
Shares issued at $26.25 per share IR compensation		201,250	'	77	201,173	'
Shares issued at $26.25 per share IR compensation (in shares)		'	'	7,667	'	'
Equity instruments upon conversion of Accounts Payable		20,000	'	0	20,000	'
Shares issued to private investor at $11.25 per share		232,000	'	206	231,794	'
Shares issued to private investor at $11.25 per share (in shares)		'	'	20,623	'	'
Vested stock options and warrants in first quarter		1,937,638	'	0	1,937,638	'
Shares issued upon exercise of options at $.75 per share		1,000	'	13	987	'
Shares issued upon exercise of options at $.75 per share (in shares)		'	'	1,334	'	'
Net loss		-4,486,879	'	'	'	-4,486,879
Balance at Dec. 31, 2011		-2,703,264	'	4,277	9,161,417	-11,868,956
Balance (in shares) at Dec. 31, 2011		'	'	427,673	'	'
Vested stock options and warrants		830,372	'	0	830,372	'
Value of equity instruments issued with debt		33,469	'	0	33,469	'
Shares issued to institutional investor upon conversion of Note Payable at $10.07 per share		8,000	'	8	7,992	'
Shares issued to institutional investor upon conversion of Note Payable at $10.07 per share (in shares)		'	'	795	'	'
Shares issued to institutional investor upon conversion of Note Payable at $9.75 per share		14,000	'	14	13,986	'
Shares issued to institutional investor upon conversion of Note Payable at $9.75 per share (in shares)		'	'	1,436	'	'
Shares issued to institutional investor upon conversion of Note Payable at $6.60 per share		15,000	'	23	14,977	'
Shares issued to institutional investor upon conversion of Note Payable at $6.60 per share (in shares)		'	'	2,273	'	'
Shares issued to institutional investor upon conversion of Note Payable at $3.35 per share		16,000	'	46	15,954	'
Shares issued to institutional investor upon conversion of Note Payable at $3.35 per share (in shares)		'	'	4,578	'	'
Shares issued to institutional investor upon conversion of Note Payable at $3.35 per share		12,000	'	36	11,964	'
Shares issued to institutional investor upon conversion of Note Payable at $3.35 per share (in shares)		'	'	3,588	'	'
Shares issued to institutional investor upon conversion of Note Payable at $3.35 per share		10,000	'	36	9,964	'
Shares issued to institutional investor upon conversion of Note Payable at $3.35 per share (in shares)		'	'	3,583	'	'
Shares issued to institutional investor upon conversion of Note Payable at $2.98 per share		8,500	'	57	8,443	'
Shares issued to institutional investor upon conversion of Note Payable at $2.98 per share (in shares)		'	'	5,709	'	'
Shares issued to a private investor at $4.88 per share		600,000	'	1,231	598,769	'
Shares issued to a private investor at $4.88 per share (in shares)		'	'	123,076	'	'
Shares issued for consulting to the then interim CEO at $4.88 per share		19,500	'	40	19,460	'
Shares issued for consulting to the then interim CEO at $4.88 per share (in shares)		'	'	4,000	'	'
Shares issued to an institutional investor upon conversion of Note Payable at $2.15 per share		10,000	'	47	9,953	'
Shares issued to an institutional investor upon conversion of Note Payable at $2.15 per share (in shares)		'	'	4,661	'	'
Shares issued to a private investor at $11.25 per share		39,500	'	35	39,465	'
Shares issued to a private investor at $11.25 per share (in shares)		'	'	3,511	'	'
Stock issued upon conversion of debt at $11.25 per share		493,884	'	439	493,445	'
Stock issued upon conversion of debt at $11.25 per share (in shares)		'	'	43,900	'	'
Stock issued upon conversion of debt at $4.88 per share		185,299	'	380	184,919	'
Stock issued upon conversion of debt at $4.88 per share (in shares)		'	'	38,010	'	'
Shares issued to a private investor per a convertible note default at $11.25 per share		1,125,000	'	1,000	1,124,000	'
Shares issued to a private investor per a convertible note default at $11.25 per share (in shares)		'	'	100,000	'	'
Shares issued to private investor upon conversion of Note Payable at $13.50 per share		57,042	'	42	57,000	'
Shares issued to private investor upon conversion of Note Payable at $13.50 per share (in shares)		'	'	4,225	'	'
Shares issued to private investor upon conversion of Note Payable at $3.90 per share		59,534	'	153	59,381	'
Shares issued to private investor upon conversion of Note Payable at $3.90 per share (in shares)		'	'	15,293	'	'
Shares issued to private investor upon conversion of Note Payable at $7.50 per share		56,584	'	75	56,509	'
Shares issued to private investor upon conversion of Note Payable at $7.50 per share (in shares)		'	'	7,543	'	'
Shares issued to an institutional investor upon conversion of Note Payable at $2.33 per share		12,000	'	52	11,948	'
Shares issued to an institutional investor upon conversion of Note Payable at $2.33 per share (in shares)		'	'	5,160	'	'
Stock issued upon conversion of debt at $11.25 per share		59,590	'	53	59,537	'
Stock issued upon conversion of debt at $11.25 per share (in shares)		'	'	5,296	'	'
Shares issued to a Director as compensation at $6.75 per share		25,000	'	37	24,963	'
Shares issued to a Director as compensation at $6.75 per share (in shares)		'	'	3,703	'	'
Shares issued under PPM at $5.25 per share		690,946	'	1,316	689,629	'
Shares issued under PPM at $5.25 per share (in shares)		'	'	131,608	'	'
Shares issued to institutional investor upon conversion of Note Payable at $2.65 per share		18,000	'	68	17,932	'
Shares issued to institutional investor upon conversion of Note Payable at $2.65 per share (in shares)		'	'	6,797	'	'
Shares issued to a private investor upon conversion of Note Payable at $2,40 per share		9,022	'	38	8,984	'
Shares issued to a private investor upon conversion of Note Payable at $2,40 per share (in shares)		'	'	3,782	'	'
Shares issued to an institutional investor upon conversion of Note Payable at $2.23 per share including $11,021 of interest.		33,021	'	99	32,922	'
Shares issued to an institutional investor upon conversion of Note Payable at $2.23 per share including $11,021 of interest. (in shares)		'	'	9,876	'	'
Shares issued at $11.25 per share as Investor Relations compensation		93,750	'	83	93,667	'
Shares issued at $11.25 per share as Investor Relations compensation (in shares)		'	'	8,333	'	'
Shares issued to a private investor upon conversion of Note Payable at $2.40 per share		50,000	'	210	49,790	'
Shares issued to a private investor upon conversion of Note Payable at $2.40 per share (in shares)		'	'	20,963	'	'
Shares issued as settlement to remove anti-dilution agreement at $4.88 per share		1,722,500	'	3,533	1,718,967	'
Shares issued as settlement to remove anti-dilution agreement at $4.88 per share (in shares)		'	'	353,333	'	'
Shares issued in settlement with former COO at $11.25 per share less shares cancelled at $6.75 per share		142,333	'	107	142,226	'
Shares issued in settlement with former COO at $11.25 per share less shares cancelled at $6.75 per share (in shares)		'	'	10,715	'	'
Equity value for options and warrants		150,189	'	0	150,189	'
Shares issued at $5.25 per share as Investor Relations compensation		21,000	'	40	20,960	'
Shares issued at $5.25 per share as Investor Relations compensation (in shares)		'	'	4,000	'	'
Shares issued at $11.25 per share as conversion of debt		23,563	'	21	23,542	'
Shares issued at $11.25 per share as conversion of debt (in shares)		'	'	2,094	'	'
Shares issued to a private investor exercising options at $.75 per share		718	'	10	708	'
Shares issued to a private investor exercising options at $.75 per share (in shares)		'	'	957	'	'
Shares issued to debtors as compensation at $7.50 per share		156,243	'	208	156,035	'
Shares issued to debtors as compensation at $7.50 per share (in shares)		'	'	20,839	'	'
Shares issued upon conversion of Note Payable at $5.25 per share		16,525	'	31	16,494	'
Shares issued upon conversion of Note Payable at $5.25 per share (in shares)		'	'	3,147	'	'
Share true-up to certified shareholders list per the stock transfer agency		2	'	0	1	'
Share true-up to certified shareholders list per the stock transfer agency (in shares)		'	'	1	'	'
Shares issued upon exercise of options at $.75 per share		4,130	'	55	4,075	'
Shares issued upon exercise of options at $.75 per share (in shares)		'	'	5,506	'	'
Net loss		-7,422,155	'	'	'	-7,422,155
Balance at Dec. 31, 2012		-3,303,203	'	13,900	15,974,008	-19,291,111
Balance (in shares) at Dec. 31, 2012		'	'	1,389,963	'	'
Value of equity instruments issued with debt		392,556	'	'	392,556	'
Shares issued to debtors as compensation at $11.25 per share		43,521	'	39	43,482	'
Shares issued to debtors as compensation at $11.25 per share (in shares)		'	'	3,869	'	'
Shares issued under PPM to five investors at $5.25 per share		500,000	'	952	499,048	'
Shares issued under PPM to five investors at $5.25 per share (in shares)		'	'	95,238	'	'
Shares issued to an escrow account underlying a debt agreement	[11]	10,000	'	133	9,867	'
Shares issued to an escrow account underlying a debt agreement (in shares)	[11]	'	'	13,333	'	'
Shares issued to debtors as compensation at $11.25 per share		34,550	'	31	34,519	'
Shares issued to debtors as compensation at $11.25 per share (in shares)		'	'	3,071	'	'
Shares issued to an institutional investor at $5.25 per share		500,000	'	952	499,048	'
Shares issued to an institutional investor at $5.25 per share (in shares)		'	'	95,238	'	'
Value of shares per an agreement with a former officer	[12]	40,480	'	0	40,480	'
Shares issued to consultant as compensation at $5.03 per share		16,750	'	33	16,717	'
Shares issued to consultant as compensation at $5.03 per share (in shares)		'	'	3,333	'	'
Shares issued to former consultant exercising options at $.75 per share		2,000	'	27	1,973	'
Shares issued to former consultant exercising options at $.75 per share (in shares)		'	'	2,667	'	'
Shares issued to former CEO exercising options at $.75 per share.		3,333	'	44	3,289	'
Shares issued to former CEO exercising options at $.75 per share. (in shares)		'	'	4,444	'	'
Shares issued upon conversion of four notes payable at $11.25 per share		156,243	'	139	156,104	'
Shares issued upon conversion of four notes payable at $11.25 per share (in shares)		'	'	13,888	'	'
Shares issued for interest to the four notes payable at $11.25 per share		11,170	'	10	11,160	'
Shares issued for interest to the four notes payable at $11.25 per share (in shares)		'	'	993	'	'
Shares issued for cashless exercise of warrants at $9.00 per share		2,778	'	37	2,741	'
Shares issued for cashless exercise of warrants at $9.00 per share (in shares)		'	'	3,704	'	'
Shares issued for cashless exercise of warrants at $12.00 per share		1,633	'	22	1,611	'
Shares issued for cashless exercise of warrants at $12.00 per share (in shares)		'	'	2,178	'	'
Shares issued for cashless exercise of warrants at $11.25 per share		6,327	'	84	6,243	'
Shares issued for cashless exercise of warrants at $11.25 per share (in shares)		'	'	8,436	'	'
Shares issued for cashless exercise of warrants at $15.00 per share		2,618	'	35	2,583	'
Shares issued for cashless exercise of warrants at $15.00 per share (in shares)		'	'	3,491	'	'
Shares issued to 24 warrant holders exercised at a reduced price for $7.50 per share		1,044,490	'	1,393	1,043,097	'
Shares issued to 24 warrant holders exercised at a reduced price for $7.50 per share (in shares)		'	'	139,265	'	'
Shares issued to 4 PPM investors converting notes at $9.00 per share		316,504	'	352	316,152	'
Shares issued to 4 PPM investors converting notes at $9.00 per share (in shares)		'	'	35,167	'	'
Shares issued to 10 PPM investors converting notes at $13.50 per share		1,020,200	'	721	1,019,479	'
Shares issued to 10 PPM investors converting notes at $13.50 per share (in shares)		'	'	72,072	'	'
Shares issued to consultant as compensation at $28.50 per share		57,000	'	20	56,980	'
Shares issued to consultant as compensation at $28.50 per share (in shares)		'	'	2,000	'	'
Shares issued for two note conversions at $1.05 per share		994,928	'	9,476	985,452	'
Shares issued for two note conversions at $1.05 per share (in shares)		'	'	947,551	'	'
Shares issued for warrant exercise at $11.25 per share		160,715	'	143	160,572	'
Shares issued for warrant exercise at $11.25 per share (in shares)		'	'	14,286	'	'
Shares issued to an investor for a cashless exercise of warrants at $12.75 per share		2,044	'	27	2,016	'
Shares issued to an investor for a cashless exercise of warrants at $12.75 per share (in shares)		'	'	2,724	'	'
Shares issued to former Board Directors as compensation at $24.38 per share		100,000	'	13	99,987	'
Shares issued to former Board Directors as compensation at $24.38 per share (in shares)		'	'	1,333	'	'
Reduced warrant exercise compensation expense		2,140,946	'	0	2,140,946	'
Options issued as part of employee bonus		147,500	'	0	147,500	'
Shares issued to one investor for cashless warrant exercised at $9.00 per share		2,778	'	37	2,741	'
Shares issued to one investor for cashless warrant exercised at $9.00 per share (in shares)		'	'	3,704	'	'
Shares issued for a cashless exercise of warrants at $7.50 per share		30,244	'	403	29,841	'
Shares issued for a cashless exercise of warrants at $7.50 per share (in shares)		'	'	40,325	'	'
Shares issued for a cashless exercise of warrants at $5.63 per share		5,447	'	73	5,374	'
Shares issued for a cashless exercise of warrants at $5.63 per share (in shares)		'	'	7,263	'	'
Shares issued for cashless warrant exercise at $9.75 per share		1,597	'	21	1,576	'
Shares issued for cashless warrant exercise at $9.75 per share (in shares)		'	'	2,130	'	'
Shares issued for interest on two note conversions at $13.50 per share		7,365	'	5	7,360	'
Shares issued for interest on two note conversions at $13.50 per share (in shares)		'	'	546	'	'
Shares issued in settlement with a former noteholder at $20.25 per share		102,060	'	50	102,010	'
Shares issued in settlement with a former noteholder at $20.25 per share (in shares)		'	'	5,040	'	'
Shares issued for a stock option exercise at $4.88 per share		650	'	1	649	'
Shares issued for a stock option exercise at $4.88 per share (in shares)		'	'	133	'	'
Shares issued to one warrant holder executed at a reduced price of $9.38 per share		125,000	'	133	124,867	'
Shares issued to one warrant holder executed at a reduced price of $9.38 per share (in shares)		'	'	13,333	'	'
Vesting expense		1,505,270	'	0	1,505,270	'
Shares issued for option exercise at $5.25 per share		1,190	'	2	1,188	'
Shares issued for option exercise at $5.25 per share (in shares)		'	'	227	'	'
Shares issued for cashless warrant exercise at $5.63 per share		1,167	'	16	1,151	'
Shares issued for cashless warrant exercise at $5.63 per share (in shares)		'	'	1,556	'	'
Net loss		-9,406,304	'	'	'	-9,406,304
Balance at Dec. 31, 2013		-3,218,453	'	29,325	25,449,636	-28,697,415
Balance (in shares) at Dec. 31, 2013		'	'	2,932,501	'	'
Value of equity instruments issued with debt		313,175	'	'	313,175	'
Shares issued for cashless warrant exercise at $15.00 per share		1,296	'	17	1,279	'
Shares issued for cashless warrant exercise at $15.00 per share (in shares)		'	'	1,728	'	'
Shares issued for option exercise at $1.25 per share		5,430	'	43	5,387	'
Shares issued for option exercise at $1.25 per share (in shares)		'	'	4,336	'	'
Shares issued at $20.63 per share as Investor Relations compensation		41,250	'	20	41,230	'
Shares issued at $20.63 per share as Investor Relations compensation (in shares)		'	'	2,000	'	'
Shares issued for cashless warrant exercise at $12.75 per share		2,493	'	33	2,460	'
Shares issued for cashless warrant exercise at $12.75 per share (in shares)		'	'	3,323	'	'
Shares issued for an option exercise at $5.25 per share		1,400	'	3	1,397	'
Shares issued for an option exercise at $5.25 per share (in shares)		'	'	267	'	'
Shares issued for cashless warrant exercise at $.75 per share		1,630	'	22	1,608	'
Shares issued for cashless warrant exercise at $.75 per share (in shares)		'	'	2,174	'	'
Shares issued for warrant exercise at $13.50 per share		36,000	'	27	35,973	'
Shares issued for warrant exercise at $13.50 per share (in shares)		'	'	2,667	'	'
Shares issued at $18.75 per share as Investor Relations compensation		25,000	'	13	24,987	'
Shares issued at $18.75 per share as Investor Relations compensation (in shares)		'	'	1,333	'	'
Reduction in escrow account per settlement agreement		-3,333	'	-44	-3,289	'
Reduction in escrow account per settlement agreement (in shares)		'	'	-4,444	'	'
Shares issued for cashless warrant exercise at $7.50 per share		3,605	'	48	3,557	'
Shares issued for cashless warrant exercise at $7.50 per share (in shares)		'	'	4,807	'	'
Shares issued for cashless warrant exercise at $5.63 per share		2,333	'	31	2,302	'
Shares issued for cashless warrant exercise at $5.63 per share (in shares)		'	'	3,112	'	'
Shares issued for cashless warrant exercise at $12.75 per share		224	'	3	221	'
Shares issued for cashless warrant exercise at $12.75 per share (in shares)		'	'	299	'	'
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $19.50 per share		0	'	10	18,909	-18,919
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $19.50 per share (in shares)		'	'	972	'	'
Vesting expense		422,184	'	'	422,184	'
Options issued as part of employee bonus		694,500	'	'	694,500	'
Shares issued for combined cashless and cash warrant exercise at $11.25 per share.		52,500	'	78	52,422	'
Shares issued for combined cashless and cash warrant exercise at $11.25 per share. (in shares)		'	'	7,778	'	'
Issuance of Preferred stock		2,055,001	206	'	2,054,795	'
Shares issued to Investor Relations consultant exercisable at $11.25 per share		24,000	'	21	23,979	'
Shares issued to Investor Relations consultant exercisable at $11.25 per share (in shares)		'	'	2,133	'	'
Shares issued to Investor Relations consultant exercisable at $18.75 per share		25,000	'	13	24,987	'
Shares issued to Investor Relations consultant exercisable at $18.75 per share (in shares)		'	'	1,333	'	'
Shares issued for cashless warrant exercise at $13.50 per share		2,794	'	37	2,757	'
Shares issued for cashless warrant exercise at $13.50 per share (in shares)		'	'	3,725	'	'
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $19.50 per share		0	'	16	30,384	-30,400
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $19.50 per share (in shares)		'	'	1,561	'	'
Shares issued for cashless warrant exercise at $9.75 per share		1,058	'	14	1,044	'
Shares issued for cashless warrant exercise at $9.75 per share (in shares)		'	'	1,410	'	'
Shares issued for a cash warrant exercise at $5.63 per share		62,500	'	111	62,389	'
Shares issued for a cash warrant exercise at $5.63 per share (in shares)		'	'	11,111	'	'
Shares issued for an option exercise at $5.25 per share		1,750	'	3	1,747	'
Shares issued for an option exercise at $5.25 per share (in shares)		'	'	333	'	'
Shares issued for a note conversion at $6.68 per share		20,000	'	30	19,970	'
Shares issued for a note conversion at $6.68 per share (in shares)		'	'	3,018	'	'
Shares issued for a note conversion at $6.68 per share		20,000	'	30	19,970	'
Shares issued for a note conversion at $6.68 per share (in shares)		'	'	3,019	'	'
Shares issued for a note conversion at $5.85 per share		20,000	'	34	19,966	'
Shares issued for a note conversion at $5.85 per share (in shares)		'	'	3,435	'	'
Shares issued for a note conversion at $5.03 per share		20,000	'	38	19,961	'
Shares issued for a note conversion at $5.03 per share (in shares)		'	'	3,894	'	'
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $19.50 per share		0	'	16	30,386	-30,401
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $19.50 per share (in shares)		'	'	1,561	'	'
Net loss		-4,468,170	'	'	'	-4,468,170
Balance at Sep. 30, 2014		($3,834,833)	$206	$29,993	$29,380,273	($33,245,305)
Balance (in shares) at Sep. 30, 2014		'	'	2,999,386	'	'

[1]	Founders shares,1,000,000 per split.
[2]	23,492 (40,000 pre-split) shares valued at $.0167 per share as compensation for loan guarantees by management
[3]	Investment including 670 shares issued as a 10% finderâ€™s fee
[4]	For payment of patent legal fees
[5]	Compensation for loan guarantees by management
[6]	For vendor contractual consideration
[7]	Employment agreements
[8]	Investment
[9]	Conversion of convertible notes by management
[10]	Investment, "October 2008 financing"
[11]	The shares reduce by 1/3 yearly and are returned to the Company as the debt is paid.
[12]	The Company purchased shares previously issued to a former officer equal to the cost of withholding taxes advanced by the Company. The value here represents the net pay from the transaction that was retained by the Company.

STATEMENTS_OF_STOCKHOLDERS_DEF1

STATEMENTS OF STOCKHOLDERS' DEFICIT [Parenthetical] (USD $)

9 Months Ended

12 Months Ended

Dec. 31, 2002

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2006

Dec. 31, 2005

Dec. 31, 2004

Dec. 31, 2003

Issuance of common stock to Founders , par value

$1.25

Issuance of common stock new issues, par value

$125.25

$26.25

Issuance of common stock, compensation for loan guarantees by management, par value

$1.25

Issuance of common stock, investment including finders fee, par value

$125.25

Issuance of common stock, payment of patent legal fees, par value

$1.25

Issuance of common stock, vendor contractual consideration, par value

$1.25

Issuance of common stock, employment agreements, par value

$1.25

Issuance of common stock, investment, par value

$125.25

Issuance of common stock, conversion of convertible securities, par value

$26.25

$125.25

Issuance of common stock, investor relations, par value

$26.25

Issuance of common stock, under PMM in 2009

$37.50

Issuance of common stock upon conversion of debt and interest, par value

$20.25

Issuance of common stock, under PPM in March 2010, par value

$37.50

Issuance of common stock to consultants for IR and consulting, par value

$37.50

Issuance of common stock to consultants, in May 2010, par value

$37.50

Issuance of common stock, under PPM in April 2010, par value

$37.50

Issuance of common stock, under PPM in September 2010, par value

$7.50

Issuance of common stock to consultants, in third quarter, par value

$16.50

Issuance of common stock, upon exercise of warrants

$10.13

Issuance of common stock, to directors as compensation

$6.75

$11.25

Issuance of common stock, under PPM one in first quarter

$5.63

Issuance of common stock, under PPM two in first quarter

$6.38

Issuance of common stock, under PPM three in first quarter

$6.75

Issuance of common stock, under PPM four in first quarter

$7.50

Issuance of common stock, under PPM two in second quarter

$5.25

Issuance of common stock, under PPM one in third quarter

$4.50

Issuance of common stock, under PPM three in third quarter

$15

Issuance of common stock, under exercise of stock options

$0.75

Issuance of common stock, under IR compensation

$11.25

$26.25

Issuance of common stock, to private investor in fourth quarter

$11.25

Issuance of common stock to institutional investor upon conversion of Note Payable one

$10.07

Issuance of common stock to institutional investor upon conversion of Note Payable two

$9.75

Issuance of common stock to institutional investor upon conversion of Note Payable three

$6.60

Issuance of common stock to institutional investor upon conversion of Note Payable four

$3.35

Issuance of common stock to institutional investor upon conversion of Note Payable five

$3.35

Issuance of common stock to institutional investor upon conversion of Note Payable six

$3.35

Issuance of common stock to institutional investor upon conversion of Note Payable seven

$2.98

Issuance of common stock to a private investor in the first quarter

$4.88

Issuance of common stock to the now Interim CEO in the first quarter for consulting

$4.88

Issuance of common stock to institutional investor upon conversion of Note Payable Eight

$2.15

Issuance of common stock to private investor upon conversion of Note Payable one

$11.25

Issuance of common stock to a private investor in the second quarter one

$11.25

Shares issued upon exercise of options

$0.75

Issuance of common stock, conversion of debt, par value one

$11.25

Issuance of common stock, conversion of debt, par value two

$11.25

Issuance of common stock to private investor upon conversion of Note Payable two

$13.50

Issuance of common stock to private investor upon conversion of Note Payable three

$3.90

Issuance of common stock to private investor upon conversion of Note Payable four

$7.50

Issuance of common stock to private investor upon conversion of Note Payable five

$2.40

Issuance of common stock to institutional investor upon conversion of Note Payable Nine

$2.33

Issuance of common stock, conversion of debt, par value three

$11.25

Issuance of common stock, under PPM one in second quarter

$5.25

Issuance of common stock to institutional investor upon conversion of Note Payable Ten

$2.65

Issuance of common stock to private investor upon conversion of Note Payable six

$2.40

Issuance of common stock to institutional investor upon conversion of Note Payable Eleven

$2.23

Shares issued as settlement to remove anti-dilution agreement

$4.88

Shares issued in settlement with former COO

$11.25

Issuance of common stock to debtors compensation

$7.50

Issuance of common stock to conversion of note payable

$5.25

Issuance Of Common Stock To Debtors Compensation One

$11.25

Shares issued under PPM to five investors

$5.25

Issuance Of Common Stock To Debtors Compensation Two

$11.25

Shares issued to an institutional investor at per share

$5.25

Issuance Of Common Stock To Debtors Compensation Three

$5.03

Common stock issued to former consultant exercising option, Par value

$0.75

Common stock issued to former CEO exercising option, par value

$0.75

Shares issued upon conversion of four notes payable, par value

$11.25

Shares issued for interest to the four notes payable, par value

$11.25

Shares Issued For Cashless Exercise Of Warrants Par Value One

$15

Shares Issued For Cashless Exercise Of Warrants Par Value Two

$12.75

$12

Shares Issued For Cashless Exercise Of Warrants Par Value Three

$0.75

$11.25

Shares Issued For Cashless Exercise Of Warrants Par Value Four

$7.50

$15

Shares Issued To Twenty Four Warrant Holders Exercised At Reduced Par Value

$7.50

Shares Issued To Four PPM Investors Converting Notes Par Value

Shares Issued To Ten PPM Investors Converting Notes Par Value

$13.50

Shares Issued To Consultant As Compensation Par Value

$28.50

Shares Issued For Two Note Conversions Par Value

$1.05

Shares Issued For Exercise Of Warrants Par Value

$13.50

$11.25

Shares Issued To Cashless Exercise Of Warrants Par Value

$12.75

Shares Issued To Former Board Directors As Compensation Par Value

$24.38

Shares Issued To One Investor For Cashless Exercise Of Warrants Par Value Two

Shares Issued For Cashless Exercise Of Warrants Par Value Five

$5.63

$7.50

Shares Issued For Interest On Conversion Of Two Note Conversions Par Value

$13.50

Shares Issued For Cashless Exercise Of Warrants Par Value Six

$12.75

$5.63

Shares Issued In Settlement With Former Noteholder Par Value

$20.25

Shares Issued To Option Holder Par Value One

$1.25

$4.88

Shares Issued For Cashless Exercise Of Warrants Par Value Seven

$13.50

$9.75

Shares Issued To One Warrant Holder Exercised At Reduced Par Value

$9.38

Shares Issued For Cashless Exercise Of Warrants Par Value Eight

$9.75

$5.63

Shares Issued To Option Holder Par Value Two

$5.25

Par Value Of Cancelled Shares, Issued In settlement With Former COO

$6.75

Par Value Of Common Stock Issued For Investor Relations Compensation One

$20.63

$5.25

Par Value Of Common Stock Issued For Investor Relations Compensation Two

$18.75

Shares Issued To Sixteen Shareholders Of Series A Convertible Preferred Stock Dividends Payable In Common Shares Par Value

$19.50

Shares Issued For Cashless And Cash Exercise Of Warrants Par Value

$11.25

Stock Issued To Investor Relations Consultants Exercise Price One

$11.25

Stock Issued To Investor Relations Consultants Exercise Price Two

$18.75

Shares Issued To Sixteen Shareholders Of Series Convertible Preferred Stock Dividends Payable In Common Shares Par Value One

$19.50

Shares Issued For Cash Exercise Of Warrants Par Value

$5.63

Shares Issued To Option Holder Par Value Three

$5.25

Shares Issued For Note Conversion Par Value One

$6.68

Shares Issued For Note Conversion Par Value Two

$6.68

Shares Issued For Note Conversion Par Value Three

$5.85

Shares Issued For Note Conversion Par Value Four

$5.03

Shares Issued To Sixteen Shareholders Of Series Convertible Preferred Stock Dividends Payable In Common Shares Par Value Two

$19.50

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended		12 Months Ended		140 Months Ended
CONDENSED STATEMENTS OF CASH FLOWS (USD $)	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Cash flow from operating activities:	'	'	'	'	'
Net loss	($4,468,170)	($7,251,965)	($9,406,304)	($7,422,155)	($28,697,415)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'	'	'
Depreciation and amortization	44,118	156,409	148,761	1,079	159,405
Vested stock options and warrants	440,117	3,791,802	3,700,070	830,372	7,197,742
Equity instruments issued for management and consulting	111,917	137,230	239,290	3,919,828	6,029,058
Stock-based registration payments	'	'	0	0	355,124
Capital contributions resulting from waivers of debt	'	'	0	0	476,398
Amortization of debt discount	87,853	413,695	413,695	57,518	756,497
(Gain) loss on valuation of equity-linked instruments	-11,599	-153,960	-157,580	3,116	-785,650
Changes in assets and liabilities:	'	'	'	'	'
Accounts receivable	-141,359	-43,480	-57,534	10,583	-97,245
Inventories	-193,445	44,142	23,034	-47,604	-122,175
Prepaid expense and other assets	-88,362	-7,053	-33,179	2,739	-60,588
Notes payable to shareholders	'	'	0	0	-14,957
Accounts payable	515,710	3,012	429,033	421,104	2,147,872
Accrued expenses	624,530	-430,998	776,548	1,039,255	2,494,237
Deferred Revenue	-64,000	5,000	69,000	0	69,000
Net cash used in operating activities:	-3,142,690	-3,336,166	-3,855,166	-1,184,165	-10,092,697
Cash flow from investing activities:	'	'	'	'	'
Purchase of fixed assets	-102,954	-49,791	-162,761	0	-175,019
Purchase of intangibles	-19,346	-52,074	-53,355	0	-195,850
Net cash used in investing activities	-122,300	-101,865	-216,116	0	-370,869
Cash flow from financing activities:	'	'	'	'	'
Proceeds from long-term and convertible debt	1,500,000	1,542,718	1,822,718	528,525	3,935,209
Repayment of convertible debt	0	0	0	-150,000	-250,000
Principal payments on debt	-305,000	0	0	0	-75,667
Issuance of preferred stock	2,055,000	0	'	'	'
Issuance of common stock	157,081	2,210,536	2,337,378	695,794	6,955,977
Net cash provided by (used in) financing activities	3,407,081	3,753,254	4,160,096	1,074,319	10,565,519
Net increase (decrease) in cash	142,091	315,223	88,814	-109,846	101,953
Cash at beginning of period	101,953	13,139	13,139	122,985	0
Cash at end of period	244,044	328,362	101,953	13,139	101,953
Non cash transactions:	'	'	'	'	'
Conversion of debt to accrued liabilities	0	415,775	415,775	100,000	515,775
Common stock issued for accrued interest/bonus	694,500	395,304	402,669	106,310	620,839
Conversion of accounts payable to convertible debt	'	'	0	0	546,600
Common stock issued to satisfy debt	80,000	2,318,568	2,318,568	817,800	3,538,935
Stock/warrant issued to satisfy accounts payable/Liabilities	$0	$100,521	$100,521	$418,644	$539,165

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

12 Months Ended

Sep. 30, 2014

Dec. 31, 2013

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations and Continuance of Operations

BioDrain Medical, Inc. (the “Company”) was incorporated under the laws of the State of Minnesota in 2002. Effective August 6, 2013, the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger dated effective December 16, 2013, the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of our proprietary cleaning fluid and filters to users of our systems. In April 2009, the Company received 510(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY FMS products.

Skyline Medical, Inc. (the “Company”) was incorporated under the laws of the State of Minnesota in 2002. Effective August 6, 2013, the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger dated effective December 16, 2013, the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of our proprietary cleaning fluid and filters to users of our systems. In April 2009, the Company received 510(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY FMS products.

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and has a stockholders’ deficit. These factors raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Since inception to September 30, 2014, the Company has raised approximately $9,248,000 in equity, inclusive of $2,055,000 from a private placement of Series A Convertible Preferred Stock, and $5,518,000 in debt financing. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources”.

Since inception to December 31, 2013, the Company raised approximately $6,956,000 in equity and $3,935,000 in debt financing, including $2,337,000 in equity and $1,823,000 in convertible debt in 2013. In 2014, the Company has completed a private offering of units of preferred stock and warrants. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources”.

Recent Accounting Developments

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers and created a new topic in the FASB Accounting Standards Codification (“ASC”), Topic 606. The new standard provides a single comprehensive revenue recognition framework for all entities and supersedes nearly all existing U.S. GAAP revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue in a manner that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and also requires enhanced disclosures. The amendments are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. We are currently evaluating the impact this guidance may have on our financial statements and related disclosures.

We reviewed all significant newly issued accounting pronouncements and determined they are either not applicable to our business or that no material effect is expected on our financial position and results of our operations.

In June 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders' equity. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. The Company evaluated and adopted ASU 2014-10 for the reporting period ended September 30, 2014.

Valuation of Intangible Assets

In June 2014, the FASB issued ASU 2014-12, “Compensation — Stock Compensation” providing explicit guidance on how to account for share-based payments granted to employees in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. We are currently evaluating the impact this guidance may have on our financial statements.

We review identifiable intangible assets for impairment in accordance with ASC 350 — Intangibles — Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which we operate. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management's best estimate of the related risks and return at the time the impairment assessment is made.

We reviewed all other significant newly issued accounting pronouncements and determined they are either not applicable to our business or that no material effect is expected on our financial position and results of our operations.

Our accounting estimates and assumptions bear various risks of change, including the length of the current economic downturn facing the United States, the expansion of the slowdown in consumer spending in the U.S. medical markets despite the early expressed opinions of financial experts that the medical market would not be as affected as other markets and failure to gain acceptance in the medical market.

Valuation of Intangible Assets

Accounting Policies and Estimates

We review identifiable intangible assets for impairment in accordance with ASC 350- Intangibles — Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which we operate. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management's best estimate of the related risks and return at the time the impairment assessment is made.

The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Presentation of Taxes Collected from Customers

Accounting Policies and Estimates

Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses.

Shipping and Handling

Presentation of Taxes Collected from Customers

Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations.

Advertising

Shipping and Handling

Advertising costs are expensed as incurred. There were no advertising expenses for 2013 and 2012.

Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations.

Research and Development

Advertising

Research and development costs are charged to operations as incurred. Research and development costs were approximately $235,000 and $15,000 for 2013 and 2012, respectively.

Advertising costs are expensed as incurred. Advertising expenses were $4,201 and $11,994 in the three and nine months ended September 30, 2014 and there were no advertising expenses in the three and nine months ended September 30, 2013.

Revenue Recognition

Research and Development

The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Topic 13 Revenue Recognition and ASC 605 — Revenue Recognition.

Research and development costs are charged to operations as incurred. Research and development expenses were $72,294 and $321,929 in the three and nine months ended September 30, 2014 and $73,621 and $207,162 for September 30, 2013.

Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company’s standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY FMS units as well as shipments of cleaning solution and filters. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company’s standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer’s right of return is limited only to the Company’s standard one-year warranty whereby the Company replaces or repairs, at its option, and it would be rare that the STREAMWAY FMS unit or significant quantities of cleaning solution and filters may be returned. Additionally, since the Company buys the STREAMWAY FMS units, cleaning solution and filters from “turnkey” suppliers, the Company would have the right to replacements from the suppliers if this situation should occur.

Revenue Recognition

Receivables

The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Topic 13 Revenue Recognition and ASC 605 — Revenue Recognition.

Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not been material to the financial statements.

Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company’s standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY FMS units as well as shipments of cleaning solution kits. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company’s standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer’s right of return is limited only to the Company’s standard one-year warranty whereby the Company replaces or repairs, at its option, and it would be rare that the STREAMWAY FMS unit or significant quantities of cleaning solution kits may be returned. Additionally, since the Company buys both the STREAMWAY FMS units and cleaning solution kits from “turnkey” suppliers, the Company would have the right to replacements from the suppliers if this situation should occur.

Inventories

Receivables

Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows:

Inventories

Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows:

December 31,

2013

2012

Finished goods

56,818

91,008

September 30,

December 31,

Raw materials

18,603

39,543

2014

2013

Work-In-Process

46,754

14,658

Finished goods

69,331

56,818

Total

122,175

145,209

Raw materials

207,928

18,603

Property and Equipment

Work-In-Process

38,361

46,754

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows:

Total

315,620

122,175

Property and Equipment

Years

Computers and office equipment

3 – 7

Leasehold improvements

Years

Manufacturing Tooling

3 – 7

Computers and office equipment

3 – 7

The Company’s investment in Fixed Assets consists of the following:

Leasehold improvements

Manufacturing tooling

3 – 7

Demo Equipment

December 31,

31-Dec-12

The Company’s investment in Fixed Assets consists of the following:

2013

Computers and office equipment

61,505

12,258

Leasehold Improvements

23,614

September 30,

December 31,

Manufacturing Tooling

89,900

2014

2013

Total

175,019

12,258

Computers and office equipment

126,234

61,505

Less: Accumulated Depreciation

16,909

8,737

Leasehold improvements

23,874

23,614

Total Fixed Assets, Net

158,110

3,521

Manufacturing tooling

97,288

89,900

Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.

Demo Equipment

30,577

—

Intangible Assets

Total

277,973

175,019

Intangible assets consist of trademarks and patent costs. These assets are not subject to amortization until the property patented is in production. The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified. The Company wrote-off the entire original STREAMWAY System patent of $140,588 in 2013.

Less: Accumulated depreciation

61,027

16,909

Income Taxes

Total Fixed Assets, Net

216,946

158,110

The Company accounts for income taxes in accordance with ASC 740 — Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.

The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties.

Intangible Assets

Tax years subsequent to 2010 remain open to examination by federal and state tax authorities.

Patents and Intellectual Property

Income Taxes

On January 25th, 2014 the Company filed a non-provisional PCT Application No. PCT/US2014/013081 claiming priority from the U.S. Provisional Patent Application, number 61756763 which was filed one year earlier on January 25th, 2013. The Patent Cooperation Treaty (“PCT”) allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the 148 countries of the PCT, including the United States. By filing this single “international” patent application through the PCT, it is easier and more cost effective than filing separate applications directly with each national or regional patent office in which patent protection is desired.

The Company accounts for income taxes in accordance with ASC 740 — Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.

Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid.

The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 and US Publication No. US20090216205 (collectively, the “Patents”). These Patents will begin to expire on August 8, 2023.

Tax years subsequent to 2010 remain open to examination by federal and state tax authorities.

Subsequent Events

Patents and Intellectual Property

Sale of Convertible Preferred Stock and Warrants. In February 2014, we raised $2,055,000 less offering expenses from a private place of convertible preferred stock. As of February 4, 2014, Skyline Medical Inc. (the “Company”) entered into a Securities Purchase Agreement with certain investors (the “Purchasers”) pursuant to which the Company agreed to offer and sell 20,550 shares of Series A Convertible Preferred Stock, par value $0.01 (the “Preferred Shares”), and warrants (the “Warrants”) to acquire an aggregate of approximately 21,334 shares of the Company’s common stock, par value $0.01 (“Common Stock”). The Preferred Shares are convertible into shares of Common Stock at an initial conversion price of $19.50 per share of Common Stock. The Warrants are exercisable at an exercise price of $24.38 per share and expire five years from the closing date. The Company received gross proceeds of $2,055,000, before offering expenses. The closing of the sale of the Preferred Shares and Warrants (collectively, the “Securities”) occurred as of February 4, 2014 (the “Closing”). If the Company’s Common Stock is not listed on the NASDAQ Stock Market, the New York Stock Exchange, or the NYSE MKT within 180 days of the Closing, the Company shall issue additional Warrants to purchase additional shares of Common Stock, equal to 30% of the shares of Common Stock which the Preferred Shares purchased by each Purchaser purchased are convertible.

The Securities Purchase Agreement requires the Company to register the resale of the shares of Common Stock underlying the Preferred Shares (the “Underlying Shares”) and the Common Stock underlying the Warrants (the “Warrant Shares”). The Company is required to prepare and file a registration statement with the Securities and Exchange Commission within 90 days of the closing of the offering, and to use commercially reasonable efforts to have the registration statement declared effective within 105 days if there is no review by the Securities and Exchange Commission, and within 150 days in the event of such review.

The Securities were offered and sold without registration under the Securities Act of 1933, as amended (the “Securities Act”), or state securities laws, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder. The Securities may not be offered or sold in the United States without an effective registration statement or pursuant to an exemption from applicable registration requirements.

The Preferred Shares are convertible at the option of the holder into the number of shares of Common Stock determined by dividing the stated value of the Preferred Shares being converted by the conversion price of $19.50, subject to adjustment for stock splits, reverse stock splits and similar recapitalization events. If the Company issues additional shares of Common Stock, other than certain stock that is excluded under the terms of the Securities Purchase Agreement, in one or more capital raising transactions with an aggregate purchase price of at least $100,000 for a price less than the then existing conversion price for the Preferred Shares (the “New Issuance Price”), then the then existing conversion price shall be reduced to the New Issuance Price, provided, however, that under no circumstances shall the New Issuance Price be less than $9.75 or reduced to a price level that would be in breach of the listing rules of any stock exchange or that would have material adverse effect on the Corporation’s ability to list its Common Stock on a stock exchange, including but not limited to the change of accounting treatment of the Preferred Stock. The Preferred Shares contain certain limitations on conversion so that the holder will not own more than 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of Preferred Shares held by the applicable holder, with the percentage subject to increase in certain circumstances. The Preferred Shares are eligible to vote with the Common Stock on an as-converted basis, but only to the extent that the Preferred Shares are eligible for conversion without exceeding the Beneficial Ownership Limitation. The Preferred Shares are entitled to receive dividends on a pari passu basis with the Common Stock, when, and if declared. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary (a “Liquidation”), after the satisfaction in full of the debts of the Company and the payment of any liquidation preference owed to the holders of shares of Common Stock ranking prior to the Preferred Shares upon liquidation, the holders of the Preferred Shares shall receive, prior and in preference to the holders of any junior securities, an amount equal to $2,055,000 times 1.2, plus all declared but unpaid dividends.

Subsequent Events

The Warrants are exercisable on any day on or after the date of issuance, have an exercise price of $19.50 per share, subject to adjustment, and a term of five years from the date they are first exercisable. However, a holder will be prohibited from exercising a Warrant if, as a result of such exercise, the holder, together with its affiliates, would exceed the Beneficial Ownership Limitation as described above for the Preferred Shares. If any Warrant has not been fully exercised prior to the first anniversary of the Closing and if during such period the Company has not installed or received firm purchase orders (accepted by the Company) for at least 500 STREAMWAY Automated Surgical Fluid Disposal Systems, then, the number of Common Stock for which such Warrant may be exercised shall be increased 2.5 times.

The Company filed a Certificate of Amendment effecting a 1:75 reverse stock split (the “Reverse Stock Split”) with the Secretary of State of the State of Delaware, which became effective under Delaware law as of October 24, 2014. At the effective time (the “Effective Time”) of the Reverse Stock Split, the issued and outstanding Common Stock of the Company was combined on a 1-for-75 basis such that every seventy-five shares of Common Stock outstanding immediately prior to the Effective Time was combined into one share of Common Stock. This share combination was effected through the exchange and replacement of certificates representing issued and outstanding shares of Common Stock as of the Effective Time, together with immediate book-entry adjustments to the stock register of the Company maintained in accordance with the Delaware General Corporation Law. In the event that the share combination would have resulted in a shareholder being entitled to receive less than a full share of Common Stock, the fractional share that would so result was rounded up to the nearest whole share of Common Stock. The par value of each share of issued and outstanding Common Stock was not affected by the share combination.

Settlement with Group of Warrantholders. In September 2013, the Company received a request to issue 66,585 shares of its common stock to a group of partnerships and individuals in connection with the cashless exercise of stock purchase warrants covering a total of 82,459 shares. In processing the exercise, the Company commenced an internal investigation regarding the warrants and withheld delivery of the certificates for a substantial majority of the shares, pending the outcome of the investigation.

For purposes of trading of the common stock, the Reverse Stock Split was approved, by FINRA and became effective as of market open on October 28, 2014.

After investigation, the Company disagreed with the group’s position that all of such shares should be delivered in connection with the exercise. Following negotiations, effective March 3, 2014, the Company and the group entered into a settlement agreement that resulted in, among other things, a net reduction of 16,867 shares. This reduction is reflected as outstanding on the balance sheet as of December 31, 2013.

In the Condensed Financial Statement and Notes thereto, and elsewhere in this Report, all numbers of shares and per share amounts, as appropriate, have been restated to reflect the Reverse Stock Split.

In September 2014 we filed a registration statement for the public offering of shares of our common stock and five-year warrants to purchase shares of common stock at an exercise price equal to 125% of the offering price per share of the common stock. We have applied to list our common stock on the NASDAQ Capital Market effective upon the completion of the public offering.

Interim Financial Statements

The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly the Company’s financial position, the results of its operations and its cash flows for the interim periods. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form 10-K filed with the SEC on March 27, 2014. The nature of the Company’s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.

DEVELOPMENT_STAGE_OPERATIONS

DEVELOPMENT STAGE OPERATIONS	9 Months Ended	12 Months Ended
DEVELOPMENT STAGE OPERATIONS	Sep. 30, 2013	Dec. 31, 2013
Development Stage Enterprises [Abstract]	'	'
Development Stage Enterprise General Disclosures [Text Block]	'	'
	NOTE 2 — DEVELOPMENT STAGE OPERATIONS	NOTE 2 — DEVELOPMENT STAGE OPERATIONS
	The Company was formed April 23, 2002. Since inception to November 3, 2014, 3,021,831 shares of common stock have been issued between par value and $125.00 (post reverse split). Operations since incorporation have been devoted to raising capital, obtaining financing, development of the Company’s product, and administrative services.	The Company was formed April 23, 2002. Since inception through December 31, 2013, 2,932,501 shares of common stock have been issued between par value and $125.25. Operations since incorporation have primarily been devoted to raising capital, obtaining financing, development of the Company’s product, administrative services, customer acceptance and sales and marketing strategies.

STOCKHOLDERS_DEFICIT_STOCK_OPT

STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS	9 Months Ended														12 Months Ended
STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS	Sep. 30, 2014														Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'														'
Stockholders' Equity Note Disclosure [Text Block]	'														'
	NOTE 3 — STOCKHOLDERS’ DEFICIT, STOCK OPTIONS AND WARRANTS														NOTE 3 — STOCKHOLDERS’ DEFICIT, STOCK OPTIONS AND WARRANTS
	The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three years. Options under this plan have terms ranging from three to ten years.														In connection with the financing completed in October 2008, the Company has effected two reverse stock splits, one on June 6, 2008 and another on October 20, 2008. In accordance with SAB Topic 4C, all stock options and warrants and their related exercise prices are stated at their post-reverse stock split values.
	On February 4, 2014, (the “Closing Date”) we raised $2,055,000 in gross proceeds from a private placement of Series A Convertible Preferred Stock, par value $0.01 (the “Preferred Shares”) pursuant to a Securities Purchase Agreement with certain investors (the “Purchasers”) purchased 20,550 Preferred Shares, and warrants (the “Warrants”) to acquire an aggregate of approximately 21,334 shares of Common Stock. The Preferred Shares are convertible into shares of Common Stock at an initial conversion price of $19.50 per share of Common Stock. The Warrants are exercisable at an exercise price of $24.38 per share and expire five years from the Closing Date. If the Common Stock is not listed on the NASDAQ Stock Market, the New York Stock Exchange, or the NYSE MKT within 180 days of the Closing, the Company was required to issue additional Warrants to purchase additional shares of Common Stock, equal to 30% of the shares of Common Stock which the Preferred Shares each Purchaser purchased are convertible into. As of August 4, 2014, the Company issued additional warrants to purchase 61,539 shares to the Purchasers in connection with this provision.														The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three years. Options under this plan have terms ranging from three to ten years.
	The Securities Purchase Agreement requires the Company to register the resale of the shares of Common Stock underlying the Preferred Shares (the “Underlying Shares”) and the Common Stock underlying the Warrants (the “Warrant Shares”). On September 9, 2014, a resale registration statement covering the Underlying Shares, the Warrant Shares and certain other securities (the “Resale Registration Statement”) was declared effective.														Accounting for share-based payment
	The Preferred Shares are convertible at the option of the holder into the number of shares of Common Stock determined by dividing the stated value of the Preferred Shares being converted by the conversion price of $19.50, subject to adjustment for stock splits, reverse stock splits and similar recapitalization events. If the Company issues additional shares of Common Stock, other than certain stock that is excluded under the terms of the Securities Purchase Agreement, in one or more capital raising transactions with an aggregate purchase price of at least $100,000 for a price less than the then existing conversion price for the Preferred Shares (the “New Issuance Price”), then the then existing conversion price shall be reduced to the New Issuance Price, provided, however, that under no circumstances shall the New Issuance Price be less than $9.75 or reduced to a price level that would be in breach of the listing rules of any stock exchange or that would have material adverse effect on the Company’s ability to list its Common Stock on a stock exchange, including but not limited to the change of accounting treatment of the Preferred Stock. In July 2014, in connection with the issuance of certain convertible notes, the conversion price of the Preferred Stock was adjusted to $9.75 per share. Further, the Company has agreed to additional shares of Common Stock to holders of the Preferred Stock in certain circumstances, as described in the following paragraph. The Preferred Shares contain certain limitations on conversion so that the holder will not own more than 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of Preferred Shares held by the applicable holder, with the percentage subject to increase in certain circumstances. The Preferred Shares are eligible to vote with the Common Stock on an as-converted basis, but only to the extent that the Preferred Shares are eligible for conversion without exceeding the Beneficial Ownership Limitation. The Preferred Shares are entitled to receive dividends on a pari passu basis with the Common Stock, when, and if declared. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary (a “Liquidation”), after the satisfaction in full of the debts of the Company and the payment of any liquidation preference owed to the holders of shares of Common Stock ranking prior to the Preferred Shares upon liquidation, the holders of the Preferred Shares shall receive, prior and in preference to the holders of any junior securities, an amount equal to $2,055,000 times 1.2, plus all declared but unpaid dividends.														The Company has adopted ASC 718 — Compensation — Stock Compensation (“ASC 718”). Under ASC 718 stock-based employee compensation cost is recognized using the fair value based method for all new awards granted after January 1, 2006 and unvested awards outstanding at January 1, 2006. Compensation costs for unvested stock options and non-vested awards that were outstanding at January 1, 2006, are being recognized over the requisite service period based on the grant-date fair value of those options and awards, using a straight-line method. We elected the modified-prospective method under which prior periods are not retroactively restated.
	In July 2014, in connection with the offering of convertible notes and warrants and in connection with the waiver of certain rights, the Company agreed to issue additional shares of Common Stock to the Preferred Stockholders (the “Additional Shares”) (A) automatically upon the closing of a Qualified Public Offering (as defined in the Certificate of Designation), to the extent that (i) the Qualified Public Offering closes within six (6) months of the first closing of the convertible notes offering (“Qualified Public Offering Deadline”) and (ii) 70% of the public offering price per share of the Common Stock in the Qualified Public Offering (the “QPO Discount Price”) is less than the Conversion Price floor contained in Section 7(e)(i) of the Certificate of Designation (the “Conversion Price Floor”), or (B) if a Qualified Public Offering has not been consummated by the Qualified Public Offering Deadline, upon the Preferred Stockholders’ conversion of their shares of Preferred Stock to the extent that 70% of the volume weighted average price of the Common Stock on the principal Trading Market (as defined in the Certificate of Designation) of the Common Stock during the ten Trading Days (as defined in the Certificate of Designation) immediately preceding the Qualified Public Offering Deadline (the “Non-QPO Discount Price”) is less than the Conversion Price Floor.														ASC 718 requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model or other acceptable means. The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future.
	The Warrants are exercisable on any day on or after the date of issuance, have an exercise price of $24.38 per share, subject to adjustment, and a term of five years from the date they are first exercisable. However, a holder will be prohibited from exercising a Warrant if, as a result of such exercise, the holder, together with its affiliates, would exceed the Beneficial Ownership Limitation as described above for the Preferred Shares. If any Warrant has not been fully exercised prior to the first anniversary of the Closing and if during such period the Company has not installed or received firm purchase orders (accepted by the Company) for at least 500 STREAMWAY® Automated Surgical Fluid Disposal Systems, then, the number of shares of Common Stock for which such Warrant may be exercised shall be increased 2.5 times.														Since the Company's common stock has no significant public trading history, and the Company has experienced no significant option exercises in its history, the Company is required to take an alternative approach to estimating future volatility and estimated life and the future results could vary significantly from the Company's estimates. The Company compiled historical volatilities over a period of 2 to 7 years of 15 small-cap medical companies traded on major exchanges and 10 mid-range medical companies on the OTC Bulletin Board and combined the results using a weighted average approach. In the case of ordinary options to employees the Company determined the expected life to be the midpoint between the vesting term and the legal term. In the case of options or warrants granted to non-employees, the Company estimated the life to be the legal term unless there was a compelling reason to make it shorter.
	In addition, in July, August and September 2014, the Company issued 71,257 warrants to investors in convertible notes as further described below.														When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized.
	Accounting for share-based payment														Since the Company has limited trading history in its stock and no first-hand experience with how its investors and consultants have acted in similar circumstances, the assumptions the Company uses in calculating the fair value of stock-based payment awards represent its best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based consulting and interest expense could be materially different in the future.
	The Company has adopted ASC 718- Compensation-Stock Compensation (“ASC 718”). Under ASC 718 stock-based employee compensation cost is recognized using the fair value based method for all new awards granted after January 1, 2006 and unvested awards outstanding at January 1, 2006. Compensation costs for unvested stock options and non-vested awards that were outstanding at January 1, 2006, are being recognized over the requisite service period based on the grant-date fair value of those options and awards, using a straight-line method. We elected the modified-prospective method under which prior periods are not retroactively restated.														Valuation and accounting for options and warrants
	ASC 718 requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model or other acceptable means. The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future.														The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. For grants issued during 2008, the Company used a 2.0 to 4.5% risk-free interest rate, 0% dividend rate, 53 – 66% volatility and estimated term of 2.5 to 7.5 years. Values computed using these assumptions ranged from $7.65 per share to $25.20 per share. Warrants or options awarded for services rendered are expensed over the period of service (normally the vesting period) as compensation expense for employees or an appropriate consulting expense category for awards to consultants and directors. Warrants granted in connection with a common equity financing are included in stockholders’ equity, provided that there is no re-pricing provision that requires them to be treated as a liability (See Note 8) and warrants granted in connection with a debt financing are treated as a debt discount and amortized using the interest method as interest expense over the term of the debt.
	Since the Company's common stock has no significant public trading history, and the Company has experienced no significant option exercises in its history, the Company is required to take an alternative approach to estimating future volatility and estimated life and the future results could vary significantly from the Company's estimates. The Company compiled historical volatilities over a period of 2 to 7 years of 15 small-cap medical companies traded on major exchanges and 10 mid-range medical companies on the OTC Bulletin Board and combined the results using a weighted average approach. In the case of ordinary options to employees the Company determined the expected life to be the midpoint between the vesting term and the legal term. In the case of options or warrants granted to non-employees, the Company estimated the life to be the legal term unless there was a compelling reason to make it shorter.														Warrants issued in connection with the $100,000 convertible debt that closed March 1, 2007 created a debt discount of $40,242 that was being amortized as additional interest over its 5-year term. Warrants issued in connection with the $170,000 convertible “bridge” debt that closed in July 2007 created a calculated debt discount of $92,700 that was fully expensed over its loan term that matured April 30, 2008.
	When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized.														The Company issued $100,000 in convertible debt in October 2009 and issued a warrant, in connection with the debt, for 2,667 shares of common stock at $48.75 per share. The Company determined that the warrant had an initial value of $30,150 that was treated as a debt discount and amortized as additional interest expense over the 24-month term of the note.
	Since the Company has limited trading history in its stock and no first-hand experience with how its investors and consultants have acted in similar circumstances, the assumptions the Company uses in calculating the fair value of stock-based payment awards represent its best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based consulting and interest expense could be materially different in the future.														The Company also issued $200,000 in convertible debt in June 2010 and issued a warrant, in connection with the debt, to purchase 14,815 shares of common stock at $34.50 per share. The Company determined that the value of the June 2010 warrant was $96,613. This value was treated as a debt discount and amortized as additional interest expense over the 22-month term of the note.
	Valuation and accounting for options and warrants														The Company also issued $32,000 in convertible debt in September 2010 and issued a warrant to purchase 4,267 shares of common stock at $13.50 per share. The Company determined that this warrant had a value of $15,553 that was treated as a debt discount and amortized as additional interest expense over the 18-month term of the note.
	The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term.														The Company also issued $16,800 in convertible debt in December 2010 and issued a warrant to purchase 2,667 shares of common stock at $6.30 per share. The Company determined that this warrant had a value of $7,232 that was treated as a debt discount and amortized as additional interest expense over the 24-month term of the note.
	In January 2013, in connection with a private placement offering we issued 8% convertible one year promissory notes in an aggregate principal amount of $300,000 convertible into 33,333 shares of common stock assuming a conversion rate of $9.00 per share and five year warrants to purchase up to an aggregate of 33,333 shares of the corporation’s common stock at an exercise price of $11.25 per share. The value of the notes are being treated as a debt discount with an aggregate discount of $77,644, and amortized as an additional interest expense over the twelve month term of the notes. In addition, we issued to the placement agent for these sales five year warrants to purchase an aggregate of 2,667 shares of common stock at an exercise price of $9.00 per share.														In January 2011, the Company issued three convertible notes of $50,000 each and also issued warrants to purchase 21,270 common shares at $15.00 per share. The value of the warrants was determined to be $47,908 and was being treated as a debt discount and amortized as additional interest expense over the 24-month term of the notes.
	In January and March 2013, in connection with a separate and new private placement offering we issued 95,238 shares of common stock at $5.25 per share and warrants to purchase 95,238 shares of common stock at $11.25 per share to 5 investors in return for their $500,000 investment in the Company.														For grants of stock options and warrants in 2011 the Company used a 0.34 to 2.44% risk-free interest rate, 0% dividend rate, 54 – 66% volatility and estimated term of 3 to 10 years. Values computed using these assumptions ranged from $0.945 to $25.59 per share.
	On March 15, 2013 the Company completed the private sale of 95,239 shares of the Company’s common stock, par value $.01 per share, at $5.25 per share for an aggregate purchase price of $500,000, warrants to purchase 95,239 shares of common stock at an exercise price of $6.00 per share, and warrants to purchase 47,619 shares of common stock at an exercise price of $11.25 per share.														In November 2012, the Company issued four convertible notes of $27,500, $27,500, $51,243 and $50,000, respectively. The note holders were issued shares of our common stock at $7.50 per share value in consideration for the notes. Though short term the value of the notes are being treated as a debt discount with an aggregate discount of $33,469 and amortized as additional interest expense over the six month term of the notes.
	In April 2013, the Company issued 2,667 shares of common stock, par value $.01 per share, to a former consultant exercising options; the Company issued 4,444 shares of common stock, par value $.01 per share, at $0.75 per share to the former CEO exercising options.														For grants of stock options and warrants in 2012 the Company used a 0.33% to 1.80% risk-free interest rate, 0% dividend rate, 54%, 59% or 66% volatility and estimated terms of 3, 5 or 10 years. Value computed using these assumptions ranged from $0.83 to $7.20 per share.
	In May 2013, the Company converted four (4) notes totaling $156,243, plus $11,169 in interest; issued in November 2012, the noteholders received 14,881 shares of common stock, par value $.01, at $7.50 per share. One of the noteholders was Dr. Samuel Horowitz who received 4,762 shares.														In January 2013, in connection with a private placement offering the Company issued 8% convertible one year promissory notes in an aggregate principal amount of $300,000 convertible into 33,334 shares of common stock assuming a conversion rate of $9.00 per share and five year warrants to purchase up to an aggregate 33,334 shares of the corporation’s common stock at an exercise price of $11.25 per share. The value of the notes were treated as a debt discount with an aggregate discount of $77,644, and amortized as an additional interest expense over the twelve month term of the notes. In addition, we issued to the placement agent for these sales five year warrants to purchase an aggregate of 2,667 shares of common stock at an exercise price of $9.00 per share.
	In May and June 2013 in connection with a private placement offering we issued 8% convertible one year promissory notes in an aggregate principal amount of $1,000,000 convertible into 80,000 shares of common stock assuming a conversion rate of $13.50 per share and five year warrants to purchase up to an aggregate of 61,481 shares of the corporation’s common stock at an exercise price of $14.85 per share. The value of the notes net of discount was $275,640 in 2013; due in May and June 2014. In addition, we issued to the placement agent for these sales five year warrants to purchase an aggregate of 5,926 shares of common stock at an exercise price of $13.50 per share.														In January and March 2013, in connection with a separate and new private placement offering we issued 95,239 shares of common stock at $5.25 per share and warrants to purchase 95,239 shares of common stock at $11.25 per share to 5 investors in return for their $500,000 investment in the Company.
	In August and September 2013 the Company entered into agreements with holders of certain of its outstanding warrants to purchase the Company’s common stock to amend the exercise price of the warrant to $7.50 per share in connection with the agreement of each such holder to exercise the warrants in full. Prior to the amendments, the exercise prices of such warrants ranged from $11.25 to $34.50 per share. Twenty-four warrants were exercised with a reduced exercise price, and nineteen warrants were exercised pursuant to a net exercise provision. Together such warrant exercises resulted in aggregate cash proceeds of $1,044,490 to the Company, and the issuance of an aggregate 139,265 shares of common stock through the reduced warrant exercise and 87,117 shares which were issued pursuant to a net exercise provision.														On March 15, 2013 the Company completed the private sale of 95,239 shares of the Company’s common stock, par value $.01 per share, at $5.25 per share for an aggregate purchase price of $500,000, warrants to purchase 95,239 shares of common stock at an exercise price of $6.00 per share, and warrants to purchase 47,620 shares of common stock at an exercise price of $11.25 per share.
	In October 2013 the Company entered into agreements with a holder of certain of its outstanding warrants to purchase the Company’s common stock to amend the exercise price of the warrant to $9.38 per share in connection with the agreement of the holder to exercise the warrants in full. Prior to the amendments, the exercise price of such warrants was $18.75 per share. Two warrants were exercised with a reduced exercise price. Together the warrant exercises resulted in aggregate cash proceeds of $125,000 to the Company, and the issuance of an aggregate 13,333 shares of common stock.														In April 2013, the Company issued 2,667 shares of common stock, par value $.01 per share, to a former consultant exercising options; the Company issued 4,445 shares of common stock, par value $.01 per share, at $.75 per share to the former CEO exercising options.
	For grants of stock options and warrants in 2013 the Company used a 0.78% to 2.04% risk-free interest rate, 0% dividend rate, 59% or 66% volatility and estimated terms of 5 or 10 years. Value computed using these assumptions ranged from $1.43 to $18.34 per share.														In May 2013, the Company converted four (4) notes totaling $156,243, plus $11,169 in interest; issued in November 2012, the noteholders received 14,882 shares of common stock, par value $.01, at $7.50 per share. One of the noteholders was Dr. Samuel Herschkowitz who received 4,763 shares.
	In January 2014 the Company issued 4,336 shares of common stock to the former CEO at $1.25 per share upon his exercising options.														In May and June 2013 in connection with a private placement offering we issued 8% convertible one year promissory notes in an aggregate principal amount of $1,000,000 convertible into 80,000 shares of common stock assuming a conversion rate of $13.50 per share and five year warrants to purchase up to an aggregate of 61,482 shares of the corporation’s common stock at an exercise price of $14.85 per share. The value of the notes net of discount was $275,640 in 2013; due in May and June 2014. In addition, we issued to the placement agent for these sales five year warrants to purchase an aggregate of 5,926 shares of common stock at an exercise price of $13.50 per share.
	In January through March 2014, 9 warrant holders exercised warrants through a cashless exercise for a total of 15,442 shares of common stock.														In August and September 2013 the Company entered into agreements with holders of certain of its outstanding warrants to purchase the Company’s common stock to amend the exercise price of the warrant to $7.50 per share in connection with the agreement of each such holder to exercise the warrants in full. Prior to the amendments, the exercise prices of such warrants ranged from $11.25 to $34.50 per share. Twenty-four warrants were exercised with a reduced exercise price, and nineteen warrants were exercised pursuant to a net exercise provision. Together such warrant exercises resulted in aggregate cash proceeds of $1,044,490 to the Company, and the issuance of an aggregate 139,266 shares of common stock through the reduced warrant exercise and 87,118 shares which were issued pursuant to a net exercise provision.
	In January and February 2014 the Company issued warrants to purchase 21,538 shares pursuant to a February 4, 2014 private placement whereby the Company issued 20,550 shares of Series A Convertible Preferred Stock raising gross proceeds of $2,055,000. The warrants are at an exercise price of $24.38.														In October 2013 the Company entered into agreements with a holder of certain of its outstanding warrants to purchase the Company’s common stock to amend the exercise price of the warrant to $9.38 per share in connection with the agreement of the holder to exercise the warrants in full. Prior to the amendments, the exercise price of such warrants was $18.75 per share. Two warrants were exercised with a reduced exercise price. Together the warrant exercises resulted in aggregate cash proceeds of $125,000 to the Company, and the issuance of an aggregate 13,334 shares of common stock.
	In February 2014 the Company issued a warrant to purchase 1,482 shares of common stock at an exercise price of $20.25 to a major shareholder Dr. Samuel Herschkowitz. The warrant is in consideration for a bridge loan extended in December 2013 that has been paid in February 2014.														For grants of stock options and warrants in 2013 the Company used a 0.78% to 2.04% risk-free interest rate, 0% dividend rate, 59% or 66% volatility and estimated terms of 5 or 10 years. Value computed using these assumptions ranged from $8.93 to $18.15 per share.
	On March 31, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $19.50 per share. As a result 970 shares of common stock were issued to 16 holders of Preferred Shares.														The following summarizes transactions for stock options and warrants for the periods indicated:
	In March 2014, the Company issued 4,444 shares of common stock to a warrant holder for a partial cash exercise at $11.25 per share; issued 3,333 shares to the holder via the cashless exercise of the remainder of the warrant.
	In June 2014, the Company issued 3,725 shares of common stock to a warrant holder exercising cashless warrants.
	On June 30, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $19.50 per share. As a result 1,561 shares of common stock were issued to 16 holders of Preferred Shares.																Stock Options⁽¹⁾						Warrants⁽¹⁾
	On June 30, 2014, the Company issued a warrant to purchase 5,431 shares of common stock at an exercise price of $12.38 to SOK Partners, LLC, in consideration for a bridge loan in the form of convertible notes. On September 9, 2014 the Resale Registration Statement went into effect. The convertible note agreement provided an immediate approximately 11% reduction to the warrant agreement. Therefore, the warrant has been adjusted to purchase 4,831 shares of common stock at an exercise price of $12.38 to SOK Partners, LLC in consideration for a bridge loan.																Number of				Average		Number of			Average
	In July 2014, the Company issued warrants to purchase 28,986 shares of common stock at an exercise price of $12.38 to two lenders in consideration for a bridge loan in the form of convertible notes. The shares above reflect approximately an 11% reduction resulting from the Resale Registration Statement that went effective September 9, 2014.																Shares				Exercise Price		Shares			Exercise Price
	In August 2014, the Company issued warrants to purchase 61,539 of common stock at an exercise price of $24.38 to the Purchasers of the Preferred Shares. The Securities Purchase Agreement with the Preferred Shareholders stipulated that if the Company was not listed on either the NASDAQ Stock Market, the New York Stock Exchange or the NYSE MKT within 180 days of closing the agreement then warrants to purchase the above additional shares would be issued in aggregate to the Preferred Shareholders.														Outstanding at December 31, 2005			239			$	125.25		279		$	196.5
	In August and September 2014, the Company issued warrants to purchase 37,440 shares of common stock at an exercise price of $12.38 to four lenders in consideration for a bridge loan in the form of convertible notes. The shares above reflect the approximate 11% reduction resulting from the Resale Registration Statement that went effective September 9, 2014.														Issued			319				125.25		958			63.75
	On September 30, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $19.50 per share. As a result 1,561 shares of common stock were issued to 16 holders of Preferred Shares.														Outstanding at December 31, 2006			558				125.25		1,237			93.75
	For grants of stock options and warrants in 2014 the Company used a 1.44% to 2.75% risk-free interest rate, 0% dividend rate, 59% to 66% volatility and estimated terms of 5 to 10 years. Value computed using these assumptions ranged from $3.21 to $13.91 per share.														Issued			80				125.25		380			26.25
	The following summarizes transactions for stock options and warrants for the periods indicated:														Outstanding at December 31, 2007			638				125.25		1,617			78
															Issued			16,577				15		67,669			33.75
															Expired									(160	)		282
			Stock Options						Warrants						Outstanding at December 31, 2008			17,215				19.5		69,126			33.75
			Number of				Average		Number of			Average			Issued			2,733				27.75		29,177			48.75
			Shares				Exercise Price		Shares			Exercise Price			Outstanding at December 31, 2009			19,948				20.25		98,303			36.75
	Outstanding at December 31, 2012			168,856			$	6.75		468,431		$	9.75		Issued			29,467				12.75		45,809			25.5
	Issued			239,816				6.75		343,196			9		Expired			(2,773	)			32.25		(120	)		125.25
	Expired			(15,467	)			18		(111,025	)		13.5		Exercised									(1,714	)		34.5
	Exercised			(7,472	)			0.75		(238,682	)		8.25		Outstanding at December 31, 2010			46,642				14.25		142,278			33
	Outstanding at December 31, 2013			385,733				6.75		461,920			10.5		Issued			33,111				0.75		242,963			10.5
	Issued			71,838				8.11		155,818			3.74		Expired			(1,119	)			54.75		(26,812	)		36
	Expired			(6,746	)			25.65		(77,685	)		9.88		Exercised			(1,333	)			0.75
	Exercised			(4,936	)			1.76		(40,722	)		8.38		Outstanding at December 31, 2011			77,301				8.25		358,429			17.25
	Outstanding at September 30, 2014			445,889			$	7.58		499,331		$	8.6		Issued			126,866				6		155,846			11.25
	At September 30, 2014, 427,051 stock options are fully vested and currently exercisable with a weighted average exercise price of $7.26 and a weighted average remaining term of 8.24 years. All warrants are fully vested and exercisable. Stock-based compensation recognized for the nine months ending September 2014 and September 30, 2013 was $440,117 and $3,791,802, respectively. The Company has $262,055 of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over a weighted average period of approximately 18 months.														Expired			(29,805	)			8.25		(44,886	)		37.5
	The following summarizes the status of options and warrants outstanding at September 30, 2014:														Exercised			(5,506	)			0.75		(958	)		0.75
															Outstanding at December 31, 2012			168,856				6.75		468,431			9.75
															Issued			239,816				6.75		343,196			9
	Range of Exercise Prices		Shares				Weighted								Expired			(15,467	)			18		(111,025	)		13.5
							Average								Exercised			(7,472	)			0.75		(238,682	)		8.25
							Remaining Life								Outstanding at December 31, 2013			385,733			$	6.75		461,920		$	10.5
	Options:
	$0.75			7,333				6.77								-1	Adjusted for the reverse stock splits in total at June 6, 2008, October 20, 2008, and October 24, 2014.
$4.88			134				8.45							At December 31, 2013, 368,783 stock options are fully vested and currently exercisable with a weighted average exercise price of $6.38 and a weighted average remaining term of 8.80 years. There are 461,920 warrants that are fully vested and exercisable. Stock-based compensation recognized in 2013 and 2012 was $3,700,070 and $830,372, respectively. The Company has $166,905 of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over the next 22 months.
$5.25			2,031				7.94							The following summarizes the status of options and warrants outstanding at December 31, 2013:
$5.63			192,000				8.46
$5.93			23,206				8.47
$6.00			123,998				7.88							Range of Exercise Prices		Shares				Weighted
$6.60			5,332				7.32													Average
$8.25			3,636				10													Remaining
$9.94			3,019				8.79													Life
$10.50			3,238				8.79							Options:
$11.25			14,799				7.72							$0.75			7,334				7.52
$12.75			10,069				9.54							$1.28			4,336				4.43
$13.88			2,160				9.51							$4.88			134				9.2
$15.00			3,334				9.47							$5.25			2,631				9.44
$17.25			40,261				9.44							$5.63			192,000				9.21
$18.75			3,335				9.4							$5.93			23,207				9.22
$20.25			4,940				9.26							$6.00			124,000				8.63
$21.75			1,336				9.02							$66.00			5,334				8.07
$23.85			1,260				9.01							$9.94			3,019				9.54
$24.75			334				8.99							$10.50			3,239				9.54
$25.61			134				8.99							$11.25			9,023				7.16
Total			445,889											$12.75			67				9.36
Warrants:														$20.25			4,939				10
$0.75			400				1.19							$21.75			1,334				9.77
$6.00			102,857				3.45							$23.85			1,258				9.75
$9.00			2,666				3.32							$24.75			1,334				9.73
$11.25			204,200				3.27							$25.61			267				9.75
$12.38			71,257				3.53							$26.25			1,000				0.37
$13.50			4,444				3.72							$43.88			1,277				0.44
$14.85			23,612				3.66							Total			385,733
$15.00			1,168				0.34							Warrants:
$18.75			4,166				0.03							$0.75			2,667				1.94
$20.25			1,481				3.03							$5.63			35,556				0.85
$24.38			83,080				4.86							$6.00			102,857				4.2
Total			499,331											$7.50			19,047				0.33
Stock options and warrants expire on various dates from October 2014 to September 2024.														$9.00			2,667				4.9
The shareholders approved an increase in authorized shares to 1,066,667 shares in an annual shareholder meeting held on June 22, 2010 and approved an increase in authorized shares to 2,666,667 shares in a special shareholder meeting held on September 7, 2011.														$11.25			221,977				3.98
The shareholders approved an increase in authorized shares to 4,000,000 shares in a special shareholder meeting held on January 15, 2013.														$12.00			2,000				0.38
The shareholders approved an amendment of the Company’s 2012 Stock Incentive Plan to increase the reserve of shares authorized for issuance to 666,667 shares and to increase the threshold of limitation on certain grants to 266,667 shares on April 15, 2013.														$12.75			17,255				0.27
An increase from 4,000,000 to 10,666,667 authorized shares, and an amendment of the Company’s 2012 Stock Incentive Plan to increase the reserve of shares authorized for issuance to 1,333,334 shares was approved at the September 10, 2013 annual meeting.														$13.50			7,112				2.83
Stock Options and Warrants Granted by the Company														$14.85			23,611				4.41
The following table is the listing of stock options and warrants as of September 30, 2014 by year of grant:														$1,500			16,500				0.18
Stock Options:														$18.75			5,000				0.77
														$34.50			1,110				0.3
														$57.68			4,561				0.5
Year		Shares				Price								Total			461,920
2010			5,466			$	11.25							Stock options and warrants expire on various dates from January 2014 to December 2023.
2011			7,333				0.75							Under the terms of the Company's agreement with investors in the October 2008 financing, 25,600 shares of common stock were the maximum number of shares allocated to the Company's existing shareholders at the time of the offering (also referred to as the original shareholders or the “Founders”). Since the total of the Company's fully diluted shares of common stock was greater than 25,600 shares, in order for the Company to proceed with the offering, the Board of Directors approved a reverse stock split of 1-for-1.2545. After this split was approved, additional options and warrants were identified, requiring a second reverse stock split in order to reach the 25,600 shares. The second reverse stock split on the reduced 1-for-1.2545 balance was determined to be 1-for-1.33176963. Taken together, if only one reverse stock split was performed, the number would have been a reverse stock split of 1-for-1.670705.
2012			126,029				5.25 – 6.00							On June 6, 2008, the Board of Directors approved the first reverse stock split. The authorized number of shares of common stock of 266,667 was proportionately divided by 1.2545 to arrive at 212,569.
2013			238,556				4.88 – 25.61							On October 20, 2008, the Board of Directors (i) approved the second reverse stock split pursuant to which the authorized number of shares of common stock of 212,569 was proportionately divided by 1.33177 to arrive at 159,614 shares and (ii) approved a resolution to increase the number of authorized shares of the Company's common stock from 159,614 to 533,334, which was approved by the Company’s shareholders holding a majority of the shares entitled to vote thereon at a special meeting of shareholders held on December 3, 2008.
2014			68,505				8.25 – 18.75							The shareholders approved an increase in authorized shares to 1,066,667 shares in an annual shareholder meeting held on June 22, 2010 and approved an increase in authorized shares to 2,666,667 shares in a special shareholder meeting held on September 7, 2011.
Total			445,889			$	.75 – 25.61							The shareholders approved an increase in authorized shares to 4,000,000 shares in a special shareholder meeting held on January 15, 2013.
Warrants:														The shareholders approved an amendment of the Company’s 2012 Stock Incentive Plan to increase the reserve of shares authorized for issuance to 666,667 shares and to increase the threshold of limitation on certain grants to 266,667 shares on April 15, 2013.
														An increase from 4,000,000 to 10,666,667 authorized shares, and an amendment of the Company’s 2012 Stock Incentive Plan to increase the reserve of shares authorized for issuance to 1,333,334 shares was approved at the September 10, 2013 annual meeting.
														Stock Options and Warrants Granted by the Company
Year		Shares				Price								The following table is the listing of stock options and warrants as of December 31, 2013 by year of grant:
2010			400			$	0.75							Stock Options:
2011			4,166				18.75
2012			71,368				11.25 – 15.00
2013			267,579				6.00 – 14.85							Year		Shares				Price
2014			155,818				12.38 – 24.38							2008			5,613			$	1.28 – 43.88
Total			499,331			$	.75 – 24.38							2009			1,000				26.25
														2010			5,467				11.25
														2011			7,334				0.75
														2012			126,636				5.25 – 6.00
														2013			239,683				4.88 – 25.61
														Total			385,733			$	.75 – 43.88
														Warrants:


														Year		Shares				Price
														2008			4,561			$	34.50 – 57.68
														2009			1,110				34.5
														2010			2,667				0.75
														2011			114,635				5.63 – 18.75
														2012			71,367				11.25 – 15.00
														2013			267,580				6.00 – 14.85
														Total			461,920			$	.75 – 57.68

SHORTTERM_NOTES_PAYABLE

SHORT-TERM NOTES PAYABLE	9 Months Ended
SHORT-TERM NOTES PAYABLE	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Short-term Debt [Text Block]	'
	NOTE 4 — SHORT-TERM NOTES PAYABLE
	On July 23, 2014, the Company entered into a Securities Purchase Agreement (the “SOK Securities Purchase Agreement”) with SOK Partners, LLC, an affiliate of the Company (“SOK”), pursuant to which the Company agreed to issue and sell (i) a senior convertible note, in an original principal amount of $122,196 (the “SOK Note”), which SOK Note shall be convertible into a certain amount of shares (the “SOK Conversion Shares”) of Common Stock, in accordance with the terms of the SOK Note, and (ii) a warrant (the “SOK Warrant”) to initially acquire up to 5,431 additional shares of Common Stock (the “SOK Warrant Shares”, and collectively with the SOK Note, the SOK Warrant and the SOK Conversion Shares, the “SOK Securities”) for an aggregate purchase price of $100,000 (with the reduced principal amount as described below representing an approximately 8.7% original issue discount) (the “SOK Convertible Notes Offering”). Upon effectiveness of the Resale Registration Statement (as defined below) on September 9, 2014, the principal amount of the note was reduced to $108,696 and the number of warrants was reduced to 4,831 shares.
	Also, on July 23, 2014, the Company entered into a Securities Purchase Agreement with 31 Group, LLC (an affiliate of Aegis Capital Corp., the underwriter for the Company’s pending public offering) pursuant to which the Company agreed to issue and sell (i) a senior convertible note, in an original principal amount of $610,978 (subsequently reduced to $543,478) (the “31 Group Note”), which shall be convertible into a certain amount of shares of Common Stock, in accordance with the terms of the 31 Group Note, (ii) a warrant (the “31 Group Warrant”) to initially acquire up to 27,155 additional shares of Common Stock (subsequently reduced to 24,155 shares) (the “31 Group Conversion Shares”, and collectively with the 31 Group Note, the 31 Group Warrant and the 31 Group Conversion Shares, the “31 Group Securities”) for an aggregate purchase price of $500,000 (representing an approximately 8.7% original issue discount) (the “31 Group Convertible Notes Offering”).
	Also, on July 23, 2014, the Company entered into a Securities Purchase Agreement with Evan Myrianthopoulos (a managing director of the representative of the underwriters), pursuant to which the Company agreed to issue and sell (i) a senior convertible note, in an original principal amount of $30,548.90 (subsequently reduced to $27,173.90) (the “Myrianthopoulos Note”), which shall be convertible into a certain amount of shares of Common Stock, in accordance with the terms of the Myrianthopoulos Note, (ii) a warrant (the “Myrianthopoulos Warrant”) to initially acquire up to 1,358 additional shares of Common Stock (subsequently reduced to 1,208 shares) (the “Myrianthopoulos Conversion Shares”, and collectively with the Myrianthopoulos Note, the Myrianthopoulos Warrant and the Myrianthopoulos Conversion Shares, the “Myrianthopoulos Securities”) for an aggregate purchase price of $25,000 (representing an approximately 8.7% original issue discount) (the “Myrianthopoulos Convertible Notes Offering”).
	On July 31, 2014, August 8, 2014, August 12, 2014, September 4, 2014 and September 5, 2014, the Company entered into Securities Purchase Agreements (collectively, the “Affiliate Securities Purchase Agreements”) with certain affiliates of the Company and certain persons with whom the Company was required to have a pre-existing relationship (the “Affiliates”) pursuant to which the Company agreed to issue and sell (i) senior convertible notes, in an original aggregate principal amount of $1,069,222 (subsequently reduced to $951,086) (the “Affiliate Notes”), which Affiliate Notes shall be convertible into a certain amount of shares (the “Affiliate Conversion Shares”) of the Company’s Common Stock in accordance with the terms of the Affiliate Notes, and (ii) warrants (the “Affiliate Warrants”) to initially acquire up to 48,879 additional shares of Common Stock (subsequently reduced to 42,271 shares) (the “Affiliate Warrant Shares”, and collectively with the Affiliate Notes, the Affiliate Warrants and the Affiliate Conversion Shares, the “Affiliate Securities”) for an aggregate purchase price of $875,000 (representing an approximately 8.7% original issue discount) (the “Affiliate Convertible Notes Offering”).
	The SOK Note, 31 Group Note, the Myrianthopoulos Note and the Affiliate Notes mature on July 23, 2015 (subject to extension as provided in the Notes) and, in addition to the original issue discount, accrue interest at a rate of 12.0% per annum. The Notes are convertible at any time after issuance, in whole or in part, at the Investor’s or SOK’s option, as the case may be, into shares of Common Stock, at a conversion price equal to the lesser of (i) the product of (x) the arithmetic average of the lowest three volume weighted average prices of the Common Stock during the ten consecutive trading days ending and including the trading day immediately preceding the applicable conversion date and (y) 72.5% (or if an event of default has occurred and is continuing, 70%), and (ii) $11.25 (as adjusted for stock splits, stock dividends, recapitalizations or similar events).
	On September 30, 2014, the SOK Note, 31 Group Note, the Myrianthopoulos Note and the Affiliate Notes had a combined amortization of $250,494. At the same point in time the SOK Note, the 31 Group Note, the Myrianthopoulos Note and the Affiliate Notes had a combined original issue discount of $103,088. Additionally, as of September 30, 2014, the 31 Group, LLC converted $40,000 of their note. One of the affiliate investors also converted $40,000 of their note by September 30, 2014.

LOSS_PER_SHARE

LOSS PER SHARE	9 Months Ended														12 Months Ended
LOSS PER SHARE	Sep. 30, 2014														Dec. 31, 2013
Earnings Per Share [Abstract]	'														'
Earnings Per Share [Text Block]	'														'
	NOTE 5 — LOSS PER SHARE														NOTE 4 — LOSS PER SHARE
	The following table presents the shares used in the basic and diluted loss per common share computations:														The following table presents the shares used in the basic and diluted loss per common share computations:


			Three Months Ended						Nine Months Ended								Year Ended December 31,						From
			September 30,						September 30,								2013			2012			April 23, 2002 (Inception) To December 31, 2013
			2014			2013			2014			2013			Numerator:
	Numerator:														Net loss available in basic and diluted calculation		$	(9,406,304	)	$	(7,422,155	)	$	(28,697,415	)
	Net loss available in basic and diluted calculation		$	(1,115,221	)	$	(3,974,903	)	$	(4,468,170	)	$	(7,251,965	)	Denominator:
	Denominator:														Weighted average common shares			2,026,115			927,838			996,362
	Weighted average common shares			259,899			1,821,006			2,052,709			1,687,625		outstanding-basic			2,026,115			927,838			996,362
	outstanding-basic			259,899			1,821,006			2,052,709			1,687,625		Effect of dilutive stock options and warrants⁽¹⁾			—			—			—
	Effect of diluted stock options and warrants⁽¹⁾			—			—			—			—		Weighted average common shares			2,026,115			927,838			996,362
	Weighted average common shares			2,984,335			1,821,006			2,967,483			1,687,625		outstanding-diluted			2,026,115			927,838			996,362
	outstanding-basic			2,984,335			1,821,006			2,967,483			1,687,625		Loss per common share-basic and diluted		$	(4.64	)	$	(8.00	)	$	(28.80	)
	Loss per common share-basic and diluted		$	(0.37	)	$	(2.18	)	$	(1.51	)	$	(4.30	)
																-1	The number of shares underlying options and warrants outstanding as of December 31, 2013 and December 31, 2012 are 847,777 and 637,277, respectively. The effect of the shares that would be issued upon exercise of such options and warrants has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.
		-1	The number of shares underlying options and warrants outstanding as of September 30, 2014 and September 30, 2013 are 945,220 and 861,287 respectively. The effect of the shares that would be issued upon exercise of such options and warrants has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

INCOME_TAXES

INCOME TAXES	9 Months Ended					12 Months Ended
INCOME TAXES	Sep. 30, 2014					Dec. 31, 2013
Income Tax Disclosure [Abstract]	'					'
Income Tax Disclosure [Text Block]	'					'
	NOTE 6 — INCOME TAXES					NOTE 5 — INCOME TAXES
	The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.					The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
	There is no income tax provision in the accompanying statements of operations due to the cumulative operating losses that indicate a 100% valuation allowance for the deferred tax assets and state income taxes is appropriate.					There is no income tax provision in the accompanying statements of operations due to the cumulative operating losses that indicate a 100% valuation allowance for the deferred tax assets and state income taxes is appropriate.
	During September 2013, the Company experienced an “ownership change” as defined in Section 382 of the Internal Revenue Code which could potentially limit the ability to utilize the Company’s net operating losses (NOLs). The general limitation rules allow the Company to utilize its NOLs subject to an annual limitation that is determined by multiplying the federal long-term tax-exempt rate by the Company’s value immediately before the ownership change.					Federal and state income tax return operating loss carryovers as of December 31, 2013 were approximately $13,969,000 and will begin to expire in 2017.
	At September 30, 2014, the Company had approximately $16.0 million of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in 2015, subject to the Section 382 limitation described above. The federal NOLs will expire beginning in 2022 if unused. The Company also had approximately $17.1 million of gross NOLs to reduce future state taxable income at September 30, 2014, which will expire in years 2022 through 2034 if unused. The Company's net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At September 30, 2014, the federal and state valuation allowances were $7.1 million and $1.5 million, respectively.					The valuation allowance has been recorded due to the uncertainty of realization of the benefits associated with the net operating losses. Future events and changes in circumstances could cause this valuation allowance to change.
	The components of deferred income taxes at September 30, 2014 and December 31, 2013 are as follows:					The components of deferred income taxes at December 31, 2013 and December 31, 2012 are as follows:


		September 30,		December 31,			December 31,		December 31,
		2014		2013			2013		2012
	Deferred Tax Asset:					Deferred Tax Asset:
	Net Operating Loss	$	7,920,000	$	3,259,000	Net Operating Loss	$	3,259,000	$	2,209,000
	Other		631,000		59,000	Other		59,000		73,000
	Total Deferred Tax Asset		8,551,000		3,318,000	Total Deferred Tax Asset		3,318,000		2,282,000
	Less Valuation Allowance		8,551,000		3,318,000	Less Valuation Allowance		3,318,000		2,282,000
	Net Deferred Income Taxes	$	—	$	—	Net Deferred Income Taxes	$	—	$	—

LONGTERM_DEBT

LONG-TERM DEBT	12 Months Ended
LONG-TERM DEBT	Dec. 31, 2013
Long-Term Debt, Unclassified [Abstract]	'
Long-term Debt [Text Block]	'
	NOTE 6 — LONG-TERM DEBT
	Long-term debt is as follows:


		31-Dec-13		31-Dec-12
	Note payable issued on October 26, 2009, net of a discount of $0 and $0 discount, with interest at 8% to March 31, 2012 when the remaining balance was payable and convertible into shares of common stock at $26.25 per share. The note was renegotiated in February 2013.		—		100,000
	Note payable issued on June 12, 2010 with interest at 12% to March 31, 2012 when the remaining balance was payable, and is convertible into shares of common stock at $13.50 per share. The note was renegotiated in February 2013.		—		200,000
	Note payable issued on December 23, 2010, with interest at 10%, matured December 23, 2012 and was convertible into shares of common stock at $6.30 per share. The note was renegotiated in February 2013.		—		16,800
	Note payable issued on September 21, 2010 with interest at 12%, matured March 30, 2012 and was convertible into shares of common stock at $13.50 per share. The note was renegotiated in February 2013.		—		32,000
	Note payable issued January 1, 2011 to a law firm that accepted this note in full payment of their past due legal fees. The note bears interest at 6%, matures January 1, 2015 and is convertible into shares of common stock at $11.25 per share. The note was renegotiated in March 2013, and has been paid in full.		—		89,300
	On November 6, 2012 the Company issued four convertible notes at 20% interest, each, net of an aggregate discount of $21,138, due on April 6, 2013. The four notes were converted into 13,889 shares at $7.50 per share.		—		122,774
	Total		—		560,874
	Less amount due within one year		—		471,574
	Long-Term Debt	$	—	$	89,300
	Cash payments for interest were $55,198 and $31,008 for 2013 and 2012, respectively.
	The four renegotiated notes above, totaling $450,958 in principal and interest, will be paid for the next two (2) years as follows: $120,000 in 2014 and $120,000 in 2015. The remaining balance including attorney’s fees and interest is due on February 1, 2016. The debt is secured by 8,889 shares of common stock held in escrow. The escrow account releases 1/3 or 4,445 shares per year to the Company if there is no default. If a default occurs the entire amount of stock left in escrow at the time of default is released to the former note holders.

RENT_OBLIGATION

RENT OBLIGATION	9 Months Ended			12 Months Ended
RENT OBLIGATION	Sep. 30, 2014			Dec. 31, 2013
Rent Obligation [Abstract]	'			'
Leases of Lessee Disclosure [Text Block]	'			'
	NOTE 7 — RENT OBLIGATION			NOTE 7 — RENT OBLIGATION
	The Company leases its principal office under a lease that can be cancelled after three years with proper notice per the lease and an amortized schedule of adjustments that will be due to the landlord. The lease extends five years and expires January 2018. In addition to rent, the Company pays real estate taxes and repairs and maintenance on the leased property. Rent expense was $15,719 and $48,775, for the three and nine months ended September 30, 2014 and was $11,162 and $46,321 for the three and nine months ended September 30, 2013 respectively.			The Company leases its principal office under a lease that can be cancelled after three years with proper notice per the lease and an amortized schedule of adjustments that will be due to the landlord. The lease extends five years and expires January 2018. In addition to rent, the Company pays real estate taxes and repairs and maintenance on the leased property. Rent expense was $61,150 and $45,961 for 2013 and 2012, respectively.
	The Company’s rent obligation for the next five years is as follows:			The Company’s rent obligation for the next five years are as follows:


	2015	$	37,000	2014	$	36,000
	2016	$	38,000	2015	$	37,000
	2017	$	39,000	2016	$	38,000
	2018	$	3,600	2017	$	39,000
	2019	$	—	2018	$	3,000

LIABILITY_FOR_EQUITYLINKED_FIN

LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS	9 Months Ended																														12 Months Ended
LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS	Sep. 30, 2014																														Dec. 31, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'																														'
Derivative Instruments and Hedging Activities Disclosure [Text Block]	'																														'
	NOTE 8 — LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS																														NOTE 8 — LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS
	The Company adopted ASC 815- Derivatives and Hedging (“ASC 815”) on January 1, 2009. ASC 815 mandates a two-step process for evaluating whether an equity-linked financial instrument or embedded feature is indexed to the entity's own stock. It was effective for fiscal years beginning after December 15, 2008, and interim periods within those fiscal years, which was the Company's first quarter of 2009. Many of the warrants issued by the Company contain a strike price adjustment feature, which upon adoption of ASC 815, changed the classification (from equity to liability) and the related accounting for warrants with a $479,910 estimated fair value of as of January 1, 2009. An adjustment was made to remove $486,564 from paid-in capital (the cumulative values of the warrants on their grant dates), a positive adjustment of $6,654 was made to accumulated deficit, representing the gain on valuation from the grant date to January 1, 2009, and $479,910 was booked as a liability. The warrants issued in 2011 do not contain a strike price adjustment feature and, therefore, are not treated as a liability.																														The Company adopted ASC 815 — Derivatives and Hedging (“ASC 815”) on January 1, 2009. ASC 815 mandates a two-step process for evaluating whether an equity-linked financial instrument or embedded feature is indexed to the entity's own stock. It was effective for fiscal years beginning after December 15, 2008, and interim periods within those fiscal years, which was the Company's first quarter of 2009. Many of the warrants issued by the Company contain a strike price adjustment feature, which upon adoption of ASC 815, changed the classification (from equity to liability) and the related accounting for warrants with a $479,910 estimated fair value of as of January 1, 2009. An adjustment was made to remove $486,564 from paid-in capital (the cumulative values of the warrants on their grant dates), a positive adjustment of $6,654 was made to accumulated deficit, representing the gain on valuation from the grant date to January 1, 2009, and $479,910 was booked as a liability. The warrants issued in 2012 and 2011 do not contain a strike price adjustment feature and, therefore, are not treated as a liability.
	The January 1, 2009 valuation was computed using the Black-Scholes valuation model based upon a 2.5-year expected term, an expected volatility of 63%, an exercise price of $34.50 per share, a stock price of $26.25, a zero dividend rate and a 1.37% risk free interest rate. Subsequent to January 1, 2009 these warrants were re-valued at the end of each quarter and a gain or loss was recorded based upon their increase or decrease in value during the quarter. Likewise, new warrants that were issued during 2009 and 2010 were valued, using the Black-Scholes valuation model on their date of grant and an entry was made to reduce paid-in capital and increase the liability for equity-linked financial instruments. These warrants were also re-valued at the end of each quarter based upon their expected life, the stock price, the exercise price, assumed dividend rate, expected volatility and risk free interest rate. A significant reduction in the liability was realized in 2010 primarily due to a reduction from $37.50 to $16.50 per share in the underlying stock price. The Company realized a slight increase in the liability for existing warrants during the first quarter of 2012. In 2013 there was a significant decrease in the liability primarily due to current expirations and the amount of warrants reaching expiration in the near term. In 2014, all warrants expired and the liability was reduced to zero.																														The January 1, 2009 valuation was computed using the Black-Scholes valuation model based upon a 2.5-year expected term, an expected volatility of 63%, an exercise price of $34.50 per share, a stock price of $26.25, a zero dividend rate and a 1.37% risk free interest rate. Subsequent to January 1, 2009 these warrants were re-valued at the end of each quarter and a gain or loss was recorded based upon their increase or decrease in value during the quarter. Likewise, new warrants that were issued during 2009 and 2010 were valued, using the Black-Scholes valuation model on their date of grant and an entry was made to reduce paid-in capital and increase the liability for equity-linked financial instruments. These warrants were also re-valued at the end of each quarter based upon their expected life, the stock price, the exercise price, assumed dividend rate, expected volatility and risk free interest rate. A significant reduction in the liability was realized in 2010 primarily due to a reduction from $37.50 to $16.50 per share in the underlying stock price. The Company realized an increase in the liability for existing warrants during 2011 primarily due to a reduction in the spread between the exercise price and the market price of the underlying shares. In 2012, there was a slight increase to the liability due to the extension of warrants. In 2013 there was a significant decrease as a result of the older warrants expiring or getting exercised.
	The inputs to the Black-Scholes model during 2009 through 2014 were as follows:																														The inputs to the Black-Scholes model during 2009 through 2013 were as follows:


																															Stock price		$26.25
	Stock price		$4.50 to $37.50																												Exercise price		$57.68
	Exercise price		$.75 to $24.38																												Expected life		.50 years
	Expected life		2.0 to 6.5 years																												Expected volatility		54%
	Expected volatility		59%																												Assumed dividend rate		—%
	Assumed dividend rate		—%																												Risk-free interest rate		.13% to 2.97%
	Risk-free interest rate		.13% to 2.97%																												The original valuations, annual gain (loss) and end of year valuations are shown below:
	The original valuations, annual gain/(loss) and end of year valuations are shown below:


																																Initial		Annual Gain (Loss)			Value at		2010		Value at		2011			Value at		2012			Value at		2013		Value at
		Initial Value		Annual			Value at		2010 Gain		Value at		2011 Gain			Value at		2012 Gain			Value at		2013 Gain		Value at		2014 Gain		Value at			Value		Annual Gain (Loss)			12/31/09		Gain (Loss)		12/31/10		Gain (Loss)			12/31/11		Gain (Loss)			12/31/12		Gain (Loss)		12/31/13
				Gain			12/31/09		(Loss)		12/31/10		(Loss)			12/31/11		(Loss)			12/31/12		(Loss)		12/31/13		(Loss)		9/30/14		January 1 2009 adoption	$	479,910	$	(390,368	)	$	870,278	$	868,772	$	1,506	$	(88,290	)	$	89,796	$	(21,856	)	$	111,652	$	100,053	$	11,599
				(Loss)																											Warrants issued in quarter ended 6/30/2009		169,854		20,847			149,007		147,403		1,604		(4,689	)		6,293		6,293			—		—		—
	January 1, 2009 adoption	$	479,910	$	(390,368	)	$	870,278	$	868,772	$	1,506	$	(88,290	)	$	89,796	$	(21,856	)	$	111,652	$	100,053	$	11,599	$	11,599	$	—	Warrants issued in quarter ended 9/30/2009		39,743		(738	)		40,481		40,419		62		(1,562	)		1,624		910			714		714		—
	Warrants issued in quarter ended 6/30/2009		169,854		20,847			149,007		147,403		1,604		(4,689	)		6,293		6,293			—		—		—		—		—	Warrants issued in quarter ended 12/31/2009		12,698		617			12,081		12,053		28		(724	)		752		415			337		337		—
	Warrants issued in quarter ended 9/30/2009		39,743		(738	)		40,481		40,419		62		(1,562	)		1,624		910			714		714		—		—		—	Subtotal		702,205					1,071,847
	Warrants issued in quarter ended 12/31/2009		12,698		617			12,081		12,053		28		(724	)		752		415			337		337		—		—		—	Warrants issued in quarter ended 3/31/2010		25,553							25,014		539		(5,570	)		6,109		3,701			2,408		2,408		—
	Subtotal		702,205					1,071,847																							Warrants issued in quarter ended 6/30/2010		31,332							30,740		592		(6,122	)		6,714		6,083			631		631		—
	Warrants issued in quarter ended 3/31/2010		25,553							25,014		539		(5,570	)		6,109		3,701			2,408		2,408		—		—		—	Warrants issued in quarter ended 9/30/2010		31,506							20,891		10,615		(44,160	)		54,775		1,338			53,437		53,437		—
	Warrants issued in quarter ended 6/30/2010		31,332							30,740		592		(6,122	)		6,714		6,083			631		631		—		—		—	Total	$	790,596	$	(369,642	)	$	1,071,847	$	1,145,292	$	14,946	$	(151,117	)	$	166,063	$	(3,116	)	$	169,179	$	157,580	$	11,599
	Warrants issued in quarter ended 9/30/2010		31,506							20,891		10,615		(44,160	)		54,775		1,338			53,437		53,437		—		—		—
	Total	$	790,596	$	(369,642	)	$	1,071,847	$	1,145,292	$	14,946	$	(151,117	)	$	166,063	$	(3,116	)	$	169,179	$	157,580	$	11,599	$	11,599	$	—

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended	12 Months Ended
RELATED PARTY TRANSACTIONS	Sep. 30, 2014	Dec. 31, 2013
Related Party Transactions [Abstract]	'	'
Related Party Transactions Disclosure [Text Block]	'	'
	NOTE 9 — RELATED PARTY TRANSACTIONS	NOTE 9 — RELATED PARTY TRANSACTIONS
	The Company, entered into agreements, in 2008, with our Chairman of the Board, Lawrence Gadbaw, and in 2009 with a board member, Peter Morawetz, to pay Mr. Gadbaw $25,000 and Dr. Morawetz $30,000 upon the Company raising $3 million in new equity. Mr. Gadbaw received 3,704 shares at $6.75 per share in June 2012 as compensation in lieu of the $25,000 cash for raising $3 million in new equity. Mr. Gadbaw was paid the balance due under his separation agreement from 2008. This amount was $46,000 upon signing the agreement in 2008 payable at $2,000 per month; the payments to Mr. Gadbaw are complete. Mr. Gadbaw also received a warrant for 400 shares at $11.25 per share on June 30, 2012 as compensation for service as Chairman. Mr. Gadbaw and Dr. Morawetz have both resigned from the Board in the third quarter of 2013. Both Mr. Gadbaw and Dr. Morawetz received 667 shares of common stock each at $24.38 per share; 267 of these shares were for compensation from serving as Board members and the remaining 400 shares were issued to satisfy previous contractual agreements.	The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements. Rick Koenigsberger, a director, is a holder of membership units in SOK Partners.
	Convertible Note Issuances to Dr. Samuel Herschkowitz and SOK Partners, LLC	The Company entered into agreements, in 2008, with our Chairman of the Board, Lawrence Gadbaw, and in 2009 with a board member, Peter Morawetz, to pay Mr. Gadbaw $25,000 and Dr. Morawetz $30,000 upon the Company raising $3 million in new equity. Mr. Gadbaw received 3,704 shares at $6.75 per share in June 2012 as compensation in lieu of the $25,000 cash for raising $3 million in new equity. Mr. Gadbaw was paid the balance due under his separation agreement from 2008. This amount was $46,000 upon signing the agreement in 2008 payable at $2,000 per month; the payments to Mr. Gadbaw are complete. Mr. Gadbaw also received a warrant for 400 shares at $11.25 per share on June 30, 2012 as compensation for service as Chairman. Mr. Gadbaw and Dr. Morawetz have both resigned from the Board in the third quarter of 2013. Both Mr. Gadbaw and Dr. Morawetz received 667 shares of common stock each at $24.38 per share; 267 of these shares were for compensation from serving as Board members and the remaining 400 shares were issued to satisfy previous contractual agreements.
	On September 11, 2013, both the Herschkowitz Note and the SOK Note (each as defined below in this Note 9) were converted in full by the holders thereof at $1.05 per share. The principal and interest balance of the Herschkowitz Note of $314,484 was converted into 299,509 shares of common stock. The principal and interest balance of the SOK Note of $680,444 was converted into 648,050 shares of common stock. The collateral that secured these notes was released back to the Company.	Convertible Note Issuances to Dr. Samuel Herschkowitz and SOK Partners, LLC
	The remaining disclosure of this Note 9 provides historical information regarding the Herschkowitz Note, the SOK Note and certain other convertible note issuances.	On September 11, 2013, both the Herschkowitz Note and the SOK Note (each as defined below in this Note 9) were converted in full by the holders thereof at $1.05 per share. The principal and interest balance of the Herschkowitz Note of $314,484 was converted into 299,509 shares of common stock. The principal and interest balance of the SOK Note of $680,444 was converted into 648,050 shares of common stock. The collateral that secured these notes was released back to the Company.
	On March 28, 2012, the Company, entered into a Convertible Note Purchase Agreement, dated as of March 28, 2012 (the “SOK Purchase Agreement”) with SOK Partners, LLC (“SOK Partners”), and an investment partnership. Josh Kornberg, who is a member of the Company’s Board of Directors, and Dr. Samuel Herschkowitz are affiliates of the manager of SOK Partners and Ricardo Koenigsberger, a director, is a holder of membership units of SOK Partners. Pursuant to the SOK Purchase Agreement, the Company issued a 20.0% convertible note due August 2012 in the principal amount of up to $600,000. Principal and accrued interest on the note is due and payable on August 28, 2012. The Company’s obligations under the note are secured by the grant of a security interest in substantially all tangible and intangible assets of the Company. The SOK Purchase Agreement and the note include customary events of default that include, among other things, non-payment defaults, covenant defaults, inaccuracy of representations and warranties, cross-defaults to other indebtedness and bankruptcy and insolvency defaults. The occurrence of an event of default could result in the acceleration of the Company’s obligations under the note, and interest rate of twenty-four (24%) percent per annum accrues if the note is not paid when due.	The remaining disclosure of this Note 9 provides historical information regarding the Herschkowitz Note, the SOK Note and certain other convertible note issuances.
	On March 28, 2012, the Company received an advance of $84,657 under the note, including a cash advance of $60,000 net of a prepayment of interest on the first $300,000 in advances under the note. The holder of the note is entitled to convert the note into shares of common stock of the Company at an initial conversion price per share of $4.88 per share, subject to adjustment in the event of (1) certain issuances of common stock or convertible securities at a price lower than the conversion price of the note, and (2) recapitalizations, stock splits, reorganizations and similar events. In addition, the Company is required to issue two installments of an equity bonus to SOK Partners in the form of common stock valued at the rate of $4.88 per share. In March 2012, the Company issued the first equity bonus to SOK Partners, consisting of 61,539 shares of common stock, with a second installment due within five business days after SOK Partners has made aggregate advances under the note of at least $300,000. In May 2012 the Company issued the second installment consisting of 61,539 shares of common stock subsequent to SOK Partners surpassing the aggregate advances of $300,000. Until the maturity date of the note, if the Company obtains financing from any other source without the consent of SOK Partners, then the Company is required to issue additional bonus equity in an amount equal to $600,000 less the aggregate advances on the note made prior to the breach. The principal balance of the SOK Note was $357,282 as of December 31, 2012.	On March 28, 2012, the Company, entered into a Convertible Note Purchase Agreement, dated as of March 28, 2012 (the “SOK Purchase Agreement”) with SOK Partners, LLC (“SOK Partners”), and an investment partnership. Josh Kornberg, who is a member of the Company’s Board of Directors, and Dr. Samuel Herschkowitz are affiliates of the manager of SOK Partners and Ricardo Koenigsberger, a director, is a holder of membership units of SOK Partners. Pursuant to the SOK Purchase Agreement, the Company issued a 20.0% convertible note due August 2012 in the principal amount of up to $600,000. Principal and accrued interest on the note is due and payable on August 28, 2012. The Company’s obligations under the note are secured by the grant of a security interest in substantially all tangible and intangible assets of the Company. The SOK Purchase Agreement and the note include customary events of default that include, among other things, non-payment defaults, covenant defaults, inaccuracy of representations and warranties, cross-defaults to other indebtedness and bankruptcy and insolvency defaults. The occurrence of an event of default could result in the acceleration of the Company’s obligations under the note, and interest rate of twenty-four (24%) percent per annum accrues if the note is not paid when due.
	As long as any amount payable under the SOK Note remains outstanding, SOK Partners or its designee is entitled to appoint a new member to the Company’s Board of Directors, who will be appointed upon request. Mr. Koenigsberger was appointed to the Board by SOK Partners on June 25, 2012.	On March 28, 2012, the Company received an advance of $84,657 under the note, including a cash advance of $60,000 net of a prepayment of interest on the first $300,000 in advances under the note. The holder of the note is entitled to convert the note into shares of common stock of the Company at an initial conversion price per share of $4.88 per share, subject to adjustment in the event of (1) certain issuances of common stock or convertible securities at a price lower than the conversion price of the note, and (2) recapitalizations, stock splits, reorganizations and similar events. In addition, the Company is required to issue two installments of an equity bonus to SOK Partners in the form of common stock valued at the rate of $4.88 per share. In March 2012, the Company issued the first equity bonus to SOK Partners, consisting of 61,539 shares of common stock, with a second installment due within five business days after SOK Partners has made aggregate advances under the note of at least $300,000. In May 2012 the Company issued the second installment consisting of 61,539 shares of common stock subsequent to SOK Partners surpassing the aggregate advances of $300,000. Until the maturity date of the note, if the Company obtains financing from any other source without the consent of SOK Partners, then the Company is required to issue additional bonus equity in an amount equal to $600,000 less the aggregate advances on the note made prior to the breach. The principal balance of the SOK Note was $357,282 as of December 31, 2012.
	On March 28, 2012, the Company signed an Amended and Restated Note Purchase Agreement, dated as of December 20, 2011, with Dr. Samuel Herschkowitz (as amended, the “Herschkowitz Purchase Agreement”). Pursuant to the Herschkowitz Purchase Agreement, the Company issued a 20.0% convertible note due June 20, 2012 in the principal amount of $240,000 for previous advances under the note. The Company’s obligations under the note are secured by the grant of a security interest in substantially all tangible and intangible assets of the Company. The Company has previously issued to Dr. Herschkowitz an equity bonus consisting of 20,623 shares of common stock. An additional 100,000 shares were transferred to Dr. Herschkowitz effective in April 2012, upon the occurrence of an event of default on the note. On August 13, 2012, the Company entered into a settlement and forbearance agreement described below, relating to the defaults under the Herschkowitz Note and other matters.	As long as any amount payable under the SOK Note remains outstanding, SOK Partners or its designee is entitled to appoint a new member to the Company’s Board of Directors, who will be appointed upon request. Mr. Koenigsberger was appointed to the Board by SOK Partners on June 25, 2012.
	As long as any amount payable under the Herschkowitz Note remains outstanding, Dr. Herschkowitz or his designee is entitled to appoint a special advisor to the Company’s Board of Directors, to be appointed as a member upon request. Pursuant to this authority, Josh Kornberg was appointed to the Board on March 9, 2012. In addition, pursuant to this authority, Mr. Koenigsberger was appointed to the Board on June 25, 2012.	On March 28, 2012, the Company signed an Amended and Restated Note Purchase Agreement, dated as of December 20, 2011, with Dr. Samuel Herschkowitz (as amended, the “Herschkowitz Purchase Agreement”). Pursuant to the Herschkowitz Purchase Agreement, the Company issued a 20.0% convertible note due June 20, 2012 in the principal amount of $240,000 for previous advances under the note. The Company’s obligations under the note are secured by the grant of a security interest in substantially all tangible and intangible assets of the Company. The Company has previously issued to Dr. Herschkowitz an equity bonus consisting of 20,623 shares of common stock. An additional 100,000 shares were transferred to Dr. Herschkowitz effective in April 2012, upon the occurrence of an event of default on the note. On August 13, 2012, the Company entered into a settlement and forbearance agreement described below, relating to the defaults under the Herschkowitz Note and other matters.
	Pursuant to a letter dated April 12, 2012, Dr. Herschkowitz advised the Company of the occurrence of numerous events of default under the terms of the Herschkowitz Note and the Herschkowitz Note Purchase Agreement. As a result of such events of default, Dr. Herschkowitz asserted significant rights as a secured creditor of the Company, including his rights as a secured creditor with a security interest in substantially all assets of the Company. Without a settlement relating to the defaults and other matters, Dr. Herschkowitz could have taken action to levy upon the Company’s assets, including patents and other intellectual property.	As long as any amount payable under the Herschkowitz Note remains outstanding, Dr. Herschkowitz or his designee is entitled to appoint a special advisor to the Company’s Board of Directors, to be appointed as a member upon request. Pursuant to this authority, Josh Kornberg was appointed to the Board on March 9, 2012. In addition, pursuant to this authority, Mr. Koenigsberger was appointed to the Board on June 25, 2012.
	In addition, the Company and Atlantic Partners Alliance LLC (“APA”) were parties to a letter agreement dated March 14, 2012, providing APA and its affiliates (including Dr. Herschkowitz and SOK) with rights to avoid dilution relating to additional issuances of equity securities by the Company through July 14, 2012, evidencing the parties’ intent that APA would be provided with significant protection against dilution. This protection was in recognition of APA’s investments in the Company involving a high degree of risk and the Company’s contemplated need for restructuring its indebtedness, which were anticipated to result, and have resulted, in significant dilution. The parties acknowledged that Dr. Herschkowitz and SOK would not have made their historical cash investments in the Company to the same degree had the dilution protection not been provided, and the investments by these parties have enabled the Company to avoid insolvency. Since the respective dates of the Herschkowitz Note Purchase Agreement and the SOK Note Purchase Agreement, the Company had issued in excess of 213,334 shares of common stock to parties other than APA and its affiliates, resulting in significant dilution.	Pursuant to a letter dated April 12, 2012, Dr. Herschkowitz advised the Company of the occurrence of numerous events of default under the terms of the Herschkowitz Note and the Herschkowitz Note Purchase Agreement. As a result of such events of default, Dr. Herschkowitz asserted significant rights as a secured creditor of the Company, including his rights as a secured creditor with a security interest in substantially all assets of the Company. Without a settlement relating to the defaults and other matters, Dr. Herschkowitz could have taken action to levy upon the Company’s assets, including patents and other intellectual property.
	Effective August 15, 2012, the Company entered into a letter agreement with Dr. Herschkowitz, APA and SOK (the “Forbearance Agreement”). Under the Forbearance Agreement, among other things, (i) Dr. Herschkowitz agreed to forbear from asserting his rights as a secured creditor to substantially all of the Company’s assets, resulting from the Company’s defaults; (ii) the Company issued an aggregate 353,334 shares of common stock to Dr. Herschkowitz and SOK and adjusted the conversion price of their convertible notes to $1.05 per share from $4.88 per share, to satisfy the Company’s obligations to adjust for dilution; (iii) Dr. Herschkowitz and SOK agreed to extend the maturity of their notes to December 31, 2012; (iv) the Company agreed to pay certain compensation to Dr. Herschkowitz upon the achievement of financial milestones and (v) Dr. Herschkowitz clarified and waived certain of his rights, including the right to interest at a penalty rate upon default.	In addition, the Company and Atlantic Partners Alliance LLC (“APA”) were parties to a letter agreement dated March 14, 2012, providing APA and its affiliates (including Dr. Herschkowitz and SOK) with rights to avoid dilution relating to additional issuances of equity securities by the Company through July 14, 2012, evidencing the parties’ intent that APA would be provided with significant protection against dilution. This protection was in recognition of APA’s investments in the Company involving a high degree of risk and the Company’s contemplated need for restructuring its indebtedness, which were anticipated to result, and have resulted, in significant dilution. The parties acknowledged that Dr. Herschkowitz and SOK would not have made their historical cash investments in the Company to the same degree had the dilution protection not been provided, and the investments by these parties have enabled the Company to avoid insolvency. Since the respective dates of the Herschkowitz Note Purchase Agreement and the SOK Note Purchase Agreement, the Company had issued in excess of 213,334 shares of common stock to parties other than APA and its affiliates, resulting in significant dilution.
	In the Forbearance Agreement, Dr. Herschkowitz agreed to forbear from exercising any of his rights arising under the Herschkowitz Note or the Herschkowitz Note Purchase Agreement with respect to the existing defaults against the Company, subject to the limitations set forth in the letter agreement and without releasing or waiving any future breach of the letter agreement. He further agreed to forbear from exercising any rights with respect to events of default, security interests in the collateral and other similar remedies against the Company or his interests under the Herschkowitz Note or the Herschkowitz Note Purchase Agreement until the occurrence of an event of default under the Herschkowitz Note: (a) that does not constitute an existing default and (b) occurs and accrues after the date of the letter agreement.	Effective August 15, 2012, the Company entered into a letter agreement with Dr. Herschkowitz, APA and SOK (the “Forbearance Agreement”). Under the Forbearance Agreement, among other things, (i) Dr. Herschkowitz agreed to forbear from asserting his rights as a secured creditor to substantially all of the Company’s assets, resulting from the Company’s defaults; (ii) the Company issued an aggregate 353,334 shares of common stock to Dr. Herschkowitz and SOK and adjusted the conversion price of their convertible notes to $1.05 per share from $4.88 per share, to satisfy the Company’s obligations to adjust for dilution; (iii) Dr. Herschkowitz and SOK agreed to extend the maturity of their notes to December 31, 2012; (iv) the Company agreed to pay certain compensation to Dr. Herschkowitz upon the achievement of financial milestones and (v) Dr. Herschkowitz clarified and waived certain of his rights, including the right to interest at a penalty rate upon default.
	Dr. Herschkowitz and the Company acknowledged that 100,000 shares of the Company’s common stock, constituting the “penalty shares” under the Herschkowitz Note Purchase Agreement, were delivered to Dr. Herschkowitz in April 2012 as provided in the Herschkowitz Note Purchase Agreement upon an event of default. Notwithstanding a provision that would have increased the rate of interest from 20% to 24% upon an event of default, Dr. Herschkowitz agreed that the Company would not pay the increased rate of interest but would accrue interest at 20% until a subsequent event of default.	In the Forbearance Agreement, Dr. Herschkowitz agreed to forbear from exercising any of his rights arising under the Herschkowitz Note or the Herschkowitz Note Purchase Agreement with respect to the existing defaults against the Company, subject to the limitations set forth in the letter agreement and without releasing or waiving any future breach of the letter agreement. He further agreed to forbear from exercising any rights with respect to events of default, security interests in the collateral and other similar remedies against the Company or his interests under the Herschkowitz Note or the Herschkowitz Note Purchase Agreement until the occurrence of an event of default under the Herschkowitz Note: (a) that does not constitute an existing default and (b) occurs and accrues after the date of the letter agreement.
	Under the Forbearance Agreement, the Herschkowitz Note and the SOK Note were amended as follows: (i) the due dates of the notes were extended to December 31, 2012 from the previous due dates of June 20, 2012 and August 28, 2012, respectively; (ii) Dr. Herschkowitz will release his security agreement after payment of all currently outstanding promissory notes to parties other than SOK; and (iii) the Herschkowitz Note was amended to add certain events of default relating to judgments against the Company or other creditors taking action with respect to the collateral. In consideration of the extension additional milestone fees were revised as described below. Pursuant to a Forbearance and Settlement Agreement with these parties dated August 15, 2012, as subsequently amended, the due date of these notes were extended to August 31, 2013.	Dr. Herschkowitz and the Company acknowledged that 100,000 shares of the Company’s common stock, constituting the “penalty shares” under the Herschkowitz Note Purchase Agreement, were delivered to Dr. Herschkowitz in April 2012 as provided in the Herschkowitz Note Purchase Agreement upon an event of default. Notwithstanding a provision that would have increased the rate of interest from 20% to 24% upon an event of default, Dr. Herschkowitz agreed that the Company would not pay the increased rate of interest but would accrue interest at 20% until a subsequent event of default.
	APA and its affiliates agreed to terminate the letter agreement regarding dilution dated March 14, 2012. In consideration of the various provisions of the letter agreement and in recognition of the understanding of the parties regarding dilution and the agreements of APA and its affiliates to forbear and to extend the due dates of the notes, the Company (i) issued 176,667 shares to Dr. Herschkowitz, (ii) issued 176,667 shares to SOK, and (iii) the conversion price of the Herschkowitz Note and the SOK Note, respectively was changed to $1.05 per share from $4.88 per share.	Under the Forbearance Agreement, the Herschkowitz Note and the SOK Note were amended as follows: (i) the due dates of the notes were extended to December 31, 2012 from the previous due dates of June 20, 2012 and August 28, 2012, respectively; (ii) Dr. Herschkowitz will release his security agreement after payment of all currently outstanding promissory notes to parties other than SOK; and (iii) the Herschkowitz Note was amended to add certain events of default relating to judgments against the Company or other creditors taking action with respect to the collateral. In consideration of the extension additional milestone fees were revised as described below. Pursuant to a Forbearance and Settlement Agreement with these parties dated August 15, 2012, as subsequently amended, the due date of these notes were extended to August 31, 2013.
	In the event that the Company consummated the following series of transactions on or prior to June 30, 2013: (i) a merger or similar transaction with a public shell company, (ii) raising between $2 million and $4 million through an offering of the securities of the public shell company concurrent with or subsequent to the shell merger and (iii) listing the Company’s shares on NASDAQ pursuant to an underwritten offering of the Company’s securities resulting in gross proceeds of between $5 million and $30 million, then the Company would have to be required to deliver to Dr. Herschkowitz the following compensation: (A) $75,000 upon consummating the shell merger, (B) $150,000 upon consummating the qualifying financing round and (C) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $1,000,000. The Company was also required to reimburse Dr. Herschkowitz at his actual out-of-pocket cost for reasonable expenses incurred in connection with the shell transactions, with a maximum limit of $10,000 for such expenses.	APA and its affiliates agreed to terminate the letter agreement regarding dilution dated March 14, 2012. In consideration of the various provisions of the letter agreement and in recognition of the understanding of the parties regarding dilution and the agreements of APA and its affiliates to forbear and to extend the due dates of the notes, the Company (i) issued 176,667 shares to Dr. Herschkowitz, (ii) issued 176,667 shares to SOK, and (iii) the conversion price of the Herschkowitz Note and the SOK Note, respectively was changed to $1.05 per share from $4.88 per share.
	In connection with the extension of the due date for the Herschkowitz Note and the SOK Note on March 6, 2013, the milestone fees were revised. The following fees were payable to Dr. Herschkowitz in the event that the Company consummates the following series of transactions on or prior to December 31, 2013: (i) financing raising not less than $1 million, compensation of $75,000; (ii) a going private transaction, compensation of $200,000 or greater and (iii) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $3,000,000. In May 2013 Dr. Herschkowitz received $75,000 after the Company surpassed raising $1 million.	In the event that the Company consummated the following series of transactions on or prior to June 30, 2013: (i) a merger or similar transaction with a public shell company, (ii) raising between $2 million and $4 million through an offering of the securities of the public shell company concurrent with or subsequent to the shell merger and (iii) listing the Company’s shares on NASDAQ pursuant to an underwritten offering of the Company’s securities resulting in gross proceeds of between $5 million and $30 million, then the Company would have to be required to deliver to Dr. Herschkowitz the following compensation: (A) $75,000 upon consummating the shell merger, (B) $150,000 upon consummating the qualifying financing round and (C) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $1,000,000. The Company was also required to reimburse Dr. Herschkowitz at his actual out-of-pocket cost for reasonable expenses incurred in connection with the shell transactions, with a maximum limit of $10,000 for such expenses.
	As a result of the transactions under the Forbearance Agreement and other investments, Dr. Herschkowitz, SOK and their affiliates currently own shares of common stock and securities representing beneficial ownership of more than 57% of the Company’s outstanding common stock, giving such parties significant control over election of the Board of Directors and other matters.	In connection with the extension of the due date for the Herschkowitz Note and the SOK Note on March 6, 2013, the milestone fees were revised. The following fees were payable to Dr. Herschkowitz in the event that the Company consummates the following series of transactions on or prior to December 31, 2013: (i) financing raising not less than $1 million, compensation of $75,000; (ii) a going private transaction, compensation of $200,000 or greater and (iii) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $3,000,000. In May 2013 Dr. Herschkowitz received $75,000 after the Company surpassed raising $1 million.
	On November 6, 2012, the Company issued and sold convertible promissory notes in the total principal amount of $156,243 to Dr. Herschkowitz and certain of his assignees. The Company issued to these parties an aggregate 20,833 shares of common stock in consideration of placement of the notes. The notes bear interest at a rate of 20% per annum and are secured by a security interest in the Company’s accounts receivable, patents and certain patent rights and are convertible into common stock upon certain mergers or other fundamental transactions at a conversion price based on the trading price prior to the transaction. The proceeds from this transaction were used to pay off approximately $155,000 in principal amount of secured indebtedness. Such notes were converted in April 2013 in to 13,889 shares of common stock at $7.50 per share.	As a result of the transactions under the Forbearance Agreement and other investments, Dr. Herschkowitz, SOK and their affiliates currently own shares of common stock and securities representing beneficial ownership of more than 65% of the Company’s outstanding common stock, giving such parties significant control over election of the Board of Directors and other matters.
	In December 2013, the Company received an additional $300,000 in debt financing from SOK Partners under a non-convertible grid note due February 28, 2014, with 10% interest based on a 365 day year. Dr. Herschkowitz received 10% of the gross proceeds in advance, and the Company received $250,000 in three tranches in December 2013. In January 2014, the Company received an additional $20,000 from SOK Partners completing the grid note maximum. Should the company default on the note the interest rate will increase to 20% interest based on a 365 day year. In February 2014, the Company paid $305,589.04 to SOK Partners in complete payment of the grid note, including interest.	On November 6, 2012, the Company issued and sold convertible promissory notes in the total principal amount of $156,243 to Dr. Herschkowitz and certain of his assignees. The Company issued to these parties an aggregate 20,833 shares of common stock in consideration of placement of the notes. The notes bear interest at a rate of 20% per annum and are secured by a security interest in the Company’s accounts receivable, patents and certain patent rights and are convertible into common stock upon certain mergers or other fundamental transactions at a conversion price based on the trading price prior to the transaction. The proceeds from this transaction were used to pay off approximately $155,000 in principal amount of secured indebtedness. Such notes were converted in April 2013 in to 13,889 shares of common stock at $7.50 per share.
	In connection with the sale of the Preferred Shares on February 4, 2014 as described in Note 3, Josh Kornberg, our CEO, was one of the Purchasers. Mr. Kornberg purchased 19,231 Preferred Shares for a purchase price of $25,000 and received warrants to purchase 52 shares of common stock.	In December 2013 the Company received an additional $300,000 in debt financing from SOK Partners under a non-convertible grid note due February 28, 2014, with 10% interest based on a 365 day year. Dr. Herschkowitz received 10% of the gross proceeds in advance, and the Company received $250,000 in three tranches in December 2013. In January 2014, the Company received an additional $20,000 from SOK Partners completing the grid note maximum. Should the company default on the note the interest rate will increase to 20% interest based on a 365 day year. In February 2014, the Company wired $305,589.04 to SOK Partners in complete payment of the grid note, including interest.
	On July 23, 2014, the Company entered into the SOK Securities Purchase Agreement pursuant to which the Company agreed to issue and sell certain securities to SOK, as described in Note 4 of this Report.

RETIREMENT_SAVINGS_PLANS

RETIREMENT SAVINGS PLANS	9 Months Ended	12 Months Ended
RETIREMENT SAVINGS PLANS	Sep. 30, 2014	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'	'
Pension and Other Postretirement Benefits Disclosure [Text Block]	'	'
	NOTE 10 — RETIREMENT SAVINGS PLAN	NOTE 10 — RETIREMENT SAVINGS PLANS
	We have a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401(k) of the Internal Revenue Code, which covers employees meeting certain eligibility requirements. In fiscal 2012, 2013 and again in 2014, we matched 100% of the employee’s contribution up to 4% of their earnings. The employer contribution was $14,102 and $9,231 for the three months ending September 30, 2014 and September 30, 2013, respectively, and was $29,596 and $27,328, for the nine months ending September 30, 2014 and September 30, 2013, respectively.	We have a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401(k) of the Internal Revenue Code, which covers employees meeting certain eligibility requirements. In fiscal 2012, its inception year, and again in 2013, we matched 100%, of the employee’s contribution up to 4.0% of their earnings. The employer contribution was $32,790 and $1,654 in 2013 and 2012. There were no discretionary contributions to the plan in 2013 and 2012.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended	12 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'	'
Commitments and Contingencies Disclosure [Text Block]	'	'
	NOTE 11 — COMMITMENTS AND CONTINGENCIES	NOTE 11 — COMMITMENTS AND CONTINGENCIES
	On July 17, 2014, Skyline Medical Inc. (the “Company”) and a stockholder entered into a settlement agreement and release (the “Settlement Agreement”) with Marshall Ryan (“Ryan”) and a company related to Ryan (together, the “Plaintiffs”). The settlement relates to a previously disclosed lawsuit by the Plaintiffs initiated in March 2014. Ryan is an engineer who previously worked with the Company on design of certain of the Company’s products. The lawsuit alleged among other things, breach of a 2008 consulting agreement, a 2006 manufacturing agreement and a 2006 supply agreement among the Plaintiffs and the Company, various claims of fraud and negligent misrepresentation, and breach of the duty of good faith and fair dealing.	Marshall Ryan & Mid-State Stainless, Inc. v. Skyline Medical Inc. & Dr. Samuel Herschkowitz. On March 5, 2014, plaintiffs filed an action in District Court in Hennepin County, Minnesota against the Company and one of its stockholders, Dr. Samuel Herschkowitz. Marshall Ryan, one of the plaintiffs, is an engineer who worked with the Company on design of certain of its products. The action alleges, among other things, breach of a consulting agreement, a manufacturing agreement and a supply agreement between plaintiffs and the Company, various claims of fraud and negligent misrepresentation and breach of the duty of good faith and fair dealing. The Company believes the claims are without merit and is preparing its response.
	Under the Settlement Agreement, the parties have agreed that the lawsuit will be dismissed. The Company has agreed to pay Ryan an aggregate of $500,000 in various cash installments through April 25, 2015, which amount includes $200,000 in installments that are payable during the remainder of 2014. The Settlement Agreement, among other things, extinguishes any prior claims of Plaintiffs for royalties or other alleged rights to payments under their prior agreements with the Company. Payment of the outstanding balance under the Settlement Agreement will be accelerated if the Company raises $2 million or more of gross dollars in a single funding round or raises aggregate funding of $4 million of gross dollars on or before April 10, 2015. If the Company defaults on the required cash payments and fails to cure as provided in the Settlement Agreement, then Ryan will have the option to either sue Skyline to enforce the Settlement Agreement or rescind the Settlement Agreement, including returning all payments previously made thereunder.
	The Settlement Agreement also contains mutual releases covering claims other than a breach of the Settlement Agreement. In the Settlement Agreement, Ryan fully, unconditionally and irrevocably affirms and ratifies the Company’s rights to Ryan’s prior patent assignments, and disclaims any right, title or interest in the Company’s Streamway product including any claims to royalties both past and future. In addition, the parties confirmed that the patents related to the Streamway product belong exclusively to Skyline and remain in full force and effect.

SUPPLEMENTAL_CASH_FLOW_DATA

SUPPLEMENTAL CASH FLOW DATA	9 Months Ended
SUPPLEMENTAL CASH FLOW DATA	Sep. 30, 2014
Supplemental Cash Flow Elements [Abstract]	'
Cash Flow, Supplemental Disclosures [Text Block]	'
	NOTE 12 — SUPPLEMENTAL CASH FLOW DATA
	Cash payments for interest were $21,627 and $14,503 for the three months ended September 30, 2014 and September 30, 2013, and $43,233 and $56,433 for the nine months ended September 30, 2014 and September 30, 2013.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

12 Months Ended

Sep. 30, 2014

Dec. 31, 2013

Accounting Policies [Abstract]

Basis Of Accounting Policy [Policy Text Block]

Nature of Operations and Continuance of Operations

New Accounting Pronouncements Policy [Policy Text Block]

Recent Accounting Developments

Valuation Of Intangible Assets [Policy Text Block]

Valuation of Intangible Assets

Use of Estimates, Policy [Policy Text Block]

Accounting Policies and Estimates

Presentation Of Taxes Collected From Customers Policy [Policy Text Block]

Presentation of Taxes Collected from Customers

Shipping and Handling Cost, Policy [Policy Text Block]

Shipping and Handling

Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations.

Advertising Costs, Policy [Policy Text Block]

Advertising

Advertising costs are expensed as incurred. There were no advertising expenses for 2013 and 2012.

Research and Development Expense, Policy [Policy Text Block]

Research and Development

Research and development costs are charged to operations as incurred. Research and development costs were approximately $235,000 and $15,000 for 2013 and 2012, respectively.

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Topic 13 Revenue Recognition and ASC 605 — Revenue Recognition.

Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company’s standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY FMS units as well as shipments of cleaning solution kits. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company’s standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer’s right of return is limited only to the Company’s standard one-year warranty whereby the Company replaces or repairs, at its option, and it would be rare that the STREAMWAY FMS unit or significant quantities of cleaning solution kits may be returned. Additionally, since the Company buys both the STREAMWAY FMS units and cleaning solution kits from “turnkey” suppliers, the Company would have the right to replacements from the suppliers if this situation should occur.

Receivables, Policy [Policy Text Block]

Receivables

Inventory, Policy [Policy Text Block]

Inventories

Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows:

September 30,

December 31,

2014

2013

2012

Finished goods

69,331

56,818

Finished goods

56,818

91,008

Raw materials

207,928

18,603

Raw materials

18,603

39,543

Work-In-Process

38,361

46,754

Work-In-Process

46,754

14,658

Total

315,620

122,175

Total

122,175

145,209

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

Years

Computers and office equipment

3 – 7

Computers and office equipment

3 – 7

Leasehold improvements

Manufacturing tooling

3 – 7

Manufacturing Tooling

3 – 7

Demo Equipment

The Company’s investment in Fixed Assets consists of the following:

December 31,

31-Dec-12

September 30,

December 31,

2013

2014

2013

Computers and office equipment

61,505

12,258

Computers and office equipment

126,234

61,505

Leasehold Improvements

23,614

Leasehold improvements

23,874

23,614

Manufacturing Tooling

89,900

Manufacturing tooling

97,288

89,900

Total

175,019

12,258

Demo Equipment

30,577

—

Less: Accumulated Depreciation

16,909

8,737

Total

277,973

175,019

Total Fixed Assets, Net

158,110

3,521

Less: Accumulated depreciation

61,027

16,909

Total Fixed Assets, Net

216,946

158,110

Intangible Assets Policy [Policy Text Block]

Intangible Assets

Income Tax, Policy [Policy Text Block]

Income Taxes

Tax years subsequent to 2010 remain open to examination by federal and state tax authorities.

Patents and Intellectual Property Policy [Policy Text Block]

Patents and Intellectual Property

Subsequent Events, Policy [Policy Text Block]

Subsequent Events

For purposes of trading of the common stock, the Reverse Stock Split was approved, by FINRA and became effective as of market open on October 28, 2014.

Interim Financial Statements Policy [Policy Text Block]

Interim Financial Statements

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended					12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	Sep. 30, 2014					Dec. 31, 2013
Accounting Policies [Abstract]	'					'
Schedule of Inventory, Current [Table Text Block]	'					'
	Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows:					Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows:


		September 30,		December 31,			December 31,		December 31,
		2014		2013			2013		2012
	Finished goods	$	69,331	$	56,818	Finished goods	$	56,818	$	91,008
	Raw materials		207,928		18,603	Raw materials		18,603		39,543
	Work-In-Process		38,361		46,754	Work-In-Process		46,754		14,658
	Total	$	315,620	$	122,175	Total	$	122,175	$	145,209

Property, Plant and Equipment [Table Text Block]	'					'
	Estimated useful asset life by classification is as follows:					Estimated useful asset life by classification is as follows:


		Years					Years
	Computers and office equipment		3 – 7			Computers and office equipment		3 – 7
	Leasehold improvements		5			Leasehold improvements		5
	Manufacturing tooling		3 – 7			Manufacturing Tooling		3 – 7
	Demo Equipment		3			The Company’s investment in Fixed Assets consists of the following:
	The Company’s investment in Fixed Assets consists of the following:

							December 31,		31-Dec-12
		September 30,		December 31,			2013		31-Dec-12
		2014		2013		Computers and office equipment	$	61,505	$	12,258
	Computers and office equipment	$	126,234	$	61,505	Leasehold Improvements		23,614
	Leasehold improvements		23,874		23,614	Manufacturing Tooling		89,900
	Manufacturing tooling		97,288		89,900	Total		175,019		12,258
	Demo Equipment		30,577		—	Less: Accumulated Depreciation		16,909		8,737
	Total		277,973		175,019	Total Fixed Assets, Net	$	158,110	$	3,521
	Less: Accumulated depreciation		61,027		16,909
	Total Fixed Assets, Net	$	216,946	$	158,110

STOCKHOLDERS_DEFICIT_STOCK_OPT1

STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS (Tables)	9 Months Ended											12 Months Ended
STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS (Tables)	Sep. 30, 2014											Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'											'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'											'
	The following summarizes transactions for stock options and warrants for the periods indicated:											The following summarizes transactions for stock options and warrants for the periods indicated:


		Stock Options					Warrants							Stock Options⁽¹⁾					Warrants⁽¹⁾
		Number of			Average		Number of			Average				Number of			Average		Number of			Average
		Shares			Exercise Price		Shares			Exercise Price				Shares			Exercise Price		Shares			Exercise Price
	Outstanding at December 31, 2012		168,856		$	6.75		468,431		$	9.75	Outstanding at December 31, 2005			239		$	125.25		279		$	196.5
	Issued		239,816			6.75		343,196			9	Issued			319			125.25		958			63.75
	Expired		(15,467	)		18		(111,025	)		13.5	Outstanding at December 31, 2006			558			125.25		1,237			93.75
	Exercised		(7,472	)		0.75		(238,682	)		8.25	Issued			80			125.25		380			26.25
	Outstanding at December 31, 2013		385,733			6.75		461,920			10.5	Outstanding at December 31, 2007			638			125.25		1,617			78
	Issued		71,838			8.11		155,818			3.74	Issued			16,577			15		67,669			33.75
	Expired		(6,746	)		25.65		(77,685	)		9.88	Expired								(160	)		282
	Exercised		(4,936	)		1.76		(40,722	)		8.38	Outstanding at December 31, 2008			17,215			19.5		69,126			33.75
	Outstanding at September 30, 2014		445,889		$	7.58		499,331		$	8.6	Issued			2,733			27.75		29,177			48.75
												Outstanding at December 31, 2009			19,948			20.25		98,303			36.75
												Issued			29,467			12.75		45,809			25.5
												Expired			(2,773	)		32.25		(120	)		125.25
												Exercised								(1,714	)		34.5
												Outstanding at December 31, 2010			46,642			14.25		142,278			33
												Issued			33,111			0.75		242,963			10.5
												Expired			(1,119	)		54.75		(26,812	)		36
												Exercised			(1,333	)		0.75
												Outstanding at December 31, 2011			77,301			8.25		358,429			17.25
												Issued			126,866			6		155,846			11.25
												Expired			(29,805	)		8.25		(44,886	)		37.5
												Exercised			(5,506	)		0.75		(958	)		0.75
												Outstanding at December 31, 2012			168,856			6.75		468,431			9.75
												Issued			239,816			6.75		343,196			9
												Expired			(15,467	)		18		(111,025	)		13.5
												Exercised			(7,472	)		0.75		(238,682	)		8.25
												Outstanding at December 31, 2013			385,733		$	6.75		461,920		$	10.5

													-1	Adjusted for the reverse stock splits in total at June 6, 2008, October 20, 2008, and October 24, 2014.

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]	'											'
	The following summarizes the status of options and warrants outstanding at September 30, 2014:											The following summarizes the status of options and warrants outstanding at December 31, 2013:


	Range of Exercise Prices	Shares			Weighted							Range of Exercise Prices		Shares			Weighted
					Average												Average
					Remaining Life												Remaining
	Options:																Life
	$0.75		7,333			6.77						Options:
	$4.88		134			8.45						$0.75			7,334			7.52
	$5.25		2,031			7.94						$1.28			4,336			4.43
	$5.63		192,000			8.46						$4.88			134			9.2
	$5.93		23,206			8.47						$5.25			2,631			9.44
	$6.00		123,998			7.88						$5.63			192,000			9.21
	$6.60		5,332			7.32						$5.93			23,207			9.22
	$8.25		3,636			10						$6.00			124,000			8.63
	$9.94		3,019			8.79						$66.00			5,334			8.07
	$10.50		3,238			8.79						$9.94			3,019			9.54
	$11.25		14,799			7.72						$10.50			3,239			9.54
	$12.75		10,069			9.54						$11.25			9,023			7.16
	$13.88		2,160			9.51						$12.75			67			9.36
	$15.00		3,334			9.47						$20.25			4,939			10
	$17.25		40,261			9.44						$21.75			1,334			9.77
	$18.75		3,335			9.4						$23.85			1,258			9.75
	$20.25		4,940			9.26						$24.75			1,334			9.73
	$21.75		1,336			9.02						$25.61			267			9.75
	$23.85		1,260			9.01						$26.25			1,000			0.37
	$24.75		334			8.99						$43.88			1,277			0.44
	$25.61		134			8.99						Total			385,733
	Total		445,889									Warrants:
	Warrants:											$0.75			2,667			1.94
	$0.75		400			1.19						$5.63			35,556			0.85
	$6.00		102,857			3.45						$6.00			102,857			4.2
	$9.00		2,666			3.32						$7.50			19,047			0.33
	$11.25		204,200			3.27						$9.00			2,667			4.9
	$12.38		71,257			3.53						$11.25			221,977			3.98
	$13.50		4,444			3.72						$12.00			2,000			0.38
	$14.85		23,612			3.66						$12.75			17,255			0.27
	$15.00		1,168			0.34						$13.50			7,112			2.83
	$18.75		4,166			0.03						$14.85			23,611			4.41
	$20.25		1,481			3.03						$1,500			16,500			0.18
	$24.38		83,080			4.86						$18.75			5,000			0.77
	Total		499,331									$34.50			1,110			0.3
												$57.68			4,561			0.5
												Total			461,920

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]	'											'
	The following table is the listing of stock options and warrants as of September 30, 2014 by year of grant:											The following table is the listing of stock options and warrants as of December 31, 2013 by year of grant:
	Stock Options:											Stock Options:


	Year	Shares			Price							Year		Shares			Price
	2010		5,466		$	11.25						2008			5,613		$	1.28 – 43.88
	2011		7,333			0.75						2009			1,000			26.25
	2012		126,029			5.25 – 6.00						2010			5,467			11.25
	2013		238,556			4.88 – 25.61						2011			7,334			0.75
	2014		68,505			8.25 – 18.75						2012			126,636			5.25 – 6.00
	Total		445,889		$	.75 – 25.61						2013			239,683			4.88 – 25.61
	Warrants:											Total			385,733		$	.75 – 43.88
												Warrants:

	Year	Shares			Price
	2010		400		$	0.75						Year		Shares			Price
	2011		4,166			18.75						2008			4,561		$	34.50 – 57.68
	2012		71,368			11.25 – 15.00						2009			1,110			34.5
	2013		267,579			6.00 – 14.85						2010			2,667			0.75
	2014		155,818			12.38 – 24.38						2011			114,635			5.63 – 18.75
	Total		499,331		$	.75 – 24.38						2012			71,367			11.25 – 15.00
												2013			267,580			6.00 – 14.85
												Total			461,920		$	.75 – 57.68

LOSS_PER_SHARE_Tables

LOSS PER SHARE (Tables)	9 Months Ended														12 Months Ended
LOSS PER SHARE (Tables)	Sep. 30, 2014														Dec. 31, 2013
Earnings Per Share [Abstract]	'														'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'														'
	The following table presents the shares used in the basic and diluted loss per common share computations:														The following table presents the shares used in the basic and diluted loss per common share computations:


			Three Months Ended						Nine Months Ended								Year Ended December 31,						From
			September 30,						September 30,								2013			2012			April 23, 2002 (Inception) To December 31, 2013
			2014			2013			2014			2013			Numerator:
	Numerator:														Net loss available in basic and diluted calculation		$	(9,406,304	)	$	(7,422,155	)	$	(28,697,415	)
	Net loss available in basic and diluted calculation		$	(1,115,221	)	$	(3,974,903	)	$	(4,468,170	)	$	(7,251,965	)	Denominator:
	Denominator:														Weighted average common shares			2,026,115			927,838			996,362
	Weighted average common shares			259,899			1,821,006			2,052,709			1,687,625		outstanding-basic			2,026,115			927,838			996,362
	outstanding-basic			259,899			1,821,006			2,052,709			1,687,625		Effect of dilutive stock options and warrants⁽¹⁾			—			—			—
	Effect of diluted stock options and warrants⁽¹⁾			—			—			—			—		Weighted average common shares			2,026,115			927,838			996,362
	Weighted average common shares			2,984,335			1,821,006			2,967,483			1,687,625		outstanding-diluted			2,026,115			927,838			996,362
	outstanding-basic			2,984,335			1,821,006			2,967,483			1,687,625		Loss per common share-basic and diluted		$	(4.64	)	$	(8.00	)	$	(28.80	)
	Loss per common share-basic and diluted		$	(0.37	)	$	(2.18	)	$	(1.51	)	$	(4.30	)
																-1	The number of shares underlying options and warrants outstanding as of December 31, 2013 and December 31, 2012 are 847,777 and 637,277, respectively. The effect of the shares that would be issued upon exercise of such options and warrants has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.
		-1	The number of shares underlying options and warrants outstanding as of September 30, 2014 and September 30, 2013 are 945,220 and 861,287 respectively. The effect of the shares that would be issued upon exercise of such options and warrants has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

INCOME_TAXES_Tables

INCOME TAXES (Tables)	9 Months Ended					12 Months Ended
INCOME TAXES (Tables)	Sep. 30, 2014					Dec. 31, 2013
Income Tax Disclosure [Abstract]	'					'
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'					'
	The components of deferred income taxes at September 30, 2014 and December 31, 2013 are as follows:					The components of deferred income taxes at December 31, 2013 and December 31, 2012 are as follows:


		September 30,		December 31,			December 31,		December 31,
		2014		2013			2013		2012
	Deferred Tax Asset:					Deferred Tax Asset:
	Net Operating Loss	$	7,920,000	$	3,259,000	Net Operating Loss	$	3,259,000	$	2,209,000
	Other		631,000		59,000	Other		59,000		73,000
	Total Deferred Tax Asset		8,551,000		3,318,000	Total Deferred Tax Asset		3,318,000		2,282,000
	Less Valuation Allowance		8,551,000		3,318,000	Less Valuation Allowance		3,318,000		2,282,000
	Net Deferred Income Taxes	$	—	$	—	Net Deferred Income Taxes	$	—	$	—

LONGTERM_DEBT_Tables

LONG-TERM DEBT (Tables)	12 Months Ended
LONG-TERM DEBT (Tables)	Dec. 31, 2013
Long-Term Debt, Unclassified [Abstract]	'
Schedule of Long-term Debt Instruments [Table Text Block]	'
	Long-term debt is as follows:


		31-Dec-13		31-Dec-12
	Note payable issued on October 26, 2009, net of a discount of $0 and $0 discount, with interest at 8% to March 31, 2012 when the remaining balance was payable and convertible into shares of common stock at $26.25 per share. The note was renegotiated in February 2013.		—		100,000
	Note payable issued on June 12, 2010 with interest at 12% to March 31, 2012 when the remaining balance was payable, and is convertible into shares of common stock at $13.50 per share. The note was renegotiated in February 2013.		—		200,000
	Note payable issued on December 23, 2010, with interest at 10%, matured December 23, 2012 and was convertible into shares of common stock at $6.30 per share. The note was renegotiated in February 2013.		—		16,800
	Note payable issued on September 21, 2010 with interest at 12%, matured March 30, 2012 and was convertible into shares of common stock at $13.50 per share. The note was renegotiated in February 2013.		—		32,000
	Note payable issued January 1, 2011 to a law firm that accepted this note in full payment of their past due legal fees. The note bears interest at 6%, matures January 1, 2015 and is convertible into shares of common stock at $11.25 per share. The note was renegotiated in March 2013, and has been paid in full.		—		89,300
	On November 6, 2012 the Company issued four convertible notes at 20% interest, each, net of an aggregate discount of $21,138, due on April 6, 2013. The four notes were converted into 13,889 shares at $7.50 per share.		—		122,774
	Total		—		560,874
	Less amount due within one year		—		471,574
	Long-Term Debt	$	—	$	89,300

RENT_OBLIGATION_Tables

RENT OBLIGATION (Tables)	9 Months Ended			12 Months Ended
RENT OBLIGATION (Tables)	Sep. 30, 2014			Dec. 31, 2013
Rent Obligation [Abstract]	'			'
Schedule of Rent Expense [Table Text Block]	'			'
	The Company’s rent obligation for the next five years is as follows:			The Company’s rent obligation for the next five years are as follows:


	2015	$	37,000	2014	$	36,000
	2016	$	38,000	2015	$	37,000
	2017	$	39,000	2016	$	38,000
	2018	$	3,600	2017	$	39,000
	2019	$	—	2018	$	3,000

LIABILITY_FOR_EQUITYLINKED_FIN1

LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS (Tables)	9 Months Ended																														12 Months Ended
LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS (Tables)	Sep. 30, 2014																														Dec. 31, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'																														'
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	'																														'
	The inputs to the Black-Scholes model during 2009 through 2014 were as follows:																														The inputs to the Black-Scholes model during 2009 through 2013 were as follows:


																															Stock price		$26.25
	Stock price		$4.50 to $37.50																												Exercise price		$57.68
	Exercise price		$.75 to $24.38																												Expected life		.50 years
	Expected life		2.0 to 6.5 years																												Expected volatility		54%
	Expected volatility		59%																												Assumed dividend rate		—%
	Assumed dividend rate		—%																												Risk-free interest rate		.13% to 2.97%
	Risk-free interest rate		.13% to 2.97%

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'																														'
	The original valuations, annual gain/(loss) and end of year valuations are shown below:																														The original valuations, annual gain (loss) and end of year valuations are shown below:



		Initial Value		Annual			Value at		2010 Gain		Value at		2011 Gain			Value at		2012 Gain			Value at		2013 Gain		Value at		2014 Gain		Value at			Initial		Annual Gain (Loss)			Value at		2010		Value at		2011			Value at		2012			Value at		2013		Value at
				Gain			12/31/09		(Loss)		12/31/10		(Loss)			12/31/11		(Loss)			12/31/12		(Loss)		12/31/13		(Loss)		9/30/14			Value		Annual Gain (Loss)			12/31/09		Gain (Loss)		12/31/10		Gain (Loss)			12/31/11		Gain (Loss)			12/31/12		Gain (Loss)		12/31/13
				(Loss)																											January 1 2009 adoption	$	479,910	$	(390,368	)	$	870,278	$	868,772	$	1,506	$	(88,290	)	$	89,796	$	(21,856	)	$	111,652	$	100,053	$	11,599
	January 1, 2009 adoption	$	479,910	$	(390,368	)	$	870,278	$	868,772	$	1,506	$	(88,290	)	$	89,796	$	(21,856	)	$	111,652	$	100,053	$	11,599	$	11,599	$	—	Warrants issued in quarter ended 6/30/2009		169,854		20,847			149,007		147,403		1,604		(4,689	)		6,293		6,293			—		—		—
	Warrants issued in quarter ended 6/30/2009		169,854		20,847			149,007		147,403		1,604		(4,689	)		6,293		6,293			—		—		—		—		—	Warrants issued in quarter ended 9/30/2009		39,743		(738	)		40,481		40,419		62		(1,562	)		1,624		910			714		714		—
	Warrants issued in quarter ended 9/30/2009		39,743		(738	)		40,481		40,419		62		(1,562	)		1,624		910			714		714		—		—		—	Warrants issued in quarter ended 12/31/2009		12,698		617			12,081		12,053		28		(724	)		752		415			337		337		—
	Warrants issued in quarter ended 12/31/2009		12,698		617			12,081		12,053		28		(724	)		752		415			337		337		—		—		—	Subtotal		702,205					1,071,847
	Subtotal		702,205					1,071,847																							Warrants issued in quarter ended 3/31/2010		25,553							25,014		539		(5,570	)		6,109		3,701			2,408		2,408		—
	Warrants issued in quarter ended 3/31/2010		25,553							25,014		539		(5,570	)		6,109		3,701			2,408		2,408		—		—		—	Warrants issued in quarter ended 6/30/2010		31,332							30,740		592		(6,122	)		6,714		6,083			631		631		—
	Warrants issued in quarter ended 6/30/2010		31,332							30,740		592		(6,122	)		6,714		6,083			631		631		—		—		—	Warrants issued in quarter ended 9/30/2010		31,506							20,891		10,615		(44,160	)		54,775		1,338			53,437		53,437		—
	Warrants issued in quarter ended 9/30/2010		31,506							20,891		10,615		(44,160	)		54,775		1,338			53,437		53,437		—		—		—	Total	$	790,596	$	(369,642	)	$	1,071,847	$	1,145,292	$	14,946	$	(151,117	)	$	166,063	$	(3,116	)	$	169,179	$	157,580	$	11,599
	Total	$	790,596	$	(369,642	)	$	1,071,847	$	1,145,292	$	14,946	$	(151,117	)	$	166,063	$	(3,116	)	$	169,179	$	157,580	$	11,599	$	11,599	$	—

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Summary Of Significant Accounting Policy [Line Items]	'	'	'
Finished goods	$69,331	$56,818	$91,008
Raw materials	207,928	18,603	39,543
Work-In-Process	38,361	46,754	14,658
Total	$315,620	$122,175	$145,209

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)	9 Months Ended	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)	Sep. 30, 2014	Dec. 31, 2013
Leasehold Improvements [Member]	'	'
Summary Of Significant Accounting Policy [Line Items]	'	'
Property, Plant and Equipment, Useful Life	'5 years	'5 years
Computers And Office Equipment [Member] \| Maximum [Member]	'	'
Summary Of Significant Accounting Policy [Line Items]	'	'
Property, Plant and Equipment, Useful Life	'7 years	'7 years
Computers And Office Equipment [Member] \| Minimum [Member]	'	'
Summary Of Significant Accounting Policy [Line Items]	'	'
Property, Plant and Equipment, Useful Life	'3 years	'3 years
Manufacturing Tooling [Member] \| Maximum [Member]	'	'
Summary Of Significant Accounting Policy [Line Items]	'	'
Property, Plant and Equipment, Useful Life	'7 years	'7 years
Manufacturing Tooling [Member] \| Minimum [Member]	'	'
Summary Of Significant Accounting Policy [Line Items]	'	'
Property, Plant and Equipment, Useful Life	'3 years	'3 years
Demo Equipment [Member]	'	'
Summary Of Significant Accounting Policy [Line Items]	'	'
Property, Plant and Equipment, Useful Life	'3 years	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Summary Of Significant Accounting Policy [Line Items]	'	'	'
Total	$277,973	$175,019	$12,258
Less: Accumulated depreciation	61,027	16,909	8,737
Total Fixed Assets, Net	216,946	158,110	3,521
Computers and office equipment [Member]	'	'	'
Summary Of Significant Accounting Policy [Line Items]	'	'	'
Total	126,234	61,505	12,258
Leasehold Improvements [Member]	'	'	'
Summary Of Significant Accounting Policy [Line Items]	'	'	'
Total	23,874	23,614	'
Manufacturing Tooling [Member]	'	'	'
Summary Of Significant Accounting Policy [Line Items]	'	'	'
Total	97,288	89,900	'
Demo Equipment [Member]	'	'	'
Summary Of Significant Accounting Policy [Line Items]	'	'	'
Total	$30,577	$0	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $)

1 Months Ended

0 Months Ended

2 Months Ended

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

140 Months Ended

2 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

9 Months Ended

12 Months Ended

Feb. 28, 2014

Oct. 31, 2013

Sep. 30, 2013

31-May-13

Apr. 30, 2013

Mar. 15, 2013

Sep. 30, 2013

Jun. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Jun. 30, 2013

Dec. 31, 2002

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2008

Dec. 31, 2013

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Apr. 30, 2012

Feb. 28, 2014

Sep. 30, 2014

Dec. 31, 2013

Minimum [Member]

Maximum [Member]

Computers and office equipment [Member]

Leasehold Improvements [Member]

Manufacturing Tooling [Member]

Samuel Herschkowitz [Member]

Series A Convertible Preferred Stock [Member]

Subsequent Event [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Series A Convertible Preferred Stock [Member]

Summary Of Significant Accounting Policy [Line Items]

Stockholders' Equity, Period Increase (Decrease)

$9,248,000

$2,337,000

$6,956,000

Debt Instrument, Increase (Decrease) for Period, Net

5,518,000

1,823,000

3,935,000

Research and Development Expense

72,294

73,621

321,929

207,162

235,000

15,000

Amortization of Intangible Assets

140,588

Property, Plant and Equipment, Useful Life

'3 years

'7 years

'5 years

'3 years

'7 years

Stock Issued During Period, Value, New Issues

5,000

2,055,000

Stock Issued During Period, Shares, New Issues

4,763

13,889

100,000

20,550

Preferred Stock, Par or Stated Value Per Share

$0.01

Warrants Issued To Purchase Common Stock

5,926

21,334

Common Stock, Par or Stated Value Per Share

$0.01

Preferred Stock Conversion Price, Per Share

$19.50

Exercisable Price Of Warrants

$24.38

Warrants Expiration

'five years

Proceeds from Issuance or Sale of Equity, Total

3,000,000

2,055,000

Percentage Of Additional Warrants Issued To Purchase Common Stock

30.00%

Convertible Preferred Stock, Terms of Conversion

'Preferred Shares are convertible at the option of the holder into the number of shares of Common Stock determined by dividing the stated value of the Preferred Shares being converted by the conversion price of $19.50, subject to adjustment for stock splits, reverse stock splits and similar recapitalization events. If the Company issues additional shares of Common Stock, other than certain stock that is excluded under the terms of the Securities Purchase Agreement, in one or more capital raising transactions with an aggregate purchase price of at least $100,000 for a price less than the then existing conversion price for the Preferred Shares (the New Issuance Price), then the then existing conversion price shall be reduced to the New Issuance Price, provided, however, that under no circumstances shall the New Issuance Price be less than $9.75 or reduced to a price level that would be in breach of the listing rules of any stock exchange

Beneficial Ownership Limitation, Percentage

4.99%

Preferred Shareholders, Receivable, Upon Any Liquidation, Description

'an amount equal to $2,055,000 times 1.2, plus all declared but unpaid dividends

Warrants Exercise Price

$18.75

$7.50

$13.50

$11.25

$34.50

$19.50

Request To Issue Common Stock, Shares, To Group Of Partnership And Individuals During Period

66,585

Cashless Exercise Of Stock Purchase Warrants, Total

82,459

Common Stock, Shares, Outstanding, Requested To Issue To Group Of Partnership And Individuals

16,867

Advertising Expense

$4,201

$11,994

Exercise Price Of Warrants To Purchase Shares Of Common Stock Equal To Offering Price Per Share Percentage

125.00%

Stockholders' Equity, Reverse Stock Split

'Under theterms of the Company's agreement with investors in the October 2008 financing, 25,600 shares of common stock were the maximum number of shares allocated to the Company's existing shareholders at the time of the offering (also referred to as the original shareholders or the Founders). Since the total of the Company's fully diluted shares of common stock was greater than 25,600 shares, in order for the Company to proceed with the offering, the Board of Directors approved a reverse stock split of 1-for-1.2545. After this split was approved, additional options and warrants were identified, requiring a second reverse stock split in order to reach the 25,600 shares. The second reverse stock split on the reduced 1-for-1.2545 balance was determined to be 1-for-1.33176963. Taken together, if only one reverse stock split was performed, the number would have been a reverse stock split of 1-for-1.670705. On June 6, 2008, the Board of Directors approved the first reverse stock split. The authorized number of shares of common stock of 266,667 was proportionately divided by 1.2545 to arrive at 212,569. On October 20, 2008, the Board of Directors (i) approved the second reverse stock split pursuant to which the authorized number of shares of common stock of 212,569 was proportionately divided by 1.33177 to arrive at 159,614 shares and (ii) approved a resolution to increase the number of authorized shares of the Company's common stock from 159,614 to 533,334, which was approved by the Companys shareholders holding a majority of the shares entitled to vote thereon at a special meeting of shareholders held on December 3, 2008.

'The Company filed a Certificate of Amendment effecting a 1:75 reverse stock split (the “Reverse Stock Split”) with the Secretary of State of the State of Delaware, which became effective under Delaware law as of October 24, 2014. At the effective time (the “Effective Time”) of the Reverse Stock Split, the issued and outstanding Common Stock of the Company was combined on a 1-for-75 basis such that every seventy-five shares of Common Stock outstanding immediately prior to the Effective Time was combined into one share of Common Stock.

DEVELOPMENT_STAGE_OPERATIONS_D

DEVELOPMENT STAGE OPERATIONS (Details Textual) (USD $)	1 Months Ended						140 Months Ended		150 Months Ended
	Nov. 30, 2012	Jan. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Oct. 31, 2009	Dec. 31, 2013	Nov. 03, 2014	Nov. 03, 2014
	Nov. 30, 2012	Jan. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Oct. 31, 2009	Dec. 31, 2013	Nov. 03, 2014	Post Reverse Stock Split [Member]
Development stage operation [Line Items]	'	'	'	'	'	'	'	'	'
Common Stock, Shares, Issued	'	'	'	'	'	'	2,932,501	3,021,831	'
Equity Issuance Per Share Amount	$7.50	$15	$6.30	$13.50	$34.50	$48.75	$125.25	'	$125

STOCKHOLDERS_DEFICIT_STOCK_OPT2

STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS (Details) (USD $)	1 Months Ended	9 Months Ended	12 Months Ended								9 Months Ended	12 Months Ended
	Mar. 31, 2014	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007	Dec. 31, 2006	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007	Dec. 31, 2006
	Mar. 31, 2014	Equity Option [Member]	Equity Option [Member]	Equity Option [Member]	Equity Option [Member]	Equity Option [Member]	Equity Option [Member]	Equity Option [Member]	Equity Option [Member]	Equity Option [Member]	Warrant [Member]	Warrant [Member]	Warrant [Member]	Warrant [Member]	Warrant [Member]	Warrant [Member]	Warrant [Member]	Warrant [Member]	Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Outstanding Number Of Shares	'	385,733	168,856	77,301	46,642	19,948	17,215	638	558	239	461,920	468,431	358,429	142,278	98,303	69,126	1,617	1,237	279
Issued - Number of Shares	'	71,838	239,816	126,866	33,111	29,467	2,733	16,577	80	319	155,818	343,196	155,846	242,963	45,809	29,177	67,669	380	958
Expired - Number of Shares	'	-6,746	-15,467	-29,805	-1,119	-2,773	'	'	'	'	-77,685	-111,025	-44,886	-26,812	-120	'	-160	'	'
Exercised - Number of shares	-4,444	-4,936	-7,472	-5,506	-1,333	'	'	'	'	'	-40,722	-238,682	-958	'	-1,714	'	'	'	'
Outstanding Number Of Shares	'	445,889	385,733	168,856	77,301	46,642	19,948	17,215	638	558	499,331	461,920	468,431	358,429	142,278	98,303	69,126	1,617	1,237
Outstanding - Average Exercise Price	'	$6.75	$6.75	$8.25	$14.25	$20.25	$19.50	$125.25	$125.25	$125.25	$10.50	$9.75	$17.25	$33	$36.75	$33.75	$78	$93.75	$196.50
Issued - Average Exercise Price	'	$8.11	$6.75	$6	$0.75	$12.75	$27.75	$15	$125.25	$125.25	$3.74	$9	$11.25	$10.50	$25.50	$48.75	$33.75	$26.25	$63.75
Expired - Average Exercise Price	'	$25.65	$18	$8.25	$54.75	$32.25	'	'	'	'	$9.88	$13.50	$37.50	$36	$125.25	'	$282	'	'
Exercised - Average Exercise Price	$11.25	$1.76	$0.75	$0.75	$0.75	'	'	'	'	'	$8.38	$8.25	$0.75	'	$34.50	'	'	'	'
Outstanding - Average Exercise Price	'	$7.58	$6.75	$6.75	$8.25	$14.25	$20.25	$19.50	$125.25	$125.25	$8.60	$10.50	$9.75	$17.25	$33	$36.75	$33.75	$78	$93.75

STOCKHOLDERS_DEFICIT_STOCK_OPT3

STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS (Details 1) (USD $)

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2009

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2006

Dec. 31, 2005

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2006

Dec. 31, 2005

Stock Options One [Member]

Stock Options Two [Member]

Stock Options Three [Member]

Stock Options Four [Member]

Stock Options Five [Member]

Stock Options Six [Member]

Stock Options Seven [Member]

Stock Options Eight [Member]

Stock Options Nine [Member]

Stock Option Ten [Member]

Stock Option Eleven [Member]

Stock Option Twelve [Member]

Stock Options Thirteen [Member]

Stock Options Fourteen [Member]

Stock Options Fifteen [Member]

Stock Options Sixteen [Member]

Stock Options Seventeen [Member]

Stock Options Eighteen [Member]

Stock Options Nineteen [Member]

Equity Option [Member]

Stock Options Twenty [Member]

Stock Option Twenty One [Member]

Warrant One [Member]

Warrant Two [Member]

Warrant Three [Member]

Warrant Four [Member]

Warrant Five [Member]

Warrant Six [Member]

Warrant Seven [Member]

Warrant Eight [Member]

Warrant Nine [Member]

Warrant Ten [Member]

Warrant Eleven [Member]

Warrant Twelve [Member]

Warrant Thirteen [Member]

Warrant Fourteen [Member]

Warrant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Range of Exercise Prices

$0.75

$4.88

$1.28

$5.25

$4.88

$5.63

$5.25

$5.93

$5.63

$5.93

$6.60

$8.25

$66

$9.94

$10.50

$11.25

$12.75

$13.88

$20.25

$15

$21.75

$17.25

$23.85

$18.75

$24.75

$20.25

$25.61

$21.75

$26.25

$23.85

$43.88

$7.58

$6.75

$8.25

$14.25

$20.25

$19.50

$125.25

$24.75

$25.61

$0.75

$5.63

$11.25

$7.50

$12.38

$13.50

$11.25

$14.85

$12

$15

$12.75

$18.75

$13.50

$20.25

$14.85

$24.38

$1,500

$18.75

$34.50

$57.68

$8.60

$10.50

$9.75

$17.25

$33

$36.75

$33.75

$78

$93.75

$196.50

7,333

7,334

134

4,336

2,031

134

192,000

2,631

23,206

192,000

123,998

23,207

5,332

124,000

3,636

5,334

3,019

3,238

3,239

14,799

9,023

10,069

2,160

4,939

3,334

1,334

40,261

1,258

3,335

1,334

4,940

267

1,336

1,000

1,260

1,277

445,889

385,733

168,856

77,301

46,642

19,948

17,215

638

558

239

334

134

400

2,667

102,857

35,556

2,666

102,857

204,200

19,047

71,257

2,667

4,444

221,977

23,612

2,000

1,168

17,255

4,166

7,112

1,481

23,611

83,080

16,500

5,000

1,110

4,561

499,331

461,920

468,431

358,429

142,278

98,303

69,126

1,617

1,237

279

Weighted Average Remaining Life

'6 months

'2 years 6 months

'6 years 9 months 7 days

'7 years 6 months 7 days

'8 years 5 months 12 days

'4 years 5 months 5 days

'7 years 11 months 8 days

'9 years 2 months 12 days

'8 years 5 months 16 days

'9 years 5 months 8 days

'8 years 5 months 19 days

'9 years 2 months 16 days

'7 years 10 months 17 days

'9 years 2 months 19 days

'7 years 3 months 25 days

'8 years 7 months 17 days

'10 years

'8 years 25 days

'8 years 9 months 14 days

'9 years 6 months 14 days

'8 years 9 months 14 days

'9 years 6 months 14 days

'7 years 8 months 19 days

'7 years 1 month 28 days

'9 years 6 months 14 days

'9 years 4 months 10 days

'9 years 6 months 4 days

'10 years

'9 years 5 months 19 days

'9 years 9 months 7 days

'9 years 5 months 8 days

'9 years 9 months

'9 years 4 months 24 days

'9 years 8 months 23 days

'9 years 3 months 4 days

'9 years 9 months

'9 years 7 days

'4 months 13 days

'9 years 4 days

'5 months 8 days

'8 years 11 months 26 days

'1 year 2 months 8 days

'1 year 11 months 8 days

'3 years 5 months 12 days

'10 months 6 days

'3 years 3 months 25 days

'4 years 2 months 12 days

'3 years 3 months 7 days

'3 months 29 days

'3 years 6 months 11 days

'4 years 10 months 24 days

'3 years 8 months 19 days

'3 years 11 months 23 days

'3 years 7 months 28 days

'4 months 17 days

'4 months 2 days

'3 months 7 days

'11 days

'2 years 9 months 29 days

'3 years 11 days

'4 years 4 months 28 days

'4 years 10 months 10 days

'2 months 5 days

'9 months 7 days

'3 months 18 days

'6 months

STOCKHOLDERS_DEFICIT_STOCK_OPT4

STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS (Details 2) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007	Dec. 31, 2006	Dec. 31, 2005
Minimum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	$3.21	$8.93	'	'	'	'	$7.65	'	'	'
Maximum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	$13.91	$18.15	'	'	'	'	$25.20	'	'	'
Warrant One [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Number of Shares	'	'	'	'	400	'	4,561	'	'	'
Shares	400	2,667	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	'	'	'	$0.75	'	'	'	'	'
Warrant One [Member] \| Minimum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	'	'	'	'	'	$34.50	'	'	'
Warrant One [Member] \| Maximum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	'	'	'	'	'	$57.68	'	'	'
Warrant Two [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Number of Shares	'	'	'	4,166	'	1,110	'	'	'	'
Shares	102,857	35,556	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	'	'	$18.75	'	$34.50	'	'	'	'
Warrant Three [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Number of Shares	'	'	71,368	'	2,667	'	'	'	'	'
Shares	2,666	102,857	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	'	'	'	$0.75	'	'	'	'	'
Warrant Three [Member] \| Minimum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	'	$11.25	'	'	'	'	'	'	'
Warrant Three [Member] \| Maximum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	'	$15	'	'	'	'	'	'	'
Warrant Four [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Number of Shares	'	267,579	'	114,635	'	'	'	'	'	'
Shares	204,200	19,047	'	'	'	'	'	'	'	'
Warrant Four [Member] \| Minimum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	$6	'	$5.63	'	'	'	'	'	'
Warrant Four [Member] \| Maximum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	$14.85	'	$18.75	'	'	'	'	'	'
Warrant Five [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Number of Shares	155,818	'	71,367	'	'	'	'	'	'	'
Shares	71,257	2,667	'	'	'	'	'	'	'	'
Warrant Five [Member] \| Minimum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	$12.38	'	$11.25	'	'	'	'	'	'	'
Warrant Five [Member] \| Maximum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	$24.38	'	$15	'	'	'	'	'	'	'
Warrant Six [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Number of Shares	'	267,580	'	'	'	'	'	'	'	'
Shares	4,444	221,977	'	'	'	'	'	'	'	'
Warrant Six [Member] \| Minimum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	$0.75	$6	'	'	'	'	'	'	'	'
Warrant Six [Member] \| Maximum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	$24.38	$14.85	'	'	'	'	'	'	'	'
Warrant Seven [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Shares	23,612	2,000	'	'	'	'	'	'	'	'
Warrant [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Number of Shares	155,818	343,196	155,846	242,963	45,809	29,177	67,669	380	958	'
Shares	499,331	461,920	468,431	358,429	142,278	98,303	69,126	1,617	1,237	279
Issued - Average Exercise Price	$3.74	$9	$11.25	$10.50	$25.50	$48.75	$33.75	$26.25	$63.75	'
Warrant [Member] \| Minimum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	$0.75	'	'	'	'	'	'	'	'
Warrant [Member] \| Maximum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	$57.68	'	'	'	'	'	'	'	'
Stock Options One [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Number of Shares	'	'	'	'	5,466	'	5,613	'	'	'
Shares	7,333	7,334	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	'	'	'	$11.25	'	'	'	'	'
Stock Options One [Member] \| Minimum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	'	'	'	'	'	$1.28	'	'	'
Stock Options One [Member] \| Maximum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	'	'	'	'	'	$43.88	'	'	'
Stock Options Two [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Number of Shares	'	'	'	7,333	'	1,000	'	'	'	'
Shares	134	4,336	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	'	'	$0.75	'	$26.25	'	'	'	'
Stock Options Three [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Number of Shares	'	'	126,029	'	5,467	'	'	'	'	'
Shares	2,031	134	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	'	'	'	$11.25	'	'	'	'	'
Stock Options Three [Member] \| Minimum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	'	$5.25	'	'	'	'	'	'	'
Stock Options Three [Member] \| Maximum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	'	$6	'	'	'	'	'	'	'
Stock Options Four [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Number of Shares	'	238,556	'	7,334	'	'	'	'	'	'
Shares	192,000	2,631	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	'	'	$0.75	'	'	'	'	'	'
Stock Options Four [Member] \| Minimum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	$4.88	'	'	'	'	'	'	'	'
Stock Options Four [Member] \| Maximum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	$25.61	'	'	'	'	'	'	'	'
Stock Options Five [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Number of Shares	68,505	'	126,636	'	'	'	'	'	'	'
Shares	23,206	192,000	'	'	'	'	'	'	'	'
Stock Options Five [Member] \| Minimum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	$8.25	'	$5.25	'	'	'	'	'	'	'
Stock Options Five [Member] \| Maximum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	$18.75	'	$6	'	'	'	'	'	'	'
Stock Options Six [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Number of Shares	'	239,683	'	'	'	'	'	'	'	'
Shares	123,998	23,207	'	'	'	'	'	'	'	'
Stock Options Six [Member] \| Minimum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	$0.75	$4.88	'	'	'	'	'	'	'	'
Stock Options Six [Member] \| Maximum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	$25.61	$25.61	'	'	'	'	'	'	'	'
Stock Options Seven [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Shares	5,332	124,000	'	'	'	'	'	'	'	'
Equity Option [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Number of Shares	71,838	239,816	126,866	33,111	29,467	2,733	16,577	80	319	'
Shares	445,889	385,733	168,856	77,301	46,642	19,948	17,215	638	558	239
Issued - Average Exercise Price	$8.11	$6.75	$6	$0.75	$12.75	$27.75	$15	$125.25	$125.25	'
Equity Option [Member] \| Minimum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	$0.75	'	'	'	'	'	'	'	'
Equity Option [Member] \| Maximum [Member]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issued - Average Exercise Price	'	$43.88	'	'	'	'	'	'	'	'

STOCKHOLDERS_DEFICIT_STOCK_OPT5

STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS (Details Textual) (USD $)

1 Months Ended

0 Months Ended

1 Months Ended

2 Months Ended

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

140 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

2 Months Ended

6 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

1 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

2 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

2 Months Ended

9 Months Ended

12 Months Ended

Jul. 23, 2014

Jun. 30, 2014

Feb. 28, 2014

Mar. 15, 2013

Mar. 31, 2014

Oct. 31, 2013

31-May-13

Apr. 30, 2013

Jan. 31, 2013

Nov. 30, 2012

Mar. 31, 2012

Jan. 31, 2011

Dec. 31, 2010

Sep. 30, 2010

Jun. 30, 2010

Oct. 31, 2009

Jul. 31, 2007

Mar. 31, 2007

Sep. 30, 2014

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2014

Mar. 31, 2013

Jun. 30, 2013

Dec. 31, 2002

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2013

Aug. 31, 2014

Aug. 04, 2014

Jul. 31, 2014

Feb. 04, 2014

Sep. 11, 2013

Jan. 15, 2013

Mar. 28, 2012

Sep. 07, 2011

Jun. 22, 2010

Jul. 23, 2014

Sep. 30, 2014

Jun. 30, 2014

Jul. 31, 2014

Jan. 31, 2014

Feb. 04, 2014

Feb. 28, 2014

Sep. 30, 2014

Jan. 31, 2013

Jun. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2006

Feb. 28, 2014

Mar. 15, 2013

Mar. 31, 2013

Jul. 31, 2014

Feb. 28, 2014

Sep. 10, 2013

Apr. 15, 2013

Nov. 30, 2012

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2008

Sep. 10, 2013

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2012

Dec. 31, 2011

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2008

Sep. 10, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

SOK Partners, LLC, [Member]

CEO [Member]

Dr Samuel Herschowitz [Member]

Purchasers [Member]

Private Placement [Member]

Private Placement 2 [Member]

Warrant [Member]

Series A Convertible Preferred Stock [Member]

Stock Incentive Plan 2012 [Member]

Convertible Notes One [Member]

Convertible Notes Two [Member]

Convertible Notes Three [Member]

Convertible Note Four [Member]

Stock Options and Warrants [Member]

Stock Options and Warrants One [Member]

Stock Options and Warrants Two [Member]

Minimum [Member]

Maximum [Member]

Private Placement [Member]

Warrant [Member]

Stock Options and Warrants [Member]

Warrant [Member]

Stock Options and Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted Average Remaining Life

'6 months

'2 years 6 months

'5 years

'3 years

'5 years

'10 years

'5 years

'10 years

'2 years

'2 years 6 months

'3 years

'6 years 6 months

'7 years 6 months

'10 years

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum

0.13%

2.00%

0.78%

0.33%

0.34%

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum

2.97%

4.50%

2.04%

1.80%

2.44%

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate

0.00%

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum

59.00%

53.00%

54.00%

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum

66.00%

Issued - Average Exercise Price

$3.74

$11.25

$10.50

$25.50

$48.75

$33.75

$26.25

$63.75

$3.21

$8.93

$7.65

$0.75

$0.83

$0.95

$13.91

$18.15

$25.20

$57.68

$7.20

$25.59

Convertible Debt, Issuance Of Warrants

$100,000

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Volatility Description

'The Company compiled historical volatilities over a period of 2 to 7 years of 15 small-cap medical companies traded on major exchanges and 10 mid-range medical companies on the OTC Bulletin Board and combined the results using a weighted average approach.

Amortization of debt discount

33,469

47,908

7,232

15,553

96,613

30,150

92,700

40,242

275,640

87,853

413,695

57,518

756,497

Debt Instrument Convertible Remaining Discount Amortization Period 1

'24 months

'18 months

'22 months

'24 months

'5 years

Convertible Bridge Debt, Issuance Of Warrants

170,000

Debt Instrument, Maturity Date

30-Apr-08

Proceeds from Issuance of Debt

50,000

16,800

32,000

200,000

100,000

27,500

51,243

50,000

Warrants Issued During Period, Shares, In Connection With Convertible Debt

21,270

2,667

4,267

14,815

2,667

Equity Issuance Per Share Amount

$7.50

$15

$6.30

$13.50

$34.50

$48.75

$125.25

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

59.00%

54.00%

63.00%

54.00%

59.00%

66.00%

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number

427,051

368,783

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price

$7.26

$6.38

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Weighted Average Remaining Contractual Term 1

'8 years 2 months 26 days

'8 years 9 months 18 days

Share-based Compensation Expense

440,117

3,791,802

3,700,070

830,372

Employee Service Share-Based Compensation, Nonvested Awards, Total Compensation Cost Not Yet Recognized, Stock Options

262,055

166,905

Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1

'18 months

'22 months

Stockholders' Equity, Reverse Stock Split

Common stock, shares authorized

10,666,667

4,000,000

2,666,667

1,066,667

1,333,334

666,667

4,000,000

10,666,667

Convertible Note Conversion Price

$13.50

Debt Instrument, Face Amount

156,243

300,000

1,000,000

Convertible Notes Converted Into Common Stock

14,882

33,334

80,000

61,482

Debt Instrument, Convertible, Conversion Price

$7.50

$1.05

$4.88

$11.25

Accumulated discounts on current portion of convertible debt (in dollars)

77,644

21,138

Debt Instrument, Convertible, Effective Interest Rate

24.00%

8.00%

Shares Grants Increase For Threshold

266,667

Shares issued under PPM to five investors at $.07 per share (in shares)

95,239

Shares issued under PPM to five investors

$5.25

Common stock, par value (in dollars per share)

$0.01

Warrants Exercise Price

$18.75

$7.50

$13.50

$14.85

$11.25

$34.50

Shares issued under PPM to five investors at $.07 per share

500,000

Warrants Issued To Purchase Common Stock

5,926

Debt Instrument Interest

11,169

Stock Issued During Period, Shares, New Issues

4,763

13,889

20,550

CommonStocksharesIssuedToConsultantExercisingOptions

2,667

Common stock issued to former CEO exercising option, par value

$0.75

Common stock issued to former consultant exercising option, Par value

$0.01

$0.75

Common stock shares issued to CEO exercising options.

4,445

Stock Issued During Period, Value, Issued To Twenty Four Warrant Holders

1,044,490

Stock Issued During Period, Shares, Issued To Twenty Four Warrant Holders

139,266

Issuance of net exercise provision shares

87,118

Share Based Compensation Arrangement By Share Based Payment Award Warrant Vested And Expected To Vest Exercisable Number

461,920

Shares Issued To One Warrant Holder Exercised At Reduced Par Value

$9.38

Stock Issued During Period Value Issued To One Warrant Holders

125,000

Stock Issued During Period Shares Issued To One Warrant Holders

13,334

Stock Issued During Period, Value, New Issues

$5,000

$2,055,000

Preferred Stock, Par or Stated Value Per Share

$0.01

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

4,831

1,482

37,440

61,539

28,986

21,538

5,431

1,561

21,334

Preferred Stock Conversion Price, Per Share

$19.50

Class of Warrant or Right, Exercise Price of Warrants or Rights

$12.38

$24.38

$12.38

$20.25

Percentage Of Additional Warrants Issued To Purchase Common Stock

30.00%

Convertible Preferred Stock, Terms of Conversion

Beneficial Ownership Limitation, Percentage

4.99%

Preferred Shareholders, Receivable, Upon Any Liquidation, Description

'an amount equal to $2,055,000 times 1.2, plus all declared but unpaid dividends

Securities Purchase Agreement Terms

'(i) a senior convertible note, in an original principal amount of $122,196 (the SOK Note), which SOK Note shall be convertible into a certain amount of shares (the SOK Conversion Shares) of Common Stock, in accordance with the terms of the SOK Note, and (ii) a warrant (the SOK Warrant) to initially acquire up to 5,431 additional shares of Common Stock (the SOK Warrant Shares, and collectively with the SOK Note, the SOK Warrant and the SOK Conversion Shares, the SOK Securities) for an aggregate purchase price of $100,000 (with the reduced principal amount as described below representing an approximately 8.7% original issue discount) (the SOK Convertible Notes Offering).

'(i) the Qualified Public Offering closes within six (6) months of the first closing of the convertible notes offering (Qualified Public Offering Deadline) and (ii) 70% of the public offering price per share of the Common Stock in the Qualified Public Offering (the QPO Discount Price) is less than the Conversion Price floor contained in Section 7(e)(i) of the Certificate of Designation (the Conversion Price Floor), or (B) if a Qualified Public Offering has not been consummated by the Qualified Public Offering Deadline, upon the Preferred Stockholders conversion of their shares of Preferred Stock to the extent that 70% of the volume weighted average price of the Common Stock on the principal Trading Market (as defined in the Certificate of Designation) of the Common Stock during the ten Trading Days (as defined in the Certificate of Designation) immediately preceding the Qualified Public Offering Deadline (the Non-QPO Discount Price) is less than the Conversion Price Floor

Sale of Stock, Price Per Share

$9.75

Warrants Expiration

'five years

Stock Issued During Period, Shares, Other

20,623

71,257

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period

4,444

4,336

40,722

238,682

958

1,714

Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price

$11.25

$1.25

$8.38

$8.25

$0.75

$34.50

Cashless Exercise Of Common Stock Warrants Total

15,442

Preferred Stock, Dividend Rate, Percentage

6.00%

Conversion Of Stock Price Per Share

$19.50

Stock Issued During Period, Shares, Conversion Of Convertible Securities

1,561

970

Cashless Exercise Of Common Stock Shares Issued

$3,725

$3,333

Percentage Of Reduction To Warrant Agreement

11.00%

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.37%

2.75%

1.44%

SHORTTERM_NOTES_PAYABLE_Detail

SHORT-TERM NOTES PAYABLE (Details Textual) (USD $)

1 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

140 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

Nov. 30, 2012

Jan. 31, 2011

Dec. 31, 2010

Sep. 30, 2010

Jun. 30, 2010

Oct. 31, 2009

Jul. 31, 2007

Mar. 31, 2007

Jun. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Jul. 23, 2014

Sep. 09, 2014

Jul. 23, 2014

Sep. 30, 2014

Jul. 31, 2014

Sep. 30, 2014

Jul. 23, 2014

SOK Partners, LLC, [Member]

Group, LLC [Member]

SOK Note, 31 Group Note And Affiliate Notes [Member]

Affiliates [Member]

Evan Myrianthopoulos [Member]

Convertible Notes Payable [Member]

Short-term Debt [Line Items]

Amortization Of Debt Discount (Premium)

$33,469

$47,908

$7,232

$15,553

$96,613

$30,150

$92,700

$40,242

$275,640

$87,853

$413,695

$57,518

$756,497

$250,494

$103,088

Debt Conversion, Converted Instrument, Amount

415,775

100,000

515,775

40,000

Securities Purchase Agreement Terms

'(i) a senior convertible note, in an original principal amount of $610,978 (subsequently reduced to $543,478) (the 31 Group Note), which shall be convertible into a certain amount of shares of Common Stock, in accordance with the terms of the 31 Group Note, (ii) a warrant (the 31 Group Warrant) to initially acquire up to 27,155 additional shares of Common Stock (subsequently reduced to 24,155 shares) (the 31 Group Conversion Shares, and collectively with the 31 Group Note, the 31 Group Warrant and the 31 Group Conversion Shares, the 31 Group Securities) for an aggregate purchase price of $500,000 (representing an approximately 8.7% original issue discount) (the 31 Group Convertible Notes Offering).

'(i) senior convertible notes, in an original aggregate principal amount of $1,069,222 (subsequently reduced to $951,086) (the Affiliate Notes), which Affiliate Notes shall be convertible into a certain amount of shares (the Affiliate Conversion Shares) of the Companys Common Stock in accordance with the terms of the Affiliate Notes, and (ii) warrants (the Affiliate Warrants) to initially acquire up to 48,879 additional shares of Common Stock (subsequently reduced to 42,271 shares) (the Affiliate Warrant Shares, and collectively with the Affiliate Notes, the Affiliate Warrants and the Affiliate Conversion Shares, the Affiliate Securities) for an aggregate purchase price of $875,000 (representing an approximately 8.7% original issue discount) (the Affiliate Convertible Notes Offering).

'(i) a senior convertible note, in an original principal amount of $30,548.90 (subsequently reduced to $27,173.90) (the “Myrianthopoulos Note”), which shall be convertible into a certain amount of shares of Common Stock, in accordance with the terms of the Myrianthopoulos Note, (ii) a warrant (the “Myrianthopoulos Warrant”) to initially acquire up to 1,358 additional shares of Common Stock (subsequently reduced to 1,208 shares) (the “Myrianthopoulos Conversion Shares”, and collectively with the Myrianthopoulos Note, the Myrianthopoulos Warrant and the Myrianthopoulos Conversion Shares, the “Myrianthopoulos Securities”) for an aggregate purchase price of $25,000 (representing an approximately 8.7% original issue discount) (the “Myrianthopoulos Convertible Notes Offering”)

Notes Payable, Current

$108,696

Class of Warrant or Right, Outstanding

4,831

Debt Instrument, Interest Rate During Period

12.00%

Debt Instrument, Maturity Date

30-Apr-08

23-Jul-15

LOSS_PER_SHARE_Details

LOSS PER SHARE (Details) (USD $)	3 Months Ended				9 Months Ended				12 Months Ended				140 Months Ended
LOSS PER SHARE (Details) (USD $)	Sep. 30, 2014		Sep. 30, 2013		Sep. 30, 2014		Sep. 30, 2013		Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2013
Numerator:	'		'		'		'		'		'		'
Net loss available in basic and diluted calculation	($1,115,221)		($3,974,903)		($4,468,170)		($7,251,965)		($9,406,304)		($7,422,155)		($28,697,415)
Denominator:	'		'		'		'		'		'		'
Weighted average common shares outstanding-basic (in shares)	259,899		1,821,006		2,052,709		1,687,625		2,026,115		927,838		996,362
Effect of dilutive stock options and warrants (in shares)	0	[1]	0	[1]	0	[1]	0	[1]	0	[2]	0	[2]	0	[2]
Weighted average common shares outstanding-diluted (in shares)	2,984,335		1,821,006		2,967,483		1,687,625		2,026,115		927,838		996,362
Loss per common share-basic and diluted (in dollars per share)	($0.37)		($2.18)		($1.51)		($4.30)		($4.64)		($8)		($28.80)

[1]	The number of shares underlying options and warrants outstanding as of September 30, 2014 and September 30, 2013 are 945,220 and 861,287 respectively. The effect of the shares that would be issued upon exercise of such options and warrants has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.
[2]	The number of shares underlying options and warrants outstanding as of December 31, 2013 and December 31, 2012 are 847,777 and 637,277, respectively. The effect of the shares that would be issued upon exercise of such options and warrants has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

LOSS_PER_SHARE_Details_Textual

LOSS PER SHARE (Details Textual) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]	'	'	'	'
Options and Warrants Outstanding	$945,220	$847,777	$861,287	$637,277

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Deferred Tax Asset:	'	'	'
Net Operating Loss	$7,920,000	$3,259,000	$2,209,000
Other	631,000	59,000	73,000
Total Deferred Tax Asset	8,551,000	3,318,000	2,282,000
Less Valuation Allowance	8,551,000	3,318,000	2,282,000
Net Deferred Income Taxes	$0	$0	$0

INCOME_TAXES_Details_Textual

INCOME TAXES (Details Textual) (USD $)	9 Months Ended	12 Months Ended
INCOME TAXES (Details Textual) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Tax Credit Carryforward [Line Items]	'	'
Valuation Allowance Percentage	100.00%	100.00%
Operating Loss Carryforwards	'	$13,969,000
Operating Loss Carryforwards, Expiration Date	31-Dec-22	31-Dec-17
Domestic Tax Authority [Member]	'	'
Tax Credit Carryforward [Line Items]	'	'
Operating Loss Carryforwards	16,000,000	'
Operating Loss Carryforwards, Valuation Allowance	7,100,000	'
Operating Loss Carry forwards Expiration Period	'beginning in 2022	'
State and Local Jurisdiction [Member]	'	'
Tax Credit Carryforward [Line Items]	'	'
Operating Loss Carryforwards	17,100,000	'
Operating Loss Carryforwards, Valuation Allowance	$1,500,000	'
Operating Loss Carry forwards Expiration Period	'2022 through 2034	'

LONGTERM_DEBT_Details

LONG-TERM DEBT (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Debt Instrument [Line Items]	'	'
Total	$0	$560,874
Less amount due within one year	0	471,574
Long-Term Debt	0	89,300
Note Payable Issued One [Member]	'	'
Debt Instrument [Line Items]	'	'
Total	0	100,000
Note Payable Issued Two [Member]	'	'
Debt Instrument [Line Items]	'	'
Total	0	200,000
Note Payable Issued Three [Member]	'	'
Debt Instrument [Line Items]	'	'
Total	0	16,800
Note Payable Issued Four [Member]	'	'
Debt Instrument [Line Items]	'	'
Total	0	32,000
Note Payable Issued Five [Member]	'	'
Debt Instrument [Line Items]	'	'
Total	0	89,300
Note Payable Issued Six [Member]	'	'
Debt Instrument [Line Items]	'	'
Total	$0	$122,774

LONGTERM_DEBT_Details_Textual

LONG-TERM DEBT (Details Textual) (USD $)	1 Months Ended			3 Months Ended		9 Months Ended		12 Months Ended
LONG-TERM DEBT (Details Textual) (USD $)	31-May-13	Jan. 31, 2013	Jul. 31, 2007	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'
Debt Instrument, Unamortized Discount	'	'	'	$353,583	'	$353,583	'	$0	'
Convertible Notes Converted Into Common Stock	14,882	33,334	'	'	'	'	'	'	'
Debt Instrument, Maturity Date	'	'	30-Apr-08	'	'	'	'	'	'
Interest Paid	'	'	'	21,627	14,503	43,233	56,433	55,198	31,008
Repayments Of Notes Payable Due	'	'	'	'	'	'	'	450,958	'
Repayments Of Notes Payable Due In Year One	'	'	'	'	'	'	'	120,000	'
Repayments Of Notes Payable Due In Year Two	'	'	'	'	'	'	'	120,000	'
Secured Debt Common Stock Shares	'	'	'	'	'	'	'	8,889	'
Escrow Account Release Of Common Stock Shares Description	'	'	'	'	'	'	'	'The escrow account releases 1/3 or 4,445 shares per year to the Company if there is no default.	'
Note Payable Issued One [Member]	'	'	'	'	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'
Note Payable Issued Date	'	'	'	'	'	'	'	26-Oct-09	'
Debt Instrument, Unamortized Discount	'	'	'	'	'	'	'	0	0
Debt Instrument, Interest Rate During Period	'	'	'	'	'	'	'	8.00%	'
Convertible Notes, Conversion Price	'	'	'	'	'	'	'	$26.25	'
Note Payable Issued Two [Member]	'	'	'	'	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'
Note Payable Issued Date	'	'	'	'	'	'	'	12-Jun-10	'
Debt Instrument, Interest Rate During Period	'	'	'	'	'	'	'	12.00%	'
Convertible Notes, Conversion Price	'	'	'	'	'	'	'	$13.50	'
Note Payable Issued Three [Member]	'	'	'	'	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'
Note Payable Issued Date	'	'	'	'	'	'	'	23-Dec-10	'
Debt Instrument, Interest Rate During Period	'	'	'	'	'	'	'	10.00%	'
Convertible Notes, Conversion Price	'	'	'	'	'	'	'	$6.30	'
Debt Instrument, Maturity Date	'	'	'	'	'	'	'	23-Dec-12	'
Note Payable Issued Four [Member]	'	'	'	'	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'
Note Payable Issued Date	'	'	'	'	'	'	'	21-Sep-10	'
Debt Instrument, Interest Rate During Period	'	'	'	'	'	'	'	12.00%	'
Convertible Notes, Conversion Price	'	'	'	'	'	'	'	$13.50	'
Debt Instrument, Maturity Date	'	'	'	'	'	'	'	30-Mar-12	'
Note Payable Issued Five [Member]	'	'	'	'	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'
Note Payable Issued Date	'	'	'	'	'	'	'	1-Jan-11	'
Debt Instrument, Interest Rate During Period	'	'	'	'	'	'	'	6.00%	'
Convertible Notes, Conversion Price	'	'	'	'	'	'	'	$11.25	'
Debt Instrument, Maturity Date	'	'	'	'	'	'	'	1-Jan-15	'
Note Payable Issued Six [Member]	'	'	'	'	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'
Note Payable Issued Date	'	'	'	'	'	'	'	6-Nov-12	'
Debt Instrument, Unamortized Discount	'	'	'	'	'	'	'	$21,138	'
Debt Instrument, Interest Rate During Period	'	'	'	'	'	'	'	20.00%	'
Convertible Notes Converted Into Common Stock	'	'	'	'	'	'	'	13,889	'
Convertible Notes, Conversion Price	'	'	'	'	'	'	'	$7.50	'
Debt Instrument, Maturity Date	'	'	'	'	'	'	'	6-Apr-13	'

RENT_OBLIGATION_Details

RENT OBLIGATION (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Operating Leased Assets [Line Items]	'	'
2014	'	$36,000
2015	37,000	37,000
2016	38,000	38,000
2017	39,000	39,000
2018	3,600	'
2019	$0	$3,000

RENT_OBLIGATION_Details_Textua

RENT OBLIGATION (Details Textual) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
RENT OBLIGATION (Details Textual) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Property Subject to or Available for Operating Lease [Line Items]	'	'	'	'	'	'
Lessee Leasing Arrangements, Operating Leases, Term of Contract	'	'	'5 years	'	'5 years	'
Lease Expiration Date	'	'	31-Jan-18	'	31-Jan-18	'
Operating Leases, Rent Expense	$15,719	$11,162	$48,775	$46,321	$61,150	$45,961

LIABILITY_FOR_EQUITYLINKED_FIN2

LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2009	Dec. 31, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock price	'	$26.25	$26.25	'
Exercise price	'	$57.68	$34.50	'
Expected life	'	'6 months	'2 years 6 months	'
Expected volatility	59.00%	54.00%	63.00%	'
Assumed dividend rate	0.00%	0.00%	'	0.00%
Risk-free interest rate - Minimum	0.13%	0.13%	'	2.00%
Risk-free interest rate - Maximum	2.97%	2.97%	'	4.50%
Minimum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock price	$4.50	'	'	'
Exercise price	$0.75	'	'	'
Expected life	'2 years	'	'	'2 years 6 months
Maximum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock price	$37.50	'	'	'
Exercise price	$24.38	'	'	'
Expected life	'6 years 6 months	'	'	'7 years 6 months

LIABILITY_FOR_EQUITYLINKED_FIN3

LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS (Details 1) (USD $)	3 Months Ended						9 Months Ended	12 Months Ended
	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2009	Sep. 30, 2009	Jun. 30, 2009	Sep. 30, 2010	Dec. 31, 2009	Dec. 31, 2008
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Initial Value	$31,506	$31,332	$25,553	$12,698	$39,743	$169,854	$790,596	$702,205	$479,910
Annual Gain (Loss)	'	'	'	617	-738	20,847	-369,642	'	-390,368
Total	'	'	'	'	'	'	790,596	'	'
Value At 2009 [Member]	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Initial Value	'	'	'	12,081	40,481	149,007	'	1,071,847	870,278
Total	'	'	'	'	'	'	1,071,847	'	'
Value At 2010 [Member]	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Initial Value	10,615	592	539	28	62	1,604	'	'	1,506
Total	'	'	'	'	'	'	14,946	'	'
Gain Loss 2010 [Member]	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Annual Gain (Loss)	20,891	30,740	25,014	12,053	40,419	147,403	'	'	868,772
Total	'	'	'	'	'	'	1,145,292	'	'
Value At 2011 [Member]	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Initial Value	54,775	6,714	6,109	752	1,624	6,293	'	'	89,796
Total	'	'	'	'	'	'	166,063	'	'
Gain Loss 2011 [Member]	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Annual Gain (Loss)	-44,160	-6,122	-5,570	-724	-1,562	-4,689	'	'	-88,290
Total	'	'	'	'	'	'	-151,117	'	'
Value At 2012 [Member]	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Initial Value	53,437	631	2,408	337	714	0	'	'	111,652
Total	'	'	'	'	'	'	169,179	'	'
Gain Loss 2012 [Member]	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Annual Gain (Loss)	1,338	6,083	3,701	415	910	6,293	'	'	-21,856
Total	'	'	'	'	'	'	-3,116	'	'
Value At 2013 [Member]	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Initial Value	0	0	0	0	0	0	'	'	11,599
Total	'	'	'	'	'	'	11,599	'	'
Gain Loss 2013 [Member]	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Annual Gain (Loss)	53,437	631	2,408	337	714	0	'	'	100,053
Total	'	'	'	'	'	'	157,580	'	'
Value At 2014 [Member]	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Annual Gain (Loss)	0	0	0	0	0	0	0	'	'
Gain Loss 2014 [Member]	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Initial Value	$0	$0	$0	$0	$0	$0	$11,599	'	'

LIABILITY_FOR_EQUITYLINKED_FIN4

LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS (Details Textual) (USD $)	9 Months Ended	12 Months Ended				9 Months Ended	12 Months Ended		9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2009	Dec. 31, 2012	Jan. 02, 2009	Sep. 30, 2014	Dec. 31, 2010	Dec. 31, 2008	Sep. 30, 2014	Dec. 31, 2010	Dec. 31, 2008
	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2009	Dec. 31, 2012	Jan. 02, 2009	Minimum [Member]	Minimum [Member]	Minimum [Member]	Maximum [Member]	Maximum [Member]	Maximum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Warrants Not Settleable In Cash, Fair Value Disclosure	'	'	'	'	$479,910	'	'	'	'	'	'
Weighted Average Remaining Life	'	'6 months	'2 years 6 months	'	'	'2 years	'	'2 years 6 months	'6 years 6 months	'	'7 years 6 months
Reduction In Stock Price	'	'	'	'	'	'	$16.50	'	'	$37.50	'
Additional Paid in Capital	'	'	'	'	486,564	'	'	'	'	'	'
Retained Earnings (Accumulated Deficit)	'	'	'	'	6,654	'	'	'	'	'	'
Total Current Liabilities	$4,842,380	$3,469,065	'	$3,414,301	$479,910	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	59.00%	54.00%	63.00%	'	'	'	'	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price	'	$57.68	$34.50	'	'	$0.75	'	'	$24.38	'	'
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Stock Price	'	$26.25	$26.25	'	'	$4.50	'	'	$37.50	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	'	'	1.37%	'	'	'	'	'	'	'	'

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details Textual) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

6 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

31-May-13

Apr. 30, 2013

Nov. 30, 2012

Aug. 31, 2012

Jun. 30, 2012

Apr. 30, 2012

Mar. 31, 2012

Jul. 31, 2007

Sep. 30, 2013

Mar. 31, 2013

Dec. 31, 2002

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Aug. 31, 2014

Aug. 04, 2014

Jul. 31, 2014

Jun. 30, 2014

Feb. 28, 2014

Feb. 04, 2014

Sep. 11, 2013

Jan. 31, 2013

Mar. 28, 2012

Dec. 31, 2008

Dec. 31, 2013

Jun. 30, 2013

Mar. 28, 2012

Dec. 31, 2008

Sep. 11, 2013

Aug. 31, 2012

Apr. 30, 2012

Aug. 15, 2012

Dec. 31, 2013

Apr. 30, 2012

Sep. 11, 2013

31-May-12

Mar. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Jan. 31, 2014

Feb. 28, 2014

Mar. 31, 2012

Mar. 14, 2012

Mar. 31, 2012

Sep. 30, 2013

Jun. 30, 2012

Feb. 04, 2014

Feb. 28, 2014

Subsequent Event [Member]

Minimum [Member]

Maximum [Member]

First Advance [Member]

Second Advance [Member]

Related Party [Member]

Samuel Herschkowitz [Member]

Sok Partners [Member]

Dr Herschkowitz and Sok Partners Llc [Member]

Gadbaw [Member]

Morawetz [Member]

Board of Directors Chairman [Member]

Director [Member]

Chief Executive Officer [Member]

Non-Convertible Grid Note [Member]

Minimum [Member]

Maximum [Member]

Non-Convertible Grid Note [Member]

Minimum [Member]

Maximum [Member]

Common Stock [Member]

Preferred Stock [Member]

Subsequent Event [Member]

Related Party Transaction [Line Items]

Payments Made To Officers One

$25,000

Proceeds from Issuance or Sale of Equity

3,000,000

2,055,000

Payments Made To Officers Two

30,000

Related Party Transaction, Due from (to) Related Party

2,000

46,000

Converible Note Percentage

20.00%

Converible Note Principal Amount

156,243

600,000

240,000

Notes Payable, Total

357,282

305,589.04

Debt Instrument, Convertible, Effective Interest Rate

24.00%

10.00%

Advance Under Note

300,000

84,657

300,000

Cash Advance Net Of Interest

60,000

Debt Instrument, Convertible, Conversion Price

$7.50

$1.05

$4.88

Stock Issued During Period, Shares, Conversion of Units

61,539

Stock Issued During Period, Value, Conversion of Units

600,000

Stock Issued During Period, Shares, Other

20,623

Stock Transferred During Period

100,000

Shares Issued Related Party Transactions One

3,704

Price Per Share Related Party Transactions

$6.75

Compensation Issued In Lieu Of Cash

25,000

Warrants Shares Related Party Transactions

400

Warrants Price Per Share Related Party Transactions

$11.25

Shares Issued Related Party Transactions Two

353,334

Debt Instrument Convertible Conversion Price Minimum

$1.05

Debt Instrument Convertible Conversion Price Maximum

$4.88

Shares Issued Related Party Transactions Three

20,833

Proceeds from Related Party Debt

155,000

Convertible Note Due Date

31-Aug-13

Related Party Transaction, Description of Transaction

'listing the Company’s shares on NASDAQ pursuant to an underwritten offering of the Company’s securities resulting in gross proceeds of between $5 million and $30 million, then the Company would have to be required to deliver to Dr. Herschkowitz the following compensation: (A) $75,000 upon consummating the shell merger, (B) $150,000 upon consummating the qualifying financing round and (C) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $1,000,000. The Company was also required to reimburse Dr. Herschkowitz at his actual out-of-pocket cost for reasonable expenses incurred in connection with the shell transactions, with a maximum limit of $10,000 for such expenses.

'(i) financing raising not less than $1 million, compensation of $75,000; (ii) a going private transaction, compensation of $200,000 or greater and (iii) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $3,000,000. In May 2013 Dr. Herschkowitz received $75,000 after the Company surpassed raising $1 million.

Equity Bonus Valued At Common Stock Rate

$1.05

$4.88

Additional Issue Of Common Stock Shares

213,334

Stock Issued During Period Shares New Issues

4,763

13,889

100,000

176,667

19,231

Percentage Of Interest Rate On Event Of Default

20.00%

24.00%

Percentage Of Accrued Interest

20.00%

Proceeds From Offering Of Securities

2,000,000

4,000,000

Compensation Payment Pursuant To Merger

'listing the Companys shares on NASDAQ pursuant to an underwritten offering of the Companys securities resulting in gross proceeds of between $5 million and $30 million, then the Company would have to be required to deliver to Dr. Herschkowitz the following compensation: (A) $75,000 upon consummating the shell merger, (B) $150,000 upon consummating the qualifying financing round and (C) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $1,000,000. The Company was also required to reimburse Dr. Herschkowitz at his actual out-of-pocket cost for reasonable expenses incurred in connection with the shell transactions, with a maximum limit of $10,000 for such expenses.

Common Shares received on resignation

667

Common shares received per share on resignation

$24.38

Compensation received from serving as board members

267

Issuance of shares to satisy previous contractual agreements

400

Debt Instrument, Periodic Payment

314,484

680,444

Conversion of Stock, Shares Converted

299,509

648,050

Proceeds from Notes Payable

300,000

Debt Instrument, Maturity Date

30-Apr-08

28-Feb-14

Debt Instrument, Interest Rate, Effective Percentage

24.00%

10.00%

Percentage Of Gross Proceeds Received In Advance

10.00%

Amount Received In Three Tranches

250,000

Additional Proceeds From Notes Payable

20,000

Percentage Of Increase In Interest In Case Of Default

20.00%

Stock Issued During Period, Value, New Issues

$5,000

$25,000

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

37,440

61,539

28,986

4,831

1,482

21,538

RETIREMENT_SAVINGS_PLANS_Detai

RETIREMENT SAVINGS PLANS (Details Textual) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
RETIREMENT SAVINGS PLANS (Details Textual) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]	'	'	'	'	'	'
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	'	'	100.00%	'	100.00%	100.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	'	'	4.00%	'	4.00%	'
Defined Contribution Plan, Employer Discretionary Contribution Amount	$14,102	$9,231	$29,596	$27,328	$32,790	$1,654

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details Textual) (USD $)	9 Months Ended
COMMITMENTS AND CONTINGENCIES (Details Textual) (USD $)	Sep. 30, 2014
Loss Contingencies [Line Items]	'
Litigation Settlement, Amount	$500,000
Estimated Litigation Liability, Current	$200,000
Loss Contingency, Settlement Agreement, Terms	'Payment of the outstanding balance under the Settlement Agreement will be accelerated if the Company raises $2 million or more of gross dollars in a single funding round or raises aggregate funding of $4 million of gross dollars on or before April 10, 2015

SUPPLEMENTAL_CASH_FLOW_DATA_De

SUPPLEMENTAL CASH FLOW DATA (Details Textual) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
SUPPLEMENTAL CASH FLOW DATA (Details Textual) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Cash Flow Supplemental Disclosures [Line Items]	'	'	'	'	'	'
Interest Paid, Total	$21,627	$14,503	$43,233	$56,433	$55,198	$31,008